Int Conf AIDS 1996 Jul 7-12; 11:2 (abstract no. We.11)
Trono D; The Salk Institute for Biological Studies, La Jolla, CA, USA. Fax: 619-534-7760. E-mail: didier_trono@qm.salk.edu.
Our growing understanding of HIV molecular biology reveals important clues on AIDS pathogenesis, and suggests novel approaches for the development and monitoring of antiviral therapies. Keys to HIV replication reside in critical interactions between virally encoded factors and normal intracellular pathways. In this lec
The scale of the HIV pandemic in Zambia and many other resource-poor settings (RPSs) has overwhelmed the existing health and social support systems. Around 65% of medical inpatients in Lusaka are HIV-seropositive. More that 80% of people have a family member or close relative, who has died of HIV. Every class in every
Epidemics of disease are milestones in the history of humanity, nodes in the intricate web of causes and consequences which shape the development of societies. HIV has been with us for long enough to reveal global patterns of distribution which can be linked to currently accepted indicators of social development. Its h
Int Conf AIDS 1996 Jul 7-12; 11:36 (abstract no. We.14)
Ungphakorn J; AIDS Counseling Centres, Education and Support Services (ACCESS), Bangkok, Thailand. Fax: 66-2-248-4857.
The problem with proliferation of HIV counseling and testing centres with regard to HIV prevention is that HIV testing itself is a questionable tool for promoting prevention, as it diverts attention from the need for universal precautions in sexual practices. HIV testing is only really of use in terms of prevention for
Int Conf AIDS 1996 Jul 7-12; 11:2 (abstract no. We.15)
Alwano-Edyegu MG, Gumisiriza E, Campbell C, Moore M, Marum E, Kaleeba N; AIDS Information Centre, Kampala, Uganda.
Presentation of the Negative Argument to the resolution/debate topic. Based on lessons learnt from HIV prevention interventions in the developing world, we believe that every country should consider HIV counseling and testing (CT), targeted as appropriate, as part of a comprehensive prevention package based on c
Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. We.A.100)
Godard CM, Serries H, Chermann JC; INSERM Unite 322, Unite de Recherches sur les Retrovirus et Maladies Associees, Marseille, France. Fax: (33) 91 41 92 50.
Objective: To elucidate the cellular interactions which take place between blood-derived macrophages (BDM) infected with an HIV1-macrophage tropic variant and CD4+ T cells. Methods: BDM cultured in the presence of GM-CSF were infected with a macrophage-tropic strain isolated from the cerebrospinal fluid of an HIV1-infe
Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. We.A.101)
Boudet F, Lecoeur H, Roue R, Gougeon ML; Unite d'Oncologie Virale, AIDS & Retroviruses Dpt, Institut Pasteur, Paris, France. Fax: 33145688909.
Objective: To investigate the genetic and molecular mechanisms involved in the enhanced susceptibility to undergo in vitro apoptosis of CD8 peripheral T lymphocytes from HIV-1-infected persons. Methods: We analyzed the ex vivo expression of the Fas molecule and the intracellular Bcl-2 protein in CD8 T cell subpopulatio
Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. We.A.102)
Kottilil S, Bowmer MI, Campbell C, Grant M; Immunology, Health Sciences Centre, St. John's, NF, Canada. Fax: 709-737-5127.
Objective: Abnormally high numbers of T cells from HIV-infected individuals spontaneously undergo apoptosis. Stimulation with mitogens, superantigens or immobilized anti-CD3 or anti-Fas santibodies further increases this number. Cytotoxic T cells (CTL) from HIV-infected individuals can also kill activated lymphocytes f
Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. We.A.104)
Algeciras A, Badley AD, Lynch DH, Paya CV; Mayo Clinic, Rochester, MN. Fax: 507-284-3757.
CD4 T lymphocyte depletion in HIV-infected individuals is associated with increased apoptosis of this lymphocyte subpopulation. Apoptosis of activated CD4 T cells is secondary to the interaction of Fas ligand (FasL) with Fas. Recent data indicates that CD4+ T cells from HIV-infected individuals are more susceptible to
Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. We.A.105)
Gilardini M, Piazza C, Cundari E, Moretti S, Tuosto L, Acuto O, Piccolella E; Dept. of Cellular and Developmental Biology, University of Rome "La Sapienza", Rome, Italy. Fax: (39-6) 499-17594.
It is well established that a temporal or absolute imbalance of signals delivered via T cell antigen receptor (TcR) and the CD4 co-receptor can lead to anergy and/or apoptosis. It has also been reported that the interaction of the accessory molecule CD2 with its ligand LFA-3, is able to provide signals that protect T c
Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. We.A.140)
Agy MB, Schmidt A, Florey M, Kennedy B, Schaffer G, Rodregues H, Katze MG, Corey L, Morton WR, Bosch ML; University of Washington, Seattle, WA, USA. E-mail: magy@u.washington.edu.
Objective: To examine virological parameters of HIV-1 infection during serial in vivo passage in M. nemestrina. Methods: Twelve pig-tailed macaques were divided into four groups. The pair of macaques in group 1 were inoculated with HIV-1LAI or HIV-1NL4-3. Group 2 contained two macaque pairs each of which received 10 ml
Int Conf AIDS 1996 Jul 7-12; 11:5 (abstract no. We.A.141)
Amedee AM, Lacour N, Bakeer M, Simpson L, Martin L, Bohm R, Murphey-Corb M; Tulane Regional Primate Center, Covington, LA, USA. Fax: (504) 898-0329. E-mail: angela@tmc.tulane.edu.
Objective: To determine whether the dramatic differences in survival observed in macaques infected with SIV is linked to selective infection of genotypes found within the viral quasispecies. Methods: The proviral content of peripheral blood mononuclear cells during the course of infection in animals undergoing variable
Int Conf AIDS 1996 Jul 7-12; 11:5 (abstract no. We.A.142)
Thompson J, Hu SL, Kuller L, Travis B, Morton WR, Agy MB; University of Washington, Seattle, WA, USA.
Objective: To determine the macaque infectious dose (MID) of SHIVIIIB in pig-tailed macaques, Macaca nemestrina, in preparation for challenging animals previously immunized with an envelope based candidate HIV-1 vaccines. Methods: SHIVIIIB used in this study was prepared and characterized by Virus Research Institute an
Int Conf AIDS 1996 Jul 7-12; 11:5 (abstract no. We.A.143)
Kuller L, Thompson J, Morton WR, Agy MB; University of Washington, Seattle, WA, USA.
Objective: To examine the early kinetics of anti-SIV antibody production in plasma and mucosa-lined compartments after transmucosal SIV infection in Macaca nemestrina. Methods: As a component of a larger study of five male-female juvenile pairs of M. nemestrina intrarectally infected by uncloned SIVMne, plasma and muco
Int Conf AIDS 1996 Jul 7-12; 11:5 (abstract no. We.A.144)
Bosch ML, Schmidt A, Agy M, Florey MJ, Anderson D, Numankadic S, Herz A, Robertson M, Morton W; Wash. Reg. Primate Res. Center, University of Washington, Seattle, WA, USA. Fax: +1 (206) 685 0305. E-mail: ASCHMIDT@bart.rprc.washington.edu.
Objective: To establish infection with HIV-1 in neonatal macaques, with the purpose to create a monkey model in which HIV-1 viral pathogenesis can be studied directly. Methods: We have infected pigtailed macaques with HIV-1 at birth. Four animals were infected orally (2 ml of tissue culture supernatant containing HIV-1
Int Conf AIDS 1996 Jul 7-12; 11:5 (abstract no. We.A.145)
Guillemin G, Boussin FD, Croitoru J, Le Grand R, Dormont D; CE-FAR, DSV/DRM/SNV, Fontenay aux Roses, France. Fax: (33 1) 46 54 77 26.
Objectives: To investigate the role of astroglial cells in the neuropathogenic processes of AIDS. Methods: Astrocyte cultures were obtained from the brain of 26 macaques (12 rhesus and 14 cynomolgus) sacrified at an average of 1 year after their infection by SIVmac251. None of these animals exhibited neurological sympt
Int Conf AIDS 1996 Jul 7-12; 11:5 (abstract no. We.A.151)
Hallenberger S, Moulard M, Sordel M, Klenk HD, Garten W; Philipps-University Marburg, Institute of Virology, Marburg, Germany.
The envelope proteins of human immunodeficiency virus type-1 and type-2 (HIV-1, HIV-2) mediate binding to the cellular receptor and subsequent fusion of the viral envelope with the cellular membrane. Proteolytic activation of the envelope proteins which is catalyzed by host cell enzymes is crucial for their ability to
Int Conf AIDS 1996 Jul 7-12; 11:6 (abstract no. We.A.152)
Tritch RJ, Corman JI, Erickson-Viitanen S; The DuPont Merck Pharmaceutical Co., Wilmington, DE, USA.
Introduction: The virally encoded protease of HIV is required for proper processing of the GAG polyprotein of the virus, to produce the four large (p17, Matrix, p24, Capsid, p7 Nucleocapsid, and p6) and two small (p2, p1) polypeptides that are essential for the mature virion architecture conferring infectivity. Both th
Int Conf AIDS 1996 Jul 7-12; 11:6 (abstract no. We.A.153)
Paulus CR, Beibetainger M, Wolf H, Wagner R; Institut fur Medizinische Mikrobiologie und Hygiene, Regensburg, Germany. Fax: +49 941 944 6402.
Objective: The frameshift protein p6* encoded directly upstream of the protease (PR) in the HIV-1 pol reading frame is supposed to play a role in the intracellular regulation of PR activity. This limitation of cytoplasmic protease activation is necessary to prevent premature processing of Gag and Gag-Pol precursors and
Objective: To analyze the influence of proper folding of Pr55gag on HIV- assembly and infectivity. Methods: Proline residues are assumed to play a key role in determining the structure of the polypeptide backbone. In the N-terminal region of p24 we substituted residues P133; P149; P166; P170; P217; P222; P225; P231 for
Int Conf AIDS 1996 Jul 7-12; 11:6 (abstract no. We.A.155)
Decroly E, Ruysschaert JM, Seidah NG; IRCM, Montreal, Canada.
Objective: Intracellular proteolytic processing of Human Immunodeficiency Virus (HIV) envelope glycoprotein precursor (gp160) into gp120 and gp41 is an essential step for virus infectivity and fusion process. Cellular proteolytic maturation requires highly conserved basic amino acid sequences also identified in the mat
Int Conf AIDS 1996 Jul 7-12; 11:6 (abstract no. We.A.156)
Martin I, Schaal H, Scheid A, Ruysschaert JM; U.L.B., LCPMI, Brussels, Belgium.
Objective: To analyze the role of the HIV-1 gp41 N-terminal domain in the viral fusogenic activity. Methods: IR spectroscopy Results: The amino-terminal extremity of the HIV-1 transmembrane protein (gp41) is thought to play a pivotal role in the fusion of virus membranes with the plasma membrane of the target cell and
Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. We.A.160)
Grandadamm, Dupin N, Calvez V, Gorin I, Blum L, Kernbaum S, Sicard D, Buisson Y, Aguth, Jescande JP, Huraux JM; Hopital Tarnier-Cochin, Paris, France. Fax: 33 1 42 34 19 68.
Multicentric Castelman s Disease (MCD) is an atypical lymphoproliferative disorder which has been reported in close association with Kaposi s sarcoma (KS) both in HIV seropositive and seronegative patients. In some cases, MCD is a persistent disease with periodic exacerbations requiring a treatment such as chemotherapy
Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. We.A.161)
Bennett J, Strand K, Schultz E, Bosch M, Tsai CC, Schaefer G, Rose TM; Dept. Pathobiology, University of Washington, Seattle, WA. E-mail: trose@u.washington.edu.
Objectives: To identify and characterize potential therapeutic, diagnostic and vaccine targets for Kaposi s sarcoma and other AIDS-related malignancies. Methods: DNA was isolated from Kaposi s sarcoma (KS) lesions of patients with AIDS and retroperitoneal fibromatosis (RF) lesions of Macaca nemistrina with simian AIDS
Objective: To assess the appearance of Kaposi s sarcoma (KS)-like spindle cells in peripheral blood from KS patients and to characterize them for hystochemical markers, cytokine profile and presence of HHV8/KSHV DNA sequences. Methods: Peripheral blood mononuclear cells (PBMC) were isolated on a Ficoll-Hypaque gradient
Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. We.A.163)
Li JJ, Friedman-Kien AE, Huang YQ, Zhang WG, Feiner D; NYU Medical Center, Department of Microbiology, New York, NY, USA. Fax: 212-263-7933.
Objective: To determine the subsets of peripheral blood cells (PBMC) infected by HHV-8 in patients with Kaposi s sarcoma (KS). Methods: Twenty-five blood samples were collected from patients with Classic KS (4), AIDS-KS (14), HIV+ without KS (4) and HIV- healthy controls (3). Subsets of PBMC cells, including CD3, CD14,
Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. We.A.164)
Klaskala W, Sosa C, Benetucci J, Wood C, Baum MK; U of Miami, Dpt. Epidemiology & Public Health, Miami, FL.
Objective: To determine whether human herpes virus 8 (HHV-8) sequences are present in AIDS patients diagnosed with Kaposi s sarcoma (KS) in Argentina . Methods: Biopsy samples were collected from four HIV+ homosexual men diagnosed with cutaneous KS. PCR was performed to amplify a 233-bp from the KS - 330 Bam fragment s
Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. We.A.165)
Briz M, Martin T, Yebra M, Laguna P, Busto MJ, Pastor C, Fernandez MN; Medicina Interna Iii Hospital Puerta De Hierro, Madrid, Spain.
Background: Herpesvirus-like DNA sequences have recently been found in lesions from patients with Kaposi s sarcoma (KS) in its several forms (classical, AIDS-associated and that affecting HIV-negative homosexual men), suggesting that this tumor may be caused by a new herpesvirus, referred to as Kaposi s sarcoma-associa
Int Conf AIDS 1996 Jul 7-12; 11:8 (abstract no. We.A.166)
Huang YO, Li JJ, Feiner D, Zhang WG, Cockerell CJ, Demopoulos RI, Friedman-Kien AE; NYU Medical Center, Department of Microbiology, New York, NY, USA. Fax: 212-263-7933.
Objective: To study the distribution in different organs of HHV-8 in AIDS-KS patients. Methods: Autopsy specimens of various organs from 5 AIDS-KS patients and 6 AIDS patients without KS were collected. DNA were extracted from paraffin sections. PCR was performed in solution containing TAQ, TAQ buffer, dNTP and primer
Int Conf AIDS 1996 Jul 7-12; 11:8 (abstract no. We.A.167)
Friedman-Kien AE, Li JJ, Jensen P, Huang YQ; NYU Medical Center, Department of Microbiology, New York, NY, USA. Fax: 212-263-7933. E-mail: FRIEDA02@pop.mail.med.nyu.edu.
Objective: To determine whether HHV-8 could be detected in KS lesions found in organ transplant recipients and other patients on immunosuppressive therapy. Methods: 14 tumor specimens were obtained from various patients with KS. Among them were 1 renal transplant recipient; 2 with rheumatoid arthritis who were on long
Int Conf AIDS 1996 Jul 7-12; 11:8 (abstract no. We.A.260)
Badley AD, Dockrell D, Holtz-Heppelmann CJ, Simpson M, Lynch D, Paya CV; Mayo Clinic, Rochester, MN. Fax: 507-284-3757.
Objective: Although the mechanisms leading to CD4 depletion in HIV-infected individuals remain undefined, recent evidence suggests that HIV-infected accessory cells (such as macrophages) may be a source of ligands capable of inducing apoptosis in primed CD4 lymphocytes from HIV seropositive individuals. We therefore ha
Int Conf AIDS 1996 Jul 7-12; 11:8 (abstract no. We.A.261)
Kolesnitchenko V, King L, Korsmeyer SJ, Cohen DI; LTCB, NCI, NIH, Bethesda, MD, USA. Fax: 301-496-8394. E-mail: vk5q@nih.gov.
Objective: To better understand the HIV-initiated cell death process, we have studied T cell lines transfected to stably overexpress the bcl-2 oncoprotein, which functions to inhibit multiple forms of PCD. Methods: Bcl-2 overexpression was engineered into Jurkat CD4+ T-cell lines and Jurkat HIVenv (Jurkat T-cell lines
Int Conf AIDS 1996 Jul 7-12; 11:8 (abstract no. We.A.262)
Korn-Muller AC, Nitschko H, Gelderblom H, von der Helm K; Max von Pettenkofer-Institute, University of Munich, Munich, Germany. Fax: 0049-89-5380584.
Objective: To investigate the ability of non-matured, non-infectious virus particles to adhere to permissive T lymphocytes and their efficacy to induce syncytia formation, cell death and apoptosis. Methods: Non-infectious HIV-1 particles were obtained from cell culture supernatant of chronically infected cells that wer
Int Conf AIDS 1996 Jul 7-12; 11:9 (abstract no. We.A.263)
Wolthers KC, Otto SA, Meyaard L, Miedema F; Dept. of Clinical Viro-Immunology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Exp. & Clin. Immunology of the University of Amsterdam, Amsterdam, The Netherlands, Holland. Fax: 31-20-5123310.
Objective: In HIV infection, CD4+ T cell turnover is thought to be as high as 1.8 x 109 per day and it is assumed that during progression, the balance between destruction and renewal of CD4+ T cells is disturbed. Renewal of CD4+ T cells might be a limiting factor, leading to progressive immune deficiency. As a possible
Int Conf AIDS 1996 Jul 7-12; 11:9 (abstract no. We.A.264)
Clark DR, Hallett CA, Ahmad N, Ampel NM, DeLuca D; AHSC-LSN 601, Tucson, AZ. Fax: 520-626-2100.
Objective: Infection with the human immunodeficiency virus is characterized by depletion of CD4+ T cells. In the past, it has been difficult to determine the effects of HIV infection on the development of the T-cell lineage. We have examined the ability of human peripheral blood from HIV-infected patients to regenerate
Int Conf AIDS 1996 Jul 7-12; 11:9 (abstract no. We.A.265)
Mosier DE, Glynn JM, Ling Y, Gulizia R, Atencio I, McKinney D, McElligott DL; The Scripps Research Institute, La Jolla, CA, USA. Fax: 619 554-6627. E-mail: dmosier@scripps.edu.
Objectives: To determine the contribution and mechanism of apoptosis in acute HIV-1 infection in vitro and in hu-PBL-SCID mice. Methods: CD4-positive human T cell lines or primary cells were infected in vitro with HIV-1. Alternatively, hu-PBL-SCID mice were infected with wild type or nef-deleted HIV-1 isolates (supplie
Int Conf AIDS 1996 Jul 7-12; 11:9 (abstract no. We.A.270)
Cohen EA, Nie Z, Mercier J, Bergeron D, Pignac-Kobinger G; Departement de microbiologie et immunologie Universite de Montreal, Montreal, Quebec. Fax: (514) 343-5995. E-mail: cohenea@ere.umontreal.ca.
Objective: Virion-targeted viral inactivation represents a novel approach to interfere with viral replication. In this strategy, a deleterious amino acid (a.a.) sequence is fused to a virion-associated component to prevent production of infectious viral particles and subsequent spread of de novo infection. The HIV-1 Vp
Int Conf AIDS 1996 Jul 7-12; 11:9 (abstract no. We.A.271)
Bauer G, Wen SF, Bahner I, Kearns K, Zaia J, Kohn DB; Childrens Hospital of Los Angeles, Los Angeles, CA, USA. Fax: (213) 660 1904. E-mail: gbauer@hsc.usc.edu.
Objective: To establish the feasibility of gene therapy for AIDS in individuals already infected with HIV-1. Methods: Long term bone marrow cultures established from CD34+ cells isolated from cord blood or bone marrow of HIV-1 negative donors transduced with several retroviral vectors containing anti HIV-1 genes strong
Int Conf AIDS 1996 Jul 7-12; 11:10 (abstract no. We.A.272)
Johnson RP, Rosenzweig M, Marks DF, Heusch M, Wong-Staal F; New England Regional Primate Research Center, Harvard Medical School, Southborough, MA, USA. Fax: 508-624-8172. E-mail: pjohnson@warren.med.harvard.edu.
Objective: To evaluate the ability of a SIV-specific ribozyme to inhibit viral replication in T cells and macrophages derived from transduced CD34+ hematopoietic cells. Methods: Rhesus CD34+ bone marrow cells were transduced with retroviral vectors containing either a hairpin ribozyme (Rz9456) that cleaves a conserved
Int Conf AIDS 1996 Jul 7-12; 11:10 (abstract no. We.A.273)
Sun LQ, Gerlach W, Symonds G; RW Johnson Pharmaceutical Research Institute, Sydney, Australia. Fax: 61-2-360 9812. E-mail: sun@angis.su.oz.au.
Objective: To develop an ribozyme-based gene therapy strategy for inhibition of HIV-1 replication in human hemopoietic lymphocytes. Methods: Hammerhead ribozymes targeted to the HIV-1 y packaging site and regions of the tat gene were designed and synthesised. The ribozymes were engineered into expression constructs and
Int Conf AIDS 1996 Jul 7-12; 11:10 (abstract no. We.A.274)
Robinson DR, Chang LJ; Heritage Medical Research Centre, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta. Fax: (403) 492-9828. E-mail: derobins@gpu.srv.ualberta.ca.
Objective: To determine the anti-HIV efficacy of an improved retroviral gene therapy vector that contains a Tat-inducible LTR and a conserved HIV packaging signal. Methods: To improve the retroviral vector for HIV gene therapy, two elements were added. The promoter was modified to respond to Tat by cloning the TAR elem
Objective: The synthesis of the viral enzymes of the human immunodeficiency virus (HIV-1) requires a -1 ribosomal frameshift, when ribosomes of infected cells translate the viral messenger. Our goal is to interfere with this frameshift, so as to inhibit viral assembly and proliferation. Methods: The ribosomal RNA (rRNA
Int Conf AIDS 1996 Jul 7-12; 11:10 (abstract no. We.A.280)
van der Ryst E, Fultz PN, Tartaglia J, Barre-Sinoussi F, Paoletti E, Nara P, Meignier B, Blondeau C, Muchmore E, Girard M; Unite de Virologie Moleculaire, Institut Pasteur, Paris, France. Fax: 33-1-40613045. E-mail: elna@pasteur.fr.
Objective: To determine whether chimpanzees could be protected from infection with cell-associated HIV-1 by immunization with a live recombinant HIV-1 canarypox virus. Methods: Two adult male chimpanzees were immunized at months 0, 1, 5, 9 and 11 with 4x108 plaque-forming units of ALVAC HIV-1 vCP250, a recombinant cana
Int Conf AIDS 1996 Jul 7-12; 11:11 (abstract no. We.A.281)
Lekutis C, Shiver JW, Liu MA, Letvin NL; Beth Israel Hospital, Boston, MA, USA. Fax: (617) 667-8210. E-mail: clekutis@bih.harvard.edu.
Objectives: To determine the breadth of the immune response elicited by HIV-1env DNA vaccination in a nonhuman primate animal model. Methods: Two rhesus monkeys were immunized intramuscularly with an HIV-1 gp120 coding plasmid DNA in saline. CD4+ helper T cell lines were generated from peripheral blood mononuclear cell
Int Conf AIDS 1996 Jul 7-12; 11:11 (abstract no. We.A.282)
Murphey-Corb M, Clements J, Amedee AM, Lacour N; Tulane Regional Primate Center, Covington, LA, USA. Fax: (504) 898-0329. E-mail: mickey@tmc.tulane.edu.
Objective: To understand how conservative changes created as a result of replication of an attenuated live virus vaccine permit evasion of immune responses which protect against a more genetically diverse virus strain. Methods: We have previously shown that the macrophage-tropic clone, SIV/17E-Cl, serves as an excellen
Int Conf AIDS 1996 Jul 7-12; 11:11 (abstract no. We.A.283)
Biberfeld G, Makitalo B, Putkonen P, Bottiger D, Rud E, Thorstensson R; Swedish Institute Of Infectious Disease Control, Stockholm, Sweden. Fax: 46-87354136.
Objective: To study protective immunity in macaques preexposed to subinfectious doses of SIVsm or HIV-2. Methods: Three cynomolgus monkeys were exposed intrarectally (i.r.) to subinfectious doses of SIVsm and challenged 10 months later with 10MID50 of SIVsm i.r. Four monkeys resistant to repeated i.v. HIV-2 inoculation
Int Conf AIDS 1996 Jul 7-12; 11:11 (abstract no. We.A.284)
Wakrim L, Le Grand R, Vaslin B, Cheret A, Matheux F, Theodoro F, Roques P, Nicol-Jourdain I, Dormont D; Service de Neurovirologie, Commissariat a l'Energie Atomique, DRM, DSV, SSA, Fontenay-aux-Roses, France. Fax: (33-1) 46 54 77 26.
Objectives: To test the potential vaccine effect of a weakly pathogenic HIV-2 isolate against the superinfection after an intrarectal inoculation with a pathogenic SIVmac251 isolate. Method: We intrarectally challenged six HIV-2-preinfected rhesus macaques with 10 AID50 of a pathogenic isolate of SIVmac251. These monke
Int Conf AIDS 1996 Jul 7-12; 11:11 (abstract no. We.A.285)
Caufour P, Neildez O, Dilda P, Cheret A, Le Grand R, Matheux F, Theodoro F, Vaslin B, Cranage M, Dormont D; Commissariat a l'Energie Atomique, Service de Neurovirologie, DSV/DRM/SSA, BP6, Fontenay aux Roses, France. Fax: 1-46-54-77-26.
Objective: 1) to confirm the absence of pathogenicity of a nef-deleted molecular clone (pC8) of SIVmac251 in cynomolgus macaques, 2) to assess the ability of C8 clone to protect from a vaginal challenge with a monkey-PBMC grown pathogenic isolate of SIVmac251. Methods: Four adult cynomolgus females, were inoculated IV
Objectives: Patients undergoing acute HIV infection often exhibit transient, high-level TCR Vb-specific expansions of CD8+ T cells. These expanded T cell subsets mediate HIV-specific cytotoxicity, and are believed to be part of the initial immune response to HIV infection. Molecular and cellular analysis were performed
Int Conf AIDS 1996 Jul 7-12; 11:12 (abstract no. We.A.381)
Pantaleo G, Soudeyns H, Demarest, Schacker T, Vaccarezza, Cohen OJ, Daucher M, Graziosi C, Schnittman SS, Quinn T, Shaw GM, Perrin L, Tambussi G, Lazzarin A, Sekaly RP, Corey L, Fauci AS; NIAID, National Institute of Health, Bethesda, MD, USA. Fax: 301-402-0070.
Downregulation of the initial burst of viremia during primary human immunodeficiency virus (HIV) infection is thought to be mediated predominantly by HIV-specific cytotoxic T lymphocytes (CTL), and the appearance of this response is associated with major perturbations of the T cell receptor (TCR) repertoire. Changes in
Int Conf AIDS 1996 Jul 7-12; 11:12 (abstract no. We.A.382)
Musey LK, Hu YX, Schacker T, Hughes J, Corey L, McElrath MJ; University of Washington, School of Medicine, Seattle, WA. Fax: 1-206-4178. E-mail: luwy@u.washington.edu.
Objectives: To identify the patterns of cellular immune responses in peripheral blood and lymph nodes during the early phases of HIV-1 infection and to correlate these responses in a large patient cohort with changes in CD4 count, viral load, and clinical disease. Methods: Thirty-nine patients with documented recent HI
Int Conf AIDS 1996 Jul 7-12; 11:12 (abstract no. We.A.383)
Murthy KK, Conley AJ, Schleif W, Cobb EK, Lunceford SM, Galvan A, Rouse SR, Johnson D, Emini E; Southwest Foundation for Biomedical Research, San Antonio, TX. Fax: (210) 670-3330. E-mail: kmurthy@icarus.sfbr.org.
Objective: To determine the pathogenesis of primary isolates of HIV-1 in chimpanzees. Methods: Two primary isolates of HIV-1 designated as DH12 and 5016, grown in PBMC cultures were intravenously inoculated into chimpanzees (n = 2; for each isolate). Results: Infection with DH12 isolate was characterized by plasma vire
Int Conf AIDS 1996 Jul 7-12; 11:12 (abstract no. We.A.384)
Cheret A, Le Grand R, Caufour P, Dereuddre-Bosquet N, Matheux F, Neildez O, Maestrali N, Theodoro F, Benveniste O, Vaslin B, Dormont D; CEA/DSV/DRM/SNV, Fontenay aux Roses, France. Fax: (33)-1- 46 54 77 26.
Objective: Our aim was to investigate the expression of mRNA monokines (IL-6; TNF-alpha; IL-1beta; IL-10) and IFN-gamma during the acute phase of the infection of cynomolgus macaques inoculated intravenously with a pathogenic isolate of SIVmac251. The quantification of mRNA was performed concomitantly in unmanipulated
Int Conf AIDS 1996 Jul 7-12; 11:13 (abstract no. We.A.385)
Chakrabarti L, Khatissian E, Tovey M, Cumont MC, Monceaux V, Montagnier L, Bruno Hurtrel B; Unite d'Oncologie Virale, Paris, France. Fax: (1) 40 61 34 65. E-mail: chakra@pasteur.fr.
Objective: To investigate the role of interferons in the containment of viral burden seen in primary SIV infection. Methods: IFN-alpha and IFN-gamma productions were evaluated in lymphoid organs of 8 rhesus macaques inoculated with SIVmac 251. For each animal, 4 lymph nodes obtained sequentially between day 7 and day 6
Int Conf AIDS 1996 Jul 7-12; 11:13 (abstract no. We.A.390)
Mitchell WM, Ding L, Baird C; Department of Pathology, Vanderbilt University, Nashville, TN, USA. Fax: 615 343-7023.
Objective: To demonstrate the utility of the calcium mobilizing steroid hormone and immunomodulator, 1alpha, 25-Dihydroxycholecalciferol [1,25(OH)2D3], in the establishment of mucosal as well as systemic humoral immune responses induced by the facilitated transfection of skeletal muscle with a DNA HIV envelope immunoge
Int Conf AIDS 1996 Jul 7-12; 11:13 (abstract no. We.A.391)
VanCott TC, Kaminski R, Lewis M, Mascola J, Wassef N, Alving C, Ulrich T, Richardson C, Lowell G, Burnett P, VanHamont J, Hallberg P, Lu Y, Amselem S, Burke D, McNeil J, Birx D; Henry M Jackson Foundation, Rockville, MD, USA. Fax: 301-762-4177. E-mail: tvancott@hiv.hjf.org.
Objectives: Study the immunogenicity of an oligomeric gp160 (o-gp160) protein administered parenterally to Rhesus Macaques, rabbits and mice and mucosally to mice. Assess the immunogenicity of vaccine formulations with respect to their efficiency in eliciting systemic and mucosal antibodies (IgG, IgA) capable of bindin
Int Conf AIDS 1996 Jul 7-12; 11:13 (abstract no. We.A.392)
Neildez O, Le Grand R, Caufour P, Cheret A, Matheux F, Theodoro F, Vaslin B, Dormont D; Service de Neurovirologie, Commissariat a l'Energie Atomique, DRM, DSV, SSA, Fontenay-aux-Roses, France. Fax: (33-1) 46 54 77 26.
Objective: To characterize the evolution of virological and immunological parameters after experimental vaginal atraumatic exposure of macaques to an SIVmac 251 cell free virus stock. Methods: Three groups of four cynomolgus macaques, previously traited by oestradiol, were inoculated atraumatically into the vagina with
Int Conf AIDS 1996 Jul 7-12; 11:13 (abstract no. We.A.393)
Girard M, Barre-Sinoussi F, Tartaglia J, van der Ryst E, Paoletti E, Nara P, Meignier B, Blondeau C, Pillot J, Mahoney J, Fultz PN; Unite de Virologie Moleculaire, Institut Pasteur, Paris, France. Fax: 33 1 40 61 30 45. E-mail: Elna@pasteur.Fr.
Objective: To determine whether female chimpanzees could be protected from genital infection with HIV-1 after parenteral and/or mucosal immunization with a recombinant HIV-1 canarypox virus and to compare the oro-nasal and recto-vaginal immunization routes. Methods: Five adult female chimpanzees were immunized at 0, 2,
Objectives: To develop and standardize sampling methods and HIV-1 antibody measurements at mucosal sites in HIV-1 infected and non-infected subjects in order - to determine cut-offs and magnitude of the immune response. Subjects: 17 HIV-1 positive CDC II/III (mean CD4 cell count: 536 plus or minus 198/mm3) and 19 HIV-n
Int Conf AIDS 1996 Jul 7-12; 11:14 (abstract no. We.A.395)
Couedel-Courteille A, Butor C, Guillet JG, Venet A; INSERM, ICGM, Paris, France.
Objectives: In order to study the evolution of the different parameters of the early cellular mucosal immune response in SIV rectally-infected macaques, we have first analysed the digestive mucosal immune system of healthy uninfected macaques. Methods: Healthy and SIV rectally-infected macaques (pathogenic isolate SIVm
Int Conf AIDS 1996 Jul 7-12; 11:14 (abstract no. We.A.400)
Grant RM, Kaur A, Johnson RP, McClure H, Staprans S, Feinberg MB; Office of AIDS Research, NIH, Bethesda, MD. Fax: 301-496-4843. E-mail: mark_feinberg@nih.gov.
To investigate the basis for asymptomatic SIV infection in naturally-infected sooty mangabeys (SMMs) quantitative-competitive PCR (QC-PCR) (to measure viral load) and heteroduplex mobility shift (HMA) assays were developed for SIVsmm and the SIVsmm-related virus SIVmac that induces AIDS in rhesus macaques. Interestingl
Int Conf AIDS 1996 Jul 7-12; 11:14 (abstract no. We.A.401)
Cheng-Mayer C, Luciw PA; Aaron Diamond AIDS Research Center, New York, NY.
Objective: To elucidate functions of HIV-1 genes in a non-human primate model, we have constructed infectious recombinant viruses (chimeras) between the pathogenic molecular clone SIVmac239 and molecular clones of HIV-1 that differ in phenotypic properties controlled by the env gene. Methods: HIV-1SF33 is a T-cell line
Int Conf AIDS 1996 Jul 7-12; 11:14 (abstract no. We.A.402)
Hufert FT, Bertram S, van Lunzen J, Schmitz J, Haller O, Racz P, von Laer D; Abt. Virologie, Institut fur Medizinische Mikrobiologie und Hygiene, Universitat Freiburg, Freiburg, Germany. Fax: +49-761-2036603. E-mail: hufert@sun1.ukl.uni-freiburg.de.
Objective: CD4+ T cells are the main target for the human immunodeficiency virus (HIV). However, the highest HIV antigen concentration in infected subjects accumulates on the cell surface of follicular dendritic cells in the germinal centers of the lymphoid tissue. Germinal centers contain a T helper cell subset which
Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. We.A.403)
Miedema F, Kersten MJ, Klein MR, Holwerda AM, Van Oers MH; Dept. of Clin. Viro-Immunology, Central Lab. Netherlands Red Cross Blood Transfusion Service and Lab. for Exp. and Clin. Immunol. of the University of Amsterdam, Amsterdam, The Netherlands. Fax: +31 20 512 3310.
Objective: The vast majority of AIDS-NHL are diffuse large-cell and immunoblastic lymphomas, thought to arise because of uncontrolled EBV-driven proliferation of B cells. EBV-specific CD8+ MHC class I-restricted cytotoxic T lymphocytes (CTL) are known to play a key role in EBV-specific immunity in healthy individuals.
Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. We.A.404)
Margolick JB, Rinaldo CR, Gupta P, Farzadegan H, Mullins JI; Dept. Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, MD, USA. Fax: (410) 955-0105. E-mail: joe@statepi.shp.jhu.edu.
Objective: To determine when changes in HIV (load and quasispecies diversity) and host immune system (T cell subsets, HIV-specific cytotoxic T lymphocyte (CTL) level) occur in relation to abrupt increases in the rate of decline of CD3+ (T) lymphocytes and CD4+ lymphocytes, termed inflection points (IP), in HIV-infected
Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. We.A.405)
Levine BL, Mosca J, Riley J, Carroll R, Vahey M, Jagodzinski L, Wagner K, Mayers D, Burke D, Weislow O, St Louis D, June C; NMRI, Tissue Bank, Bethesda, MD. Fax: 301-295-6857. E-mail: rin0bll@bumed30.med.navy.mil.
Human immunodeficiency virus type 1 (HIV-1) infection is associated with a progressive decline in CD4+ lymphocytes. Because stimulation of CD4+ lymphocytes leads to activation of HIV-1 replication, viral spread and cell death, adoptive CD4+ cell therapy has not been possible. We report here that CD28 receptor costimula
Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. We.A.500)
Levy JA, Blackbourn DJ, Barker E, Mackewicz C, Stranford S; Cancer Research Institute and Dept. of Medicine, University of California, San Francisco, CA, USA. Fax: 415-476-8365. E-mail: jalevy@itsa.ucsf.edu.
HIV undergoes genetic mutations in the infected host leading to the emergence of a variant virus with properties associated with virulence. These include an expanded host cell range, rapid kinetics of virus replication with high levels of virus production, and increased killing of CD4+ lymphocytes. Asymptomatic individ
Apoptotic T cell death has been suggested to contribute to the depletion of CD4+ T lymphocytes characteristic of progression to AIDS. However, both CD4+ and CD8+ T cell exhibit apoptotic death, either without stimulation or when stimulated via pan-T cell receptor signaling. Thus, both subsets appear to be activated to
Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. We.A.503)
Bentwich Z, Kalinkovich Z, Weisman Z, Grossman Z; Ruth Ben Ari Institute of Clinical Immunology, Kaplan Hospital, Rehovot, Israel. Fax: 972-8-941-0461.
Background: We have previously proposed that several of the manifestations of HIV infection reflect the chronicity of the infection rather than dysregulation of the immune system, unique to HIV. This proposition is based the tunable-activation threshold hypothesis (Grossman & Paul, PNAS, 89:10365, 1992), which impl
Int Conf AIDS 1996 Jul 7-12; 11:16 (abstract no. We.A.510)
Malamud D, Douglas A, Rest R; Biosyn, Phila., PA. Fax: 215-387-5332.
Objective: To extend our studies on the range of activities of a C31G-based microbicide to include isolates of Neisseria gonorrhoeae that are sialylated on the terminal galactose moiety of the gonococcal lipooligosaccharide and/or grown anaerobically, and thus mimic the in vivo situation. Methods: C31G is a broad-spect
Objective: To evaluate the antimicrobial activity of F-5 spermicidal gel (0.125% w/w of nonoxynol-9 and benzalkonium chloride, and 0.5% of sodium cholate), used in the new Protectaid contraceptive sponge, against Chlamydia trachomatis serotypes D, E, G, H,I, J and K, using a co-treatment assay. Methods: The C. trachoma
Int Conf AIDS 1996 Jul 7-12; 11:16 (abstract no. We.A.512)
Bergeron MG, Gagne N, Gourde P, Perron S, Tremblay M, Beauchamp D, Juhasz J, Desormeaux A; Centre de Recherche en Infectiologie, Centre Hospitalier de l'Universite Laval, Quebec, Canada. Fax: (418) 654-2715. E-mail: Michel.G.Bergeron@crchul.ulaval.ca.
Objective: To prevent the sexual transmission of HIV with the use of a microbicidal gel applied topically to the vaginal, cervical and/or ano-rectal mucosa. Methods: In vitro experiments have been performed to evaluate the cytotoxicity of the gel formulation in human cervical (ME-180) and colon epithelial (HT-29) cells
Int Conf AIDS 1996 Jul 7-12; 11:16 (abstract no. We.A.513)
Bourinbaiar AS, Fruhstorfer EC, Lopes R; Metatron, Inc., New York, NY, USA. Fax: 212-598-0074. E-mail: emballon@pipeline.com.
Objective: Currently available spermicides with anti-HIV activity, such as nonoxynol-9, are not effective. Since 80% of AIDS cases are sex-borne, better alternative substances are urgently needed. Methods: The serial ten-fold dilutions of gramicidin were tested in vitro for the suppression of HIV and Herpes simplex vir
Int Conf AIDS 1996 Jul 7-12; 11:16 (abstract no. We.A.520)
Wathen LK, Nuorala KW, Patel RK, DeYoung DP, Re' KA, Cromie MA, Crampton DJ, Krieger KS, Greenwald CA, Freimuth WW; Pharmacia & Upjohn, Inc., Kalamazoo, MI, USA. Fax: 616-385-7219.
Objective: To analytically and clinically validate a precise quantitative DNA PCR assay to evaluate the therapeutic responsiveness of the HIV-1 viral load in the lymphocyte compartment of infected patients. Methods: A quantitative HIV-1 cellular DNA assay was rigorously standardized. Standard material, control lymphocy
Int Conf AIDS 1996 Jul 7-12; 11:16 (abstract no. We.A.521)
Gomes P, Taveira N, Moniz-Pereira J, Santos-Ferreira MO, Lourenco MH; Dep. Microbiology, University of Lisbon, Lisbon, Portugal. Fax: 351.1.7934212.
Objective: Development of a quantitative competitive polymerase chain reaction (cPCR) with ELISA detection of amplified products to quantify HIV-2 proviral load. Methods: For the quantification of the HIV-2 proviral load we built an internal standard (pPG) which has almost the same size and the same primer recognition
Int Conf AIDS 1996 Jul 7-12; 11:17 (abstract no. We.A.522)
Bremer JW, Brambilla D, Reichelderfer P; Rush Medical College, Chicago, IL, USA. Fax: 312-942-6787.
Objective: To compare the results obtained from four algorithms that have been used to estimate HIV RNA copy number from the PCR based Roche Amplicor HIV Monitor assay. Methods: Twenty-one virology laboratories participating in the DAIDS Virology Quality Assurance Program used the Roche assay to estimate RNA concentrat
Int Conf AIDS 1996 Jul 7-12; 11:17 (abstract no. We.A.523)
Izopet J, Bargues G, Bocket-Mouton L, Brun-Vezinet F, Burgard M, Cottalorda J, Descamps D, Dussaix E, Krivine A, Fleury H, Pellegrin I, Poggi C, Profizi N, Rouzioux C, Seigneurin JM, Tamalet C, Puel J; Laboratoire de Virologie, CHU Purpan, Toulouse, France. Fax: (33) 61 77 25 42.
Objective: We recently assessed the intra-assay, inter-assay, and inter-lot reproducibilities of a standardized RT-PCR assay (Izopet et al., J. Virol. Methods, in press). This study used the same panel to assess the inter-laboratory reproducibility. Methods: A panel consisting of 10 coded plasma samples was obtained fr
Due to the apparent safety of live attenuated measles vaccine and the possibly devastating consequences of measles infection in people with HIV disease, measles vaccine has been part of routine immunization in HIV-infected children and recommended for HIV-infected adults when an indication arises. This is in con
Int Conf AIDS 1996 Jul 7-12; 11:17 (abstract no. We.B.111)
Fuller JD, Chernoff D, Steger K, Rossi V, Allen D, Barrus S, Cox N, Craven D; Adult Clinical AIDS Program, Boston University School of Medicine and Boston City Hospital, Boston, MA, USA. Fax: (617) 536-4128. E-mail: jfuller@bu.edu.
Objective: To measure HIV-1 plasma RNA (pRNA) levels following influenza vaccination. Methods: HIV-infected patients being offered annual influenza vaccination (trivalent, types A and B subvirion antigens, Wyeth-Ayerst Laboratories) were enrolled in a study to evaluate the effect of vaccination on pRNA. pRNA levels wer
Int Conf AIDS 1996 Jul 7-12; 11:17 (abstract no. We.B.112)
Ajana F, Senneville E, Valette M, Bourez JM, Chidiac C, Mouton Y; Service des Maladies Infectieuses, Tourcoing, France.
Objectives: 19 HIV-infected patients and presenting idiopathic thrombocytopenia were follow up on clinical and biological level. 9 patients were splenectomized after failure of Retrovir, steroids and IVIG. The other 10 patients refused splenectomy. Polysaccharide vaccine pneumo 23 was performed in the whole patients an
Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. We.B.113)
Nelson RP Jr, Ledford D, Vincent A, Zhou L, Bergen-Losee L, Lockey R; University of South Florida, Petersburg, FL. Fax: 813 892 8619. E-mail: rpnelson@coml.med.usf.edu.
Objective: To determine the effect of influenza immunization on plasma RNA levels in a cohort of HIV-infected adults. Methods: Quantitative plasma RNA levels were determined by RT-PCR (Roche Biomedical, Research Triangle Park, NC) at baseline and from 3-5 wk following immunization with the 1994 trivalent influenza vacc
Objective: To determine if HIV replication increases in peripheral blood of seropositive patients after Influenza vaccination. Methods: Tcells and HIV RNA levels were drawn prior to Influenza vaccination in 86 HIV patients (CD4 5 - 615, mean of x 186). Patients were immunized with a one (1) time dose of .5 cc IM of the
Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. We.B.115)
Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R; Dept of Infectious Diseases, University Hospital Leiden, Leiden, The Netherlands. Fax: -31-71-5266758.
Introduction: HIV-infected individuals have an increased susceptibility to Streptococcus pneumoniae infections. Therefore immunization with the 23-valent polysaccharide vaccine is recommended. This T-lymphocyte independent vaccine elicits an IgG antibody response against the combination of 23 polysaccharides in HIV-inf
Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. We.B.170)
French P, Steel S, Shepherd D; The Mortimer Market Centre, London, UK. Fax: 0171 380 9949.
Objective: To evaluate the shared care of patients with cytomegalovirus ( CMV ) retinitis attending a UK HIV centre. Methods: All 41 patients who were diagnosed with CMV during the study period (November 1993 - March 1995) were enroled into a programme of shared care with their local general practitioner (GP).
Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. We.B.171)
Reiter GS; Hospice LifeCare and River Valley HIV Clinic of Holyoke, Holyoke, MA, USA. Fax: (413) 534-6465.
Issues: Effective and compassionate hospice care for persons dying from AIDS requires a combination of traditional palliative and restorative treatments. Current hospice reimbursement is based primarily on the needs of patients with cancer; funds are sufficient for analgesics, nursing visits and durable medical goods.
Int Conf AIDS 1996 Jul 7-12; 11:19 (abstract no. We.B.172)
Milanese G, Cancelli A, Fenianos F, Sarrecchia C, Rocchi G; University Tor Vergata, Rome, Italy.
Objectives: To assess the type and the number of interventions which are necessary to meet People with AIDS (PwA) s needs and the possible correlation between the demographic and clinical variables and the required care, in order to plan assistance. Methods: A multidisciplinary service of Home Care (HC) for PwA was sta
Objectives: In France , the entire population theoretically benefits from health coverage, but in fact a fraction of the population does not have access to it. In 1992, for the first time in Paris, a medico-social consultation for destitute patients was incorporated into the outpatients clinic of a University hospital.
Int Conf AIDS 1996 Jul 7-12; 11:19 (abstract no. We.B.174)
Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH; University of Washington, Seattle, WA. Fax: (206)-720-4209. E-mail: kitahata@u.washington.edu.
Objective: To determine the utilization of services and costs of care for patients with AIDS cared for by generalist physicians with increasing levels of experience in AIDS management. To examine whether patterns of resource utilization among physicians with greater AIDS experience contribute to survival among their pa
Int Conf AIDS 1996 Jul 7-12; 11:19 (abstract no. We.B.175)
Agins BD, Jemiolo D, Simino P, Fox K, Kulpa B, Palumbo M, Rotunno F, Glaros R; NYS Department of Health AIDS Institute (NYSDOH/AIDS Institute), Albany, NY. Fax: 212 613-4996.
Objective: To evaluate the quality of care provided to persons with HIV in NYS, and compare clinical practice patterns among different demographic groups of patients receiving care in hospital clinics, community health centers and drug-treatment programs. Method: Data abstraction from medical records of 1,975 patients
Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. We.B.176)
Solomon L, Stein M, Flynn CP, Schoenbaum E, Moore J, Schuman P, Holmberg S, Graham NM; Johns Hopkins U., Baltimore, MD, USA. Fax: 410-955-1836.
Objective: To characterize health services utilization among urban women with, and at risk, for HIV-1 infection. Methods: 1293 women at risk for HIV-1 infection were recruited at four urban centers (Baltimore, The Bronx, Detroit, and Providence). At a baseline study visit the women received physical examinations, had s
Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. We.B.177)
Orofino GC, De Agostini M, Busso M, Bonasso M, Pellegrini W; H.C.S., Amedeo di Savoia Hospital of Turin, Torino, Italy. Fax: 039117761757.
Home Care Service (H.C.S.) for AIDS patients and evaluation of its development in the future. Project: In 1992 we established a H.C.S. of AIDS patients in our hospital of I.D. in Turin. The access to this service was only for patients living at home or in community in the city limits of Turin. Patients eligibili
Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. We.B.180)
Sharp M, Getty J, Chambers S, Sekeres G; Healing Alternatives Foundation, San Francisco, CA, USA. Fax: 415-626-0451. E-mail: haf@out.org.
Objective: To evaluate the usefulness of the tumor necrosis factor-alpha inhibitor thalidomide for weight gain in HIV-1 (+) clients buying the drug at a community based organization. Methods: Since August 15, 1995, 205 HIV-1 (+) clients were surveyed monthly by mail about demographics, medical history, current symptoms
Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. We.B.181)
Schambelan M, Mulligan K, Tai VW; San Francisco General Hospital, San Francisco, CA, USA. Fax: (415) 476-4918. E-mail: morrie@sfghgcrc.ucsf.edu.
Objective: To evaluate body composition in men with HIV -associated weight loss and changes in body composition over time in HIV+ men with and without wasting. Methods: Weight and body composition in 38 HIV+ men with documented weight loss greater than or equal to 10% (mean -11.5 plus or minus 0.5 kg) were compared wit
Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. We.B.182)
Smith DK, Graham NH, Flynn M, Greenberg B, Sowell A, Ing D, Vlahov D; CDC, Atlanta, GA, USA. Fax: 404-639-6118. E-mail: dkso@cidhivl.em.cdc.gov.
Objective: To evaluate the nutritional status of women in the HIV Epidemiology Research Study (HERS) and assess its correlation with behaviors and clinical outcomes. Methods: Women at three sites being followed prospectively with biannual visits were recruited to answer standardized vitamin intake questions and to dona
Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. We.B.183)
Strawford A, Neese R, Hoh R, Pelfini A, Turner S, Papageorgopoulos C, Faix D, Hellerstein M; Dept of Nutritional Sciences, University of California, Berkeley, CA. Fax: 510-642-0535. E-mail: march@nature.berkeley.edu.
Published data concerning metabolic alterations contributing to AWS have been contradictory. This may reflect differences among clinical populations (i.e. heterogeneity). We have compiled 6 yr of baseline metabolic/nutritional data in AWS prior to interventions (n= 170 men, 37 women). Weight (wt), body composition, die
Int Conf AIDS 1996 Jul 7-12; 11:21 (abstract no. We.B.184)
Clark RA, Bessinger R, Kissinger P, Thomas C; HIV Outpatient Program, Medical Center of Louisiana at New Orleans, New Orleans, LA. Fax: 504-568-5313.
Objective and Methods: Women have comprised less than 3% of subjects enrolled in clinical trials to evaluate the use of megace, a successful therapy for AIDS related wasting. To better understand the effectiveness of megace in women with HIV-related cachexia we undertook a retrospective review of 30 women enrolled into
Int Conf AIDS 1996 Jul 7-12; 11:21 (abstract no. We.B.185)
Avila-Figueroa C, Graham NM, Hughes MD, Willett WC, Saah AJ; Hospital Infantil de Mexico, Mexico. Fax: 761-8530.
Objective: To investigate the associations between nutrient intake and CD4 lymphocyte decline as well as the relations of specific dietary fatty acids to the occurrence of AIDS in HIV-infected men. Methods: A prospective cohort of 279 HIV-positive men 34 to 59 years of age, without AIDS or anti-retroviral treatment at
Int Conf AIDS 1996 Jul 7-12; 11:21 (abstract no. We.B.186)
Fulgaro C, Spinosa Guzman S, Dentale N, Colangeli V, Borderi M, Tumietto F, Chiodo F; Dpt of Clinical and Experimental Medicine, Division of Infectious Diseases, Bologna, Italy. Fax: +39-51-343500.
Objective: Evaluation of an escalating nutritional intervention using diet plus oral food supplements and appetite stimulation in patients with HIV infection. Subjects and methods: Our two step study included 46 HIV patients with an unintentional weight loss of 5-25% of their ideal body weight (I.B.W). Nutritional stat
Int Conf AIDS 1996 Jul 7-12; 11:21 (abstract no. We.B.191)
Anderson VM, Feldman F, Zevallos E, Bard E, Moroso G, Landesman G, Mendez H, Minkoff H, Gu J; SUNY Health Science Center Brooklyn (SUNYHSCB), Brooklyn, NY, USA.
Objective: To study how placental HIV infection mediates the effect of maternal CD4% and viral load on maternal fetal transmission, (MFT). Methods: In situ PCR on HIV exposed placentae detected latent HIV in trophoblasts, Hofbauer cells and fetal endothelium in 56% of 46 placentae. Findings were correlated with materna
Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. We.B.192)
Van Dyke RB, Amedee A, Sokol D, Holton D, Perrin M, Bienvenu S, McBride E, Murphey-Corb M; Tulane University School of Medicine, Pediatrics, New Orleans, LA, USA. Fax: 504-584-2613. E-mail: vandyke@tmc.tulane.edu.
Objective: To determine and compare the nucleotide sequence of the gp120 V3 loop of HIV DNA and RNA derived from HIV-infected mothers and their infected infants. Methods: Maternal and infant blood samples were collected, fractionated into mononuclear cells (PBMC) and plasma, and frozen at -70 C. A 102-nucleotide sequen
Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. We.B.193)
Panther L, Xu C, Tucker L, Tuomala RE, Anderson DJ; Brigham and Women's Hospital, Boston, MA, USA.
Objective: We evaluated HIV load and HIV envelope gene diversity in the genital tract of HIV-infected pregnant women in order to assess the relative importance of these two factors in the perinatal transmission of HIV. Methods: Longitudinal sets of cervicovaginal lavage (CVL) specimens collected in the peripartum perio
Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. We.B.194)
Kilani R, Winkler B, Chang LJ, Guilbert LJ; Dept Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada. Fax: (403) 492-0368.
To infect the fetus during pregnancy, HIV-1 must cross the placental trophoblast. Whether trophoblast can be infected is controversial. A major experimental problem involves the purity and differentiation state of cultured trophoblasts. We have therefore challenged highly purified (greater than 99.99%) populations of t
Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. We.B.195)
Mussi-Pinhata MM, Yamamoto AY, Cervi MC, Figueiredo LT, Duarte GD; Faculty of Medicine of Ribeirao Preto, Sao Paulo, Brazil. Fax: (016) 6330136 or (016) 6331144. E-mail: mmmpinha@fmrp.usp.br.
Objectives: To determine the rate of congenital cytomegalovirus ( CMV ) infection in infants born to HIV-infected (HIV+) mothers compared to newborns of non-HIV-infected mothers (HIV-), presuming that newborns of HIV-infected mothers might be more frequently affected by congenital CMV infection than the general populat
Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. We.B.196)
Taneepanichsakul S, Phuapradit W, Chaturachinda K; Dept. of OB & GYN, Ramathibodi Hospital, Bangkok, Thailand. Fax: 66-2-201-1416.
Objective: To survey the acceptability of Zidovudine treatment in pregnancy among Thai HIV-1 positive parturients. Method: 65 cases of HIV-1 positive parturients were interviewed during post-test counselling session about the acceptability of using Zidovudine in pregnancy to reduce vertical transmission. Results: 53 ca
Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. We.B.290)
Davey RT, Chaitt D, Kovacs J, Walker R, Polis M, Falloon J, Masur H, Metcalf J, Piscitelli S, Fyfe G, Lane HC; National Institutes of Health, Bethesda, MD, USA. Fax: 301-402-4097.
Objectives: Previous studies using 5-day infusions of continuous intravenous interleukin-2 (civ IL-2 ) every 8 weeks have established that this therapy is capable of inducing major sustained rises in CD4 counts in many HIV-infected recipients. However, a substantial limitation of civ IL-2 is that it is associated with
Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. We.B.291)
Pakker NG, Roos MT, Jong de M, Koot M, Leeuwen van R, Reiss P, Schellekens PT, Danner SA, Miedema F; Dept. of Clin. Viro-Immunol., Central Lab. Netherlands Red Cross Blood Transf. Service and Lab. Exp. & Clin. Immunol., Univ. of Amsterdam, Amsterdam, The Netherlands. Fax: + 31 20 512 3310. E-mail: a306clb1@horus.sara.nl.
Objective: To investigate increase of T cell counts in peripheral blood during antiviral therapy in relation to improvement of T cell proliferative capacity in patients treated with: protease inhibitor, non-nucleoside or nucleoside-analogue RT inhibitors. Methods: CD4+ and CD8+ T cell numbers and T cell reactivity to C
Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. We.B.292)
Carr A, Lloyd A, Emery S, Hoy J, Garsia R, Stewart G, French M, Fyfe G, Cooper DA; National Centre in HIV Epidemiology and Clinical Research (NCHECR), Sydney, NSW, Australia. Fax: (612) 332 1837.
Aim: To determine the safety and immunological effects of intermittent continuous intravenous infusion IL2 (CIV- IL2 plus AR) versus escalating doses of subcutaneous PEG-IL2 (SC PEG-IL2 plus AR) versus AR alone in asymptomatic HIV-infected patients with 200 - 500 CD4+ cells microliter-1 managed in an outpatient setting
Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. We.B.293)
MacGregor RR, Gluckman S, Lacy K, Kaniefski B, Boyer J, Wang B, Bagarazzi M, William WV, Francher D, Ginsberg R, Higgins T, Weiner D; University of PA, Division of Infectious Disease, Philadelphia, PA.
Objective: Determine the safety, viral, and immune effects of a facilitated HIV DNA plasmid vaccine in HIV-positive subjects. Methods: We have demonstrated that facilitated DNA injection using plasmid constructs that drive expression of HIV-1 genes can induce both cellular and humoral immune responses in non-human prim
Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. We.B.294)
Sutor GC, Schedel I; Dept. Internal Medicine, Div. Immunology, Medical School of Hannover, Hannover, Germany.
Objective: The mAb (monoclonal antibody) IOT4a (13B8.2) directed against the CDR(Complementarity-determining region) 3-homologous CD4/D1 region was shown to elicit an HIV-neutralising immune response in rabbits1. Specific anti-Id to IOT4a were capable of inhibiting gp120-CD4 interaction as well as HIV-infection of susc
Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. We.B.300)
Tacconelli E, Tumbarello M, Pirronti T, Cauda R, Ortona L; Istituto Clinica Malattie Infettive, Universita Cattolica, Roma, Italia. Fax: +39-6-3051343.
Objective: to identify risk factors for, clinical and radiological findings of, treatment and outcome of pneumothorax (PTX) associated with HIV infection. Design: a retrospective logistic regression analysis, conducted between Jan 1987 and Dec 1994, considering 2,954 hospital admissions relative to 2,094 HIV-infected p
Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. We.B.301)
Bornschlegel K, Thomas P, Channing K, Saletan S, Kaye K; New York City Department of Health - OAS, NY, NY. E-mail: born104w@wonder.em.cde.gov.
Objective: To describe tuberculosis disease (TB) in HIV-exposed children in NYC. Methods: The Pediatric Spectrum of HIV Disease Project (PSD) has followed 2,759 HIV-exposed children at 11 NYC sites since 1989. Charts were reviewed every 6 months for clinical information. Seroreverters were followed to a median age of 2
Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. We.B.302)
Rosario AT, Peters B, Afessa B, Green W, Greaves W, Frederick W; Howard University Hospital, Department of Medicine, Washington, DC, USA. Fax: 202-865-4607.
Objective: To describe the characteristics of mycobacterial infection among inner city hospital patients between 1986 -1995. Methods: We reviewed records from the mycobacteriology laboratory and autopsy files of all patients with mycobacterial infection based on positive Fite or Ziehl-Neelsen stains, culture or both. R
Objectives: To determine the seroprevalence for HIV-infection in a population of 932 pulmonary smear positive tuberculous patients. To evaluate the results of standardized 8 month chemotherapy among this cohort. Methods: This is a retrospective study carried out among 932 pulmonary smear positive tuberculous patients,
Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. We.B.304)
Gonzalez ML, Palmero D, Alberti F, Ambroggi M, Gonzalez MP, Abbate E; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Tisioneumonologia, Buenos Aires, Argentina. Fax: (54-1) 304-1129.
Objective: To describe the characteristics of all cases of MDR-TB among AIDS patients diagnosed at our institution between the years 1992 and 1995. Study Design: All cases of bacteriologically confirmed MDR-TB among patients diagnosed between the years 1992 and 1995 were reviewed using a standardized case report form.
Int Conf AIDS 1996 Jul 7-12; 11:25 (abstract no. We.B.305)
Easterbrook PJ, Bell A, Hannan M, Hayward A, Troop M, Shave A, Nelson M, Hawkins D, Gazzard BG, Azadian B, Lau YK; Chelsea & Westminster Hospital, London, UK. Fax: 0181-846-6530.
Background: Multidrug resistant tuberculosis (MDRTB) is rare in the UK (less than 0.1% of TB isolates, 1982-1991). We report an epidemiological investigation of the first UK nosocomial outbreak of MDRTB in a London HIV unit. Methods: The index case was a homosexual man from Lisbon,
Int Conf AIDS 1996 Jul 7-12; 11:25 (abstract no. We.B.306)
Mudido-Musoke P, Marum L, Bagenda D, Aceng E, Kalyesubula I, Olness K, Ndugwa C; Makerere University Kampala, Kampala, Uganda. Fax: 011 256 41 541 044.
Objective: To examine incidence, presentation and treatment response of TB in HIV-infected children. Methods: Charts of 22 children treated for tuberculosis were reviewed from a cohort of 89 HIV-1 infected, 259 seroreverting, 30 indeterminate, and 144 controls followed from birth to 3-4 years. Results: Sixteen of 89 (1
Objectives: The virus-specific cytotoxic T lymphocytes (CTL) are required for recovery from viral infections, for clearance of virus or control of persistent infections. Our goal is to define the role of HIV-specific CTL in pediatric AIDS infection. Methods: HIV-infected children have been followed-up since 1990 for ex
Int Conf AIDS 1996 Jul 7-12; 11:25 (abstract no. We.B.311)
Abrams EJ, Weedon JC, Lambert G, Steketee R; Harlem Hospital Center, New York, NY, USA. Fax: (+1) 212-939-4048.
Objective: To assess the utility of infants measured HIV viral load (VL) in predicting (a) progression to severe HIV clinical symptoms or death, and (b) progression to severe immunosuppression or death. Methods: Plasma samples drawn during the first 43 months of life from 49 HIV-infected children, who were followed pro
Int Conf AIDS 1996 Jul 7-12; 11:25 (abstract no. We.B.312)
Marum LH, Bagenda D, Guay L, Aceng E, Kalyesubula I, Tindyebwa D, Ndugwa C, Olness K; Uganda-CWRU Research Collaboration, Kampala, Uganda. Fax: 256-41-541044. E-mail: cwru@mukla.gn.apc.org.
Objectives: To assess the mortality and clinical status of infants born to HIV-infected and seronegative mothers. Methods: From 1990-92, 387 infants born to HIV+ mothers and 146 controls born to HIV- mothers were enrolled in a study of the natural history of HIV in pregnancy and of the neurodevelopmental effects of HIV
Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. We.B.313)
Cooper ER, Hanson C, Diaz C, Abboud R, Mendez H, Hittelman J, Mellius C, Smith R, Rodriguez E, Nugent R, Smeriglio V; Boston City Hosp., Boston, MA, USA. Fax: (617) 534-5806.
Purpose: To describe the incidence, clinical characteristics, and survival of children with HIV and encephalopathy in a cohort enrolling since 12/89. Methods: Using data prior to 4/1/95, retrospective clinical and immunological staging of HIV-infected infants was based on the CDC Classification System. Immunologic asse
Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. We.B.314)
Kalyesubula I, Musoke-Mudido P, Marum L, Bagenda D, Ndugwa CM, Aceng E, Olness K; Makerere Medical School, Dept. of Paediatrics, Kampala, Uganda. Fax: 256-41-541044. E-mail: cwru@mukla.gn.apc.org.
Introduction: There are many unanswered questions with respect to the impact of HIV-1 infection on malaria or malaria on HIV-1 infection in children. Both malaria and HIV-1 infection are known to reduce cellular immunity. Repeated malaria infections might accelerate the progression of HIV-related disease. Objective: To
Objective: To examine the association between HIV-1 RNA copy number and likelihood of death in HIV-infected children prospectively followed during the NICHD IVIG Clinical Trial. Methods: Blood was collected for central repository storage at entry and 3 month intervals during the trial. Ultra-frozen serum specimens from
Int Conf AIDS 1996 Jul 7-12; 11:31 (abstract no. We.C.120)
Ishikawa N, Matsuda M, Sawanpanyalert P, Yanai H, Sawazaki Y, Yamagata S; The Research Institute of Tuberculosis, Tokyo, Japan. Fax: 81-424-92-8258. E-mail: hyanai@jata.or.jp.
Most international training courses limit their methods of evaluation to participants reactions and/or learning. While actual impact of performance evaluation is vital, it is rarely carried out. Project: In 1994, the Ministry of Health and Welfare of Japan , designated JFAP and RIT to organize an annual Internat
Int Conf AIDS 1996 Jul 7-12; 11:32 (abstract no. We.C.121)
Daniels E, Goosby EP, Macher AM, von Zinkernagel D, Brady B, Lee PR; Office of HIV/AIDS Policy, US Public Health Service (USPHS), Washington, DC.
The paucity of HIV providers seriously impairs the health care delivery system. Federal HIV provider education and training programs have activities that reflect the specific missions of individual agencies and often have limited funding. There has been no comprehensive integration of functions among and across
Int Conf AIDS 1996 Jul 7-12; 11:32 (abstract no. We.C.122)
Shea F, Ager J, Naqvi A; Wayne State University, Detroit, MI, USA. Fax: 313-962-4440. E-mail: arep@sun.science.wayne.edu.
Objectives: To assess the overall impact of HIV training programs as well as the effects that program and trainee characteristics have on the degree of attitude change of health care providers. Methods: Seven HIV training sites across the U.S.A. participated in the study. Health care providers who attended educational
Int Conf AIDS 1996 Jul 7-12; 11:32 (abstract no. We.C.123)
Suazo M, Alcantara R, Butler M, Sanchez J, Ryan C; AIDSCAP, Arlington, VA, USA. Fax: (703) 516-9781.
Objectives: Health personnel in the Dominican Republic are often unaware of the connection between STDs and HIV infection and the importance of STD management to diminish HIV prevalence. To address this and to improve overall management of STDs within the limitations of a developing country s health system, an STD synd
Int Conf AIDS 1996 Jul 7-12; 11:32 (abstract no. We.C.124)
Betts CD, Carrington C, San Martin A, Guerrero E, Bracho A, Casanova J; ULACETS, Kensington, MD, USA. Fax: 301-942-7296. E-mail: bettscarr@aol.com.
Preparing a new breed of committed, flexible, and effective team players, capable of addressing the challenges of rapid change, conveying effectively a sense of direction that facilitates the coordination of interventions by multiple actors involved in STD/HIV prevention and control is being addressed and evalua
The increasing trend of HIV Infection and AIDS in the Middle East and the advent of the peace initiative has paved the way for collaborations between Israeli and Arab Health professionals for HIV/AIDS Education as a preventive intervention in the region. Project: An HIV/AIDS Education training-workshop was given
Int Conf AIDS 1996 Jul 7-12; 11:33 (abstract no. We.C.201)
Butler M, Brito C, De la Rosa J; AIDSCAP, Arlington, VA, USA. Fax: 703.516.9781.
Objectives: Existing data on adolescents reveal that 90% had knowledge of prevention measures, but only 13% females and 65% males reported changing their sexual behavior. The need was evident for a mass media campaign targeting youth to increase STD/HIV/AIDS awareness levels and risk perception and to promote health-se
Int Conf AIDS 1996 Jul 7-12; 11:33 (abstract no. We.C.202)
Hill S, Gillies P; BC Puppets Against AIDS, Vancouver, B.C., Canada. Fax: (604) 253 5150.
There is a critical need for educators to address highly sensitive issues such as HIV/AIDS in an effective, understanding and non-threatening manner. Project: In 1992 the African Research and Educational Puppetry Program (AREPP) presented a series of workshops across Canada using puppetry to raise awareness abou
Int Conf AIDS 1996 Jul 7-12; 11:33 (abstract no. We.C.203)
Sankaran S, Ganesh V, Chandhok K, Meloot J, Manoharan S, Thomas S; Deepam Educational Society for Health (DESH), Madras, India. Fax: 91-44-5340288.
Objective: To develop, in AIDS Prevention Education (APET/S) Programs addressing teachers and adolescent students, a user-friendly, scientific questionnaire and appropriate formula with indicators to enable an objective assessment of effective change in Information/ Awareness(IA), Empowerment with Accountability (EA) a
Int Conf AIDS 1996 Jul 7-12; 11:33 (abstract no. We.C.204)
Pinto T, Guirao LJ, Rodrigues LR, Peixoto M, Damas W, Sammamed JM; AIDS Prevention and Treatment Association (APTA), Sao Paulo, S.P., Brasil. Fax: 55 011 825 7701.
Issues: Three years ago we began behavioral intervention work with teenagers - 11 and 12 years old - seeking to create groups of opinion builders for HIV/AIDS/STD issues, within first degree schools in Sao Paulo. Project: Based on peer-system working through group dynamics techniques, broaching sexuality, specialized i
Int Conf AIDS 1996 Jul 7-12; 11:33 (abstract no. We.C.205)
Bartelli D, VanDevanter N, Litwak E, Fullilove M; University of Medicine & Dentistry of New Jersey (UMDNJ), Newark, NJ. Fax: 201-982-7128. E-mail: bartelli@umdnj.edu.
Urban adolescent women in New York City are increasingly vulnerable to STDs and HIV infection. There is an urgent need to better understand factors which influence sexual decision-making in this population. Such data is essential to the development of effective interventions for STD/HIV prevention. Project: A se
Int Conf AIDS 1996 Jul 7-12; 11:33 (abstract no. We.C.206)
Positano K, Vardy G; Vardy G
Street-involved youth are characterized by personal histories of neglect or abuse, homelessness, limited employment skills, and increased vulnerability to numerous health related risks, including AIDS. The rate of HIV infection for the general population in Canada is .003%. For street youth, the rate is 2.2%, al
Objectives: Current phase III trials are designed to assess only a vaccine candidate s ability to reduce susceptibility to infection or disease, i.e., vaccine efficacy for susceptibility (VES). HIV vaccination, however, may reduce infectiousness of vaccines who become infected. This could produce an important indirect
Int Conf AIDS 1996 Jul 7-12; 11:34 (abstract no. We.C.211)
Chinaworapong S, Buapunth P, Morgan P, Chiu J, Yutabootr Y, Sontirat A, Khamboonruang C, Nitayaphan S, Michael RA; AFRIMS, Bangkok, Thailand. Fax: 66-2-245-0582. E-mail: rmichael@mozart.inet.co.th.
Objectives: To define motives of potential volunteers for a Phase I/II HIV-1 vaccine trial in Thailand and to define and document reasons for failure of potential volunteers to complete pre-trial screening and successfully enroll in a vaccine trial. Methods: Recruitment for a phase I/II HIV-1 vaccine trial was conducte
Int Conf AIDS 1996 Jul 7-12; 11:34 (abstract no. We.C.212)
Bartholow BN, MacQueen K, Douglas J, Buchbinder S, McKirnan D, Judson F; Centers for Disease Control and Prevention, Atlanta, GA, USA. E-mail: bnb1@cidhiv1.em.cdc.gov.
Objective: To prospectively evaluate the willingness of homosexual men to participate in HIV vaccine efficacy trials. Methods: From January 1993 to July 1994, 2191 men from Chicago, Denver, and San Francisco were enrolled in the study. As of May 1995, 1267 men completed baseline (BL), 6-, 12-, and 18-month interviews.
Int Conf AIDS 1996 Jul 7-12; 11:34 (abstract no. We.C.213)
Ippolito TM, Francis DP, Migasena S, Pitisuttitham P, Savarese B, Fast P; Genentech Inc., South San Francisco, CA, USA. Fax: 415-225-3957. E-mail: ippolito.tina@gene.com.
Issues: Assessing clinical safety of an experimental HIV-1 vaccine is critical because a large number of people will eventually receive the vaccine. In blinded clinical trials, defining the relationship between observed adverse events (AEs) and the vaccine is challenging because we do not know the expected rate of such
Issues In 1988, prevalence of HIV-1 infection among Bangkok IDUs in treatment increased from 1% to 40%. Despite available interventions, HIV transmission continues at an alarming rate. In response to this epidemic, efforts are underway to establish cohorts of persons at high risk for HIV infection for possible HIV-1 va
Int Conf AIDS 1996 Jul 7-12; 11:35 (abstract no. We.C.215)
Koblin BA, Metzger D, Sheon A, Critchlow C, Heagerty P; New York Blood Center, New York, NY. Fax: (212) 570-3385.
Objective: To assess the readiness of U.S. high-risk populations to participate in HIV vaccine efficacy trials. Methods: Data collected at baseline visit from 3272 gay men (GM)826 male IDUs346 female IDUs and 488 women at increased sexual risk but no IDU history (HxF) recruited in 7 cities of the Vaccine Preparedness S
Int Conf AIDS 1996 Jul 7-12; 11:35 (abstract no. We.C.220)
Khamboonruang C, Beyrer C, Natpratan C, Eiumtrakul S, Celentano DD, Nelson KE; Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand. Fax: [66]53 221-849.
Objectives: To study HIV and STD incidence rates follow up rates risk factors for HIV infection HIV-1 viral subtypes and to develop infrastructure and human resources for intervention trials including HIV vaccines. Methods: In January 1995 we began enrolling and following 2 cohorts of HIV-1 at risk seronegative adults
Int Conf AIDS 1996 Jul 7-12; 11:35 (abstract no. We.C.221)
Grosskurth H, Munguti K, Todd J, Balira R, Mayaud P, ka-Gina G, Klokke A, Mosha F, Mabey D, Hayes R; AMREF Mwanza, Tanzania & London School of Hygiene and Tropical Medicine, London, UK.
Objective: To identify risk factors associated with HIV seroconversion. Methods: Following an intervention trial to study the impact of STD control on HIV incidence over a 2-years period a nested unmatched case control study was performed involving all adults who seroconverted for HIV-1 infection and controls who were
Int Conf AIDS 1996 Jul 7-12; 11:35 (abstract no. We.C.222)
Van Hove D, Declercq E, Stroobant A; Institute of Hygiene and Epidemiology, Brussels, Belgium. Fax: +322 640 50 10. E-mail: dirk.vanhove@epinov.ihe.be.
Introduction and objective: The European Concerted Action Project on the monitoring of HIV prevalence in sentinel populations of STD patients started in June 1990. In this surveillance system HIV prevalence has remained stable over time. However stable prevalence may not be a good public health indicator as it may hide
Int Conf AIDS 1996 Jul 7-12; 11:35 (abstract no. We.C.223)
Dia MC, Mboup S, Traore I, Siby T, Gueye-Ndiaye A, Marlink R, Essex M, Kanki P; Laboratoire Bacterio-Virologie CHU A LeDantec, Dakar, Senegal. Fax: 221.21.64.42. E-mail: mboups@dantec.dantec.sn.
Objectives: The measurement of HIV incidence is critical to our understanding the dynamics of both HIV-1 and HIV-2 spread in populations at-risk. These incidence estimates in high risk population cohorts will be necessary for future vaccine efficacy trials. Methods: Since 1985 we have prospectively studied 1790 registe
Int Conf AIDS 1996 Jul 7-12; 11:36 (abstract no. We.C.224)
Cleghorn FR, Jack N, Edwards J, Murphy J, Palace C, Mahabir B, O'Brien T, Bartholomew C, Blattner W; Univ. of MD at Baltimore, Baltimore, MD. Fax: 410/706-8645. E-mail: fcleghorn@umppal.ab.umd.edu.
Objective: To estimate HIV incidence rates in a population of heterosexual STD clinic attenders with a documented high prevalence of infection suitable for vaccine efficacy trials. Methods: Serial cross-sectional studies of HIV-1 prevalence; passive follow-up of recidivists; screening for early markers of infection; pr
Objectives: To assess and explain temporal changes in HIV prevalence and incidence among injection drug users (IDU) who attend the CACTUS-Montreal needle exchange. Methods: In a weekly 3-hour randomly chosen period IDU are asked to provide a dried blood spot by fingerprick or a saliva/gingival specimen for HIV antibody
Int Conf AIDS 1996 Jul 7-12; 11:36 (abstract no. We.C.226)
Edlin BR, McCoy CB, Word CO, Faruque S, Von Bargen JC, Holmberg SD; Division of HIV/AIDS Prevention, CDC, Atlanta, GA, USA. Fax: 404/639-6118. E-mail: bxe2@cidhivl.em.cdc.gov.
Background: HIV is highly prevalent among smokers of crack cocaine in some areas because of their high-risk sex practices. HIV incidence rates among crack smokers however have not been measured. Methods: Crack smokers and nonsmokers aged 18-29 years were recruited from the streets of neighborhoods where drug use was pr
Int Conf AIDS 1996 Jul 7-12; 11:36 (abstract no. We.C.322)
Peckham C; Epidemiology and Biostatistics Institute of Child Health, London, UK. Fax: 44-171-813-8233.
The increasing numbers of women with HIV infection worldwide has serious implications for children as the large majority of infected children acquire HIV from mother-to-child transmission. The successful prevention of HIV in women through education the treatment of STD and possibly the use of female controlled barrier
Int Conf AIDS 1996 Jul 7-12; 11:36 (abstract no. We.C.330)
Loussert-Ajaka I, Delmas MC, Mandelbrot L, Bastian H, Benifla JL, Farfara I, de Vincenzi I, Saragosti S, Simon F, Brun-Vezinet F; Laboratoire de Virologie Hopital, Paris, France. Fax: 46 27 02 08.
Objective: To develop reliable methods for HIV-1 detection in cervicovaginal secretions (CVS) using DNA and RNA PCR in pregnant women. Methods: Peripheral blood was collected in 43 HIV-1 infected pregnant women. PBMC DNA was detected by Amplicor (Roche Diagnostics Systems USA) and gag nested PCR. The genotype in PBMC w
Int Conf AIDS 1996 Jul 7-12; 11:36 (abstract no. We.C.331)
John G, Nduati R, Mbori-Ngacha D, Overbaugh J, Welch M, Richardson B, Ndinya-Achola J, Bwayo J, Kreiss J; IARTP, University of Washington, Seattle, WA, USA.
Objectives: To determine the prevalence and correlates of HIV-1 DNA in cervical and vaginal secretions of HIV-1 seropositive pregnant women. Methods: Pregnant HIV-1 seropositive women enrolling in the Breastfeeding and Transmission of HIV-1 Study in Nairobi Kenya were evaluated with an interview and physical examinatio
Int Conf AIDS 1996 Jul 7-12; 11:37 (abstract no. We.C.332)
Ghys PD, Fransen K, Diallo MO, Ettiegne-Traore V, Maurice C, Hoyi-Adonsou YM, Kalish M, Brown T, Steketee R, Coulibaly IM, Greenberg AE, Laga M; Projet RETRO-CI, Abidjan, Cote d'Ivoire. Fax: (225) 24-29-69.
Objectives: To study risk factors for cervico-vaginal (CV) HIV shedding in female sex workers (FSW) in Abidjan Cote d Ivoire and to determine the effect of STD treatment on CV HIV-1 shedding. Methods: At an initial visit to a confidential clinic in Abidjan consenting FSW were screened for HIV serum antibodies and class
Int Conf AIDS 1996 Jul 7-12; 11:37 (abstract no. We.C.333)
Mostad S, Welch M, Chohan B, Reilly M, Overbaugh J, Mandaliya K, Martin H, Nyange P, Ndinya-Achola JO, Kreiss J; IARTP, University of Washington, Seattle, WA, USA.
Objectives: Factors governing the infectivity of HIV-1 seropositive individuals are poorly understood. We conducted a study to characterize shedding of HIV-1 DNA in cervical and vaginal secretions of HIV-1 infected women. Methods: HIV-1 seropositive women attending an STD clinic in Mombasa Kenya underwent an int
Int Conf AIDS 1996 Jul 7-12; 11:37 (abstract no. We.C.334)
Speck CE, Coombs R, Koutsky L, Zeh J, Corey L, Hooton T, Ross S, Krieger J; Los Angeles, CA, USA. Fax: 818.564.3430. E-mail: cspeck@kpsc.org.
Objective: To define the determinants of HIV shedding in semen in a cohort of HIV-seropositive men. Methods: At each of up to three monthly visits 149 HIV+ men provided blood and semen specimens and were administered a brief behavioral questionnaire. To control for intra-subject correlations between outcomes and covari
Int Conf AIDS 1996 Jul 7-12; 11:37 (abstract no. We.C.335)
Dyer JR, Gilliam BL, Eron JJ, Fiscus SA, Vernazza P, Cohen MS; University of North Carolina, Div. of Infect. Dis., Chapel Hill, NC. Fax: 919-966-6714. E-mail: JRDyer@eworld.com.
Objective: To examine shedding of HIV-1 in semen. Methods: 52 HIV-1-seropositive subjects at varying stages of infection were studied. Viral shedding was measured using NASBA amplification of cell free RNA and by seminal cell HIV-1 culture. Patterns of HIV-1 RNA shedding were examined by quantitation in seminal and blo
Int Conf AIDS 1996 Jul 7-12; 11:37 (abstract no. We.C.340)
Babu PG, Cassol S, Weniger BG, Myo TH, Zheng X, Delaney A, Ou CY; CDC, Atlanta, Georgia, USA. Fax: (404) 639-8616. E-mail: bgw2@nipl.em.cdc.gov.
Objective: Global genetic surveillance of HIV-1 subtypes is hampered by the biohazard of processing and the difficulties of shipping whole blood or cells from many developing country regions. Dried blood spots (DBS) on absorbent paper can be mailed unrefrigerated in sturdy paper envelopes with low biohazard risk. Metho
Int Conf AIDS 1996 Jul 7-12; 11:38 (abstract no. We.C.341)
Yiming S, Zhao Q, Guan Y, Zeng Y, Chang J, Koestler J, Wolf H; Institute of Virology, Chineses Academy of Preventive Medicine, Beijing, China. Fax: 3532053. E-mail: yshao@net.tsinghua.edu.cn.
Objectives: To genetically characterize HIV-1 strains and their evolution in injecting drug users (IDU) in Ruili region on the southwest boarder of China . Methods: HIV-1 positive IDU and their spouses in Ruili were followed regularly since 1990. HIV-1 env gene was amplified by nested polymerase chain reaction (PCR) fr
Background: The heterosexual HIV-1 epidemic in Thailand is due primarily to subtype E while the initial epidemic among Bangkok IDUs was largely due to subtype B. Only subtypes B and E have been identified in Thailand. Methods: HIV+ serum specimens were collected from MOPH sentinel surveys in all regions of Thailand in
Int Conf AIDS 1996 Jul 7-12; 11:38 (abstract no. We.C.343)
Fransen K, Buve A, Nkengasong J, Janssens W, Heyndrickx L, Colebunders R, Vandenbruaene M, Laga M, van der Groen G; Institute of Tropical Medicine, Antwerpen, Belgium. Fax: 32 3 247 63 33. E-mail: kfransen@microbiol.itg.be.
Objective: To study the molecular epidemiology of HIV-1 among the Belgian population. Material and Methods: HIV isolates of co-cultured PBMC s of 190 Belgian seropositive individuals visiting the Institute of Tropical Medicine between 1985 and 1994 were amplified for a 700 bp fragment in the env region and the genotype
Int Conf AIDS 1996 Jul 7-12; 11:38 (abstract no. We.C.344)
Luo CC, Downing R, Dela Torre N, Candal D, Hu D, Otten RA, George JR, Schochetman G, Rayfield M, Biryahwaho B; CDC, Atlanta, GA, USA. Fax: (404) 639-2660. E-mail: cxll @ciddas1.em.cdc.gov.
Objective: To develop a method for large-scale HIV-1 genetic study in Uganda using DNA probe hybridization. Methods: To date over 1200 HIV-1 seropositive specimens have been collected. We have developed a screening method for large-scale study of HIV-1 genetic variation based on DNA probe hybridization. Nested PCR ampl
Int Conf AIDS 1996 Jul 7-12; 11:38 (abstract no. We.C.345)
Irwin KL, Pau CP, Hu D, Lupo D, Schable CA, Olivo N, Minor P, Weber JT, Janssen R, Ernst J, Rayfield M; Division of HIV/AIDS Prevention, CDC, Atlanta, GA, USA. Fax: (404) 639-6118. E-mail: klil@cidhiv1.em.cdc.gov.
Objectives: Surveillance for HIV variants that diverge from common North American (N.A.) subtype B strains is needed to evaluate diagnostic tests ensure blood safety and develop HIV vaccines. To monitor the possible spread of divergent strains in North America we studied patients in a hospital that serves a Bronx NY co
Int Conf AIDS 1996 Jul 7-12; 11:50 (abstract no. We.D.470)
Scherbakov SP, Saldanha V, Panchenko N; "The International AIDS Project", Saint Petersburg, Russia. Fax: 7-812-113-8601. E-mail: davlet@ok.spb.su; iap@aids.spb.su.
Breakdown of the state systems of medical and social care and support brought a lot of PLWHAs to the edge of physical extermination. Project: A survey to reveal various aspects related with the disclosure and living with HIV/AIDS in present Russia by means of processing data from questionnaire forms filled by PL
Sharing information and experiences of the Philly Lutaaya Initiative of people with HIV/AIDS (PLI/PWA) going public for behaviour change. The Project: PLI/PWA was set up in 1991 by the concert efforts of four non-governmental organizations. It brings together PWA volunteers to utilise their experiences of living
Int Conf AIDS 1996 Jul 7-12; 11:51 (abstract no. We.D.472)
Michael C; Asian Project, Darlinghurst, NSW, Australia. Fax: ++ 61 2 206 2092.
The diversity of language and culture of Asian migrants living with HIV/AIDS has proven to be one of the main barriers in running multicultural HIV support groups. Several attempts to address this through frameworks for mainstream workshops for HIV-positive English speaking background people have had very little
Int Conf AIDS 1996 Jul 7-12; 11:51 (abstract no. We.D.480)
Clements KD, Gleghorn A, Garcia D, Sabin M, Katz M; San Francisco AIDS Office, San Francisco, CA. Fax: 415/431-7547.
Objective: To assess the impact and acceptability of an enhanced street outreach program for homeless youth. Methods: Using a fixed random sampling design 1,146 street youth (mean age=19 yrs) were interviewed using repeated cross-sectional surveys in intervention (San Francisco) and comparison sites (Berkeley Santa Cru
Int Conf AIDS 1996 Jul 7-12; 11:51 (abstract no. We.D.481)
Pradeep K, Senthil K, Tawil O, O'Reilly K, Kantharaj K; Community Action Network (CAN), Madras, India.
Objectives: An ethnographic assessment of sexual behaviour in Madras revealed that same-sex contacts between men takes place in certain parks deserted grounds and beach side promenades. With support from WHO the Community Action Network (CAN) developed a project to reduce the risk of HIV/AIDS infection for an estimated
Int Conf AIDS 1996 Jul 7-12; 11:51 (abstract no. We.D.482)
Mishra SI, Conner R, Lewis M; University of California, Irvine, CA, USA. Fax: 714-824-8091. E-mail: simishra@uci.edu.
Objective: To evaluate the effectiveness of an AIDS prevention educational program that was specifically developed for and targeted low-literacy Spanish-speaking Latino migrant farm workers. Methods: We used a quasi-experimental cohort analytic study design with randomization of matched and paired study sites to two gr
Int Conf AIDS 1996 Jul 7-12; 11:52 (abstract no. We.D.483)
Liao SS, Choi K, Zhang K, Mandel J, Qi B, Deng Y, Fang J, Liu W, Yang Y, Wang A, Qin Z, Shen H; Peking Union Medical College, Beijing, China. Fax: 8610-512-4876. E-mail: dengxx@sun.ihep.ac.cn.
Objective: To assess awareness of AIDS STD s condoms and sources of health information among Dai ethnic minority villagers in China s Yunnan Province bordering Laos near Thailand . Methods: In 1994 we conducted face-to-face interviews with a convenience sample of 177 villagers aged 15-49 of Dai origin in Me
Int Conf AIDS 1996 Jul 7-12; 11:52 (abstract no. We.D.484)
McLeod AW, Johnson L, Gardiner L, Kakeway G; Manitoba Aboriginal AIDS Task Force (MAATF), Winnipeg, Manitoba, Canada. Fax: 204-942-6308.
The language and content of standard HIV/AIDS resources are not effective for reaching Aboriginal populations. Project: In the past five years Aboriginal and non-Aboriginal educators in western Canada have been trained to promote HIV/AIDS awareness to Aboriginal communities. Standard teaching methods deemed inap
Int Conf AIDS 1996 Jul 7-12; 11:52 (abstract no. We.D.485)
Coronado M, Cruz M, Amat A; Fundacion Amigos por la Vida, Guayaquil, Ecuador. Fax:(593) 4-533-999.
The homeless youth (children and adolescents) need for awareness in the dangers of HIV/AIDS and Sexually transmitted diseases(STD). Project: An investigation was conducted seeking to locate the places where the homeless youth hangs (Bus station parks etc.). Immediately a program was launched with the goal of mak
Int Conf AIDS 1996 Jul 7-12; 11:52 (abstract no. We.D.490)
Jurgens RE, Guillot-Hurtubise B, Elliott R; Canadian HIV/AIDS Legal Network, Montreal, Quebec, Canada. Fax: 514-526-5543. E-mail: aidslaw@web.apc.org.
Objectives: (1) Stimulate discussion on the local regional and national level on legal and ethical issues raised by HIV/AIDS; (2) develop a series of discussion papers on priority legal and ethical issues raised by HIV/AIDS; (3) organize a series of workshops on these issues; (4) produce comprehensive resource and advo
Int Conf AIDS 1996 Jul 7-12; 11:52 (abstract no. We.D.491)
Cooper EB; Fordham University School of Law, New York, NY. Fax: 212/636-6923. E-mail: ecooper@mail.lawnet.fordham.edu.
Results from clinical trial ACTG 076 have been used to support calls in the US for mandatory HIV testing of pregnant/delivering women & newborns. As mandatory testing would challenge established standards of informed consent (IC) analysis must be conducted using legal and ethical principles and data concerni
Int Conf AIDS 1996 Jul 7-12; 11:52 (abstract no. We.D.492)
Nsubuga YK, Bossa SB; Uganda AIDS Commission/Uganda Network on Law Ethics & HIV/AIDS, Kampala, Uganda. Fax: 258173.
Issues:The HIV/AIDS challenge has necessitated a complete overhaul of some of our systems and cultures that enhance the spread of HIV e.g. the need for an appropriate legal and ethical response to HIV/AIDS pandemic the enactment of Laws that regulate the cultural practices and distribution of marital property. The need
Int Conf AIDS 1996 Jul 7-12; 11:53 (abstract no. We.D.493)
Morozov AV, Saldanha VP, Gardner K; The Charity Fund "The International AIDS Project", St. Petersburg, Russia. Fax: +7-812-113-8601. E-mail: iap@aids.spb.su.
New Russian Law on AIDS caused strong critical reaction from foreign press as well as serious concern in HIV-community and ASOs. Project: The opinion of legal experts medical professionals social workers from GOs and NGOs as well as foreign diplomats accredited in different Russian cities was studied by personal
Objectives: To study the issue of criminalization of HIV transmission (and endangerment thereof) as well as public health measures in order to develop a coherent and informed approach to the behaviour of persons who knowingly put others at risk of contracting HIV. Methods: (1) An analysis of the existing literature and
Int Conf AIDS 1996 Jul 7-12; 11:53 (abstract no. We.D.495)
Vazquez-Acuna M; Buenos Aires, Argentina. Fax: 371 9966.
Discrimination and marginalization are fundamental obstacles that have repercussion on the AIDS epidemic. The implementation of penal or administrative norms that punish possession of drugs for personal use as well as using drugs as well as prostitution hinder prevention and attention activities in health matter
Int Conf AIDS 1996 Jul 7-12; 11:53 (abstract no. We.D.590)
Beadle de Palomo F, Anderson T, Scofield J; Academy for Educational Development (AED), Washington, DC. Fax: (202) 884-8713. E-mail: fbeadle@aed.org.
HIV has forced the public health system to respond to prevention issues in more innovative and effective ways- HIV prevention community planning national/local partnerships and a focus on community-based and driven program services. Project: HIV Prevention Community Planning announced in Dec. 1993 and initiated
Int Conf AIDS 1996 Jul 7-12; 11:53 (abstract no. We.D.591)
Parker RG, Barbosa RM, Galvao J, Teixeira PR, Terto V; Institute of Social Medicine, State University of Rio de Janeiro, Maracana, Rio de Janeiro, Brazil. Fax: 55-21-228-9526. E-mail: parker@vmesa.uerj.br.
Objective: To monitor and evaluate the development of HIV/AIDS policy in Brazil . Methods: Detailed studies of the history of HIV/AIDS policy in Brazil were developed focusing on public programs and policies non-governmental AIDS-service organizations religious responses to the epidemic private sector and labor movemen
Int Conf AIDS 1996 Jul 7-12; 11:54 (abstract no. We.D.592)
Burzynski R, Hernandez J, Bagasao T, Sy A, Boneberg P, Levy P, O'Rourke N; ICASO, Ottawa, ON, Canada. Fax: 613 563 4998. E-mail: icaso@web.apc.org.
Objective: To determine the qualitative impact of the Paris Summit on AIDS within 52 countries. The Summit took place on 1 December 1994. There remains considerable difficulty in assessing the impact in many countries which signed the Declaration. Both governments and non-governmental organizations need to work
Int Conf AIDS 1996 Jul 7-12; 11:54 (abstract no. We.D.600)
Hertz E; Rigshospitalet, Copenhagen, N Denmark.
Objectives: Social support is found to act as a buffer against the impact of stress contributing to the individual s general well being. Coping is a constellation of cognitive and affective responses to a stressful encounter. This study analyzes the relationship between social support and coping among AIDS patients liv
Objective: To raise awareness of the importance of Global linking within the diverse Black communities. In order to address HIV/AIDS effectively in the Black communities we first had to identify who the Black communities are our diversities. Project: The Lime Tree an HIV/AIDS social support group targeting PHAs within
Int Conf AIDS 1996 Jul 7-12; 11:54 (abstract no. We.D.602)
Perez Silva R, Cervantes R, Romero M; Republica de Bolivia, Mexico. Fax: (525) 772 07 78. E-mail: amac@laneta.apc.org.
Social network building to provide practical and emotional support when a person presents health problems related to AIDS can be promoted through a Buddy Project. Project: A buddy gives emotional and practical support to a person living with AIDS (PWA) and at the same time can promote that other social actors co
Int Conf AIDS 1996 Jul 7-12; 11:54 (abstract no. We.D.603)
Lin OC; Shaukeiwan Jockey Club Clinic, Shaukeiwan, Hong Kong. Fax: 852-25604154.
Support Groups for people living with HIV/AIDS and their loved ones have been widely used in different communities. In Hong Kong similar intervention with modification with regard to culture and social specificity has been found to be well accepted and helpful to people with HIV/AIDS. Project: Support groups was
Int Conf AIDS 1996 Jul 7-12; 11:54 (abstract no. We.D.610)
Seibert MS; Projekt Frauen und AIDS, Gottingen, Berlin, Germany. Fax: +49 551/41027.
Although the rate of HIV infection for women in Germany is steadily rising the topic women and AIDS is still not given it s deserved attention and services are inadequate. Women with HIV/AIDS come from very diverse segments of the population not one homogeneous group. Project: Women and AIDS is a country-wide
Int Conf AIDS 1996 Jul 7-12; 11:55 (abstract no. We.D.611)
Booker N, Brotherton AJ; National Association of People with HIV/AIDS (NAPWA), Sydney, Australia. Fax: 61 - 2 - 231 5440.
Issues: Discrimination against and stigmatisation of people with HIV/AIDS while decreasing remains widespread and is especially marked in health and community care settings in lower prevalence areas (Kippax & Herdman 1995). Discrimination can result in denial of services economic disadvantage loss of self esteem an
Int Conf AIDS 1996 Jul 7-12; 11:55 (abstract no. We.D.612)
Chuaprapaisilp A, Parsons CD; Faculty of Nursing, Prince of Songkla University, Songkla, Thailand. Fax: 66-74-21-2901.
There is a need to develop innovative strategies for developing countries to take a community development approach to HIV prevention and care. Project: This collaborative project involves 4 villages (3 Buddhist 1 Muslim) in south Thailand the villages ranging from metropolitan to outer suburban and rural locatio
Int Conf AIDS 1996 Jul 7-12; 11:55 (abstract no. We.D.613)
Kiwanuka R; The AIDS Support Organization (T.A.S.O.), Kampala-Uganda. Fax: 00256-41-53041.
Issues: Going and acting with the community creates empowerment to PWAs and their communities for a collective participation in HIV/AIDS Prevention and Awareness Programmes. Project: A project IT WORKS was started by The AIDS Support Organization (TASO) Uganda in July 1995 (Case Study Mulego Branch). Material support a
Int Conf AIDS 1996 Jul 7-12; 11:55 (abstract no. We.D.614)
Badiani R, Costa N, Becker J; Republica do Chile, Rio de Janeiro, Brazil. Fax: (55-21) 220 4057. E-mail: bemfam@ax.ibase.org.bra.
Issues: Integration of HIV/STD prevention and STD diagnosis and treatment in reproductive health services is an important and effective strategy for addressing the evolving sexual and reproductive health needs of family planning clients in Brazil . Project: In response to the rapid expansion of the AIDS epidemic among
Int Conf AIDS 1996 Jul 7-12; 11:39 (abstract no. We.A.3001)
Zhang C, Houston S, Chang LJ; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Alberta. Fax: 403-4929828. E-mail: cszhang@gpu.srv.ualberta.ca.
Objective: To investigate whether high-risk HIV-seronegative individuals are resistant to HIV infection by using SCID/Beige mice reconstituted with their peripheral blood mononuclear cells (PBMC). Methods: High and low risk HIV-seronegative individuals were screened by coculture and polymerase chain reaction (PCR). PBM
Int Conf AIDS 1996 Jul 7-12; 11:39 (abstract no. We.A.3002)
Riviere Y, Lu CY, Corbet S, Georges-Courbot MC; UVIC, Institut Pasteur, Paris, France. Fax: 33140613012.
Objectives: Mandrills which are naturally infected with simian immunodeficiency virus (SIVmnd) remain asymptomatic despite persistent infection. The objective of this study is to investigate whether SIV-specific CTL activities have a role on the absence of disease in the natural infection of mandrills with SIVmnd. Meth
Int Conf AIDS 1996 Jul 7-12; 11:39 (abstract no. We.A.3003)
Garcia S, Dadaglio G, Gougeon ML; Unite d'Oncologie Virale, Institut Pasteur, Paris, France. Fax: 33 1 45 68 89 09.
Objectives: The Hu-PBL SCID chimera are obtained by injection of SCID (Severe Combined Immunodeficiency) mice, characterized by a genetic defect in TCR and Ig gene recombination, with human PBL. This model has been used by different groups for in vivo studies of AIDS pathogenesis. However, although no GVHD was observed
Int Conf AIDS 1996 Jul 7-12; 11:58 (abstract no. We.A.3004)
Forte P, Simeoni L, Aiuti A, Campese A, Uccini S, Stopacciaro A, Bona R, Federico M, Verani P, Fantoni A; Universita di Roma "La Sapienza," Roma, Italy. Fax: 39-6-4462891. E-mail: Fortenservl.dbu.uniroma.it.
Objective: To produce an animal model of HIV infection and possibly of AIDS pathology. Methods: We produced HuCD4 transgenic mice where the CD4 gene is under the control of regulatory regions of human CD2 which direct gene expression in a T cell-specific manner. As shown by cytofluorimetric analysis, HuCD4 is expressed
Int Conf AIDS 1996 Jul 7-12; 11:58 (abstract no. We.A.3005)
Koyanagi Y, Tanaka Y, Tanaka R, Misawa N, Kawano Y, Tanaka T, Miyasaka M, Ito M, Ueyama Y, Terada E, Kumazawa Y, Yamamoto N; Tokyo Medical and Dental University, Tokyo, Japan. Fax: 81-35803-0124. E-mail: koyanagi.mmb@med.tmd.ac.jp.
Objective: To develop a new in vivo infection system using immunodeficient mice with multiple defects for the study of HIV-1 infection, vaccine, and drug testing. Methods: Immunodeficient mice were developed by either backcrossing of scid mutant onto the other mutant mice such as beige, nude, Dh, and NOD or knocking ou
Int Conf AIDS 1996 Jul 7-12; 11:58 (abstract no. We.A.3006)
Tanaka R, Koyanagi Y, Tanaka Y, Ito M, Ueyama Y, Terada E, Kumazawa Y, Tanaka T, Miyasaka M, Yamamoto N; Kitasato University, Kanagawa, Japan. Fax: +427-78-9480.
Objective: To establish a better Hu-PBL SCID model for study of pathogenesis of HIV-1 infection. Methods: The various scid congenic mice including C.B-17-scid, BALB/cA-scid, BALB/cA Dh. scid, BALB/cA bg. scid, BALB/cA nu. scid, C57BL/6-scid and NOD/Shi-scid, and RAG2 gene-deficient strains C57BL/6-RAG0/0 and BALB/cA-RA
Int Conf AIDS 1996 Jul 7-12; 11:58 (abstract no. We.A.3007)
King PJ, McDougall B, Robinson WE; University of California, Irvine, CA, USA. Fax: (714) 824-2505.
Objective: Complement-mediated, antibody-dependent enhancement (C -ADE) of SIV infection has been demonstrated against uncloned SIVmac251 both in vivo and in vitro. To determine whether C -ADE could be observed using infectious molecular clones of SIV, the in vitro kinetics of SIVmac239 infection in the presence of com
Int Conf AIDS 1996 Jul 7-12; 11:58 (abstract no. We.A.3008)
Salha MD, Ringuette N, Arthos J, Fournier J, Beausoleil N, Scherring A, Bogdonovic B, Rud E, Sekaly RP; McGill University, Montreal, Canada.
Objectives: Clarify whether viral load is responsible for the perturbations in the T cell receptor (TCR) Vbeta repertoire of SIV-infected cynomolgus macaques. Methods: Flow cytometry analysis of TCR Vbeta repertoire in cynomolgus macaques non-infected and infected with either SIVmac32H(J5), Nef deficient virus SIVmac32
Int Conf AIDS 1996 Jul 7-12; 11:58 (abstract no. We.A.3009)
Fen GC, Xiaoxian W, Yaozeng L, Shuling X; China Academy of Traditional Chinese Medicine, Beijing, China. Fax: 00861-4013896.
Objective: Traditional Chinese medicine-ZY-1 Recipe revealed some effects in 104 AIDS patients treated in Tazania. Experimental study was made in animal model monkey, the antivitral, immunomodulatory and pathological effect of ZY-1 Recipe was observed. Methods: The ZY-1 Recipe was used for experimental treatment on mod
Int Conf AIDS 1996 Jul 7-12; 11:59 (abstract no. We.A.3010)
Gallicchio VS, Mayhew C, Oakley OO, Hughes NK, Piper J, Elford HL; University of Kentucky, Lexington, KY, USA. Fax: 606-257-7715. E-mail: VSGALL1@ukcc.uky.edu.
Objective: To obtain additional in vivo experimental evidence to determine whether a new series of ribonucleotide reductase inhibitors (RRI), 3,4-dihydroxybenzohydroxamic acid (Didox) and 3,4,5-trihydroxybenzamidoxime (Trimidox) can inhibit retrovirus replication by depriving virus of its source of the deoxynucleotides
Int Conf AIDS 1996 Jul 7-12; 11:59 (abstract no. We.A.3012)
Li X, Major C, Blake MS, Murray K, Gomez P, McNeil P, Bain RM, Strunc GV, Read S; Hospital for Sick Children, Toronto, Canada. Fax: 416-813-5032.
Objective: To evaluate HIV-specific IgA antibodies as a diagnostic marker for vertical HIV infection in babies. Study Design: A modified IgA antibody-capture enzyme -linked immunoabsorbent assay was used to detect HIV-specific IgA antibodies in serial plasma samples collected from 65 infants born to HIV-infected mother
Objective: To isolate and characterize human monoclonal antibodies (HMabs) against the envelope proteins of HIV-1 in view of therapeutic applications as passive immunotherapy. Methods: HMabs were produced by Epstein Barr virus transformation or/and fusion with murine myeloma of peripheral blood B lymphocytes of subject
Int Conf AIDS 1996 Jul 7-12; 11:59 (abstract no. We.A.3014)
Schreiber M, Wachsmuth C, Muller H, Hufert FT, van Laer MD, Laue T, Schmitz H, van Lunzen J; Bernhard Nocht Institue for Tropical Medicine, Hamburg, Germany. Fax: 49-40-31182-309.
Objective: To determine if the selective loss of type-specific anti-V3 antibodies is associated with viral escape and selection of HIV-1 variants in progressive HIV-1 disease. Results: The autologous antibody response directed against the V3 domains of HIV-1 cell-free virus (CFV) and cell-associated virus (CAV) variant
Int Conf AIDS 1996 Jul 7-12; 11:59 (abstract no. We.A.3015)
Rusconi S, Berlusconi A, Papagno L, de Maddalena C, Kurtagic S, Citterio P, Galli M; Clinica delle Malattie Intettive, Milano, Italy. Fax: +39.2.3560805.
Objective: Specific anti-HIV-1 antibodies (Abs) in vitro production (IVAP) shows to be different in various phases of HIV-1 infection (Rusconi et al., Clin Exp Immunol 1995). The aim of this study was to evaluate the specific pattern of IVAP in HIV-1-infected long term non progressors (LTNP). Methods: We tested 8 subje
Int Conf AIDS 1996 Jul 7-12; 11:59 (abstract no. We.A.3016)
Matsuda S, Noda M, Tokumoto S, Miyata M; Kure National Hospital, Hiroshima, Japan. Fax: (0823)21-0478.
Objective: Recently, mucosal immune system which is present in mucosal site,such as intestine and genital organs, was reported to be important for HIV-infection and maintenance. IgA antibodies have been suggested to play a role on prevention of mirobial invasion at mucosal site and secretory IgA can be assessable for m
Int Conf AIDS 1996 Jul 7-12; 11:60 (abstract no. We.A.3017)
Moritaka G, Gohchi K, Kawasugi K, Saitoh N, Tsukamoto M, Matsuda J; Teikyo University School of Medicine, Tokyo, Japan. Fax: 03-5375-0272.
Objective: We investigated whether or not a relationship exists between anti phospholipid antibody (aPL), especially anti cardiolipin antibody (aCL) and HIV-1 and/or hepatitis C virus (HCV). We attempted to clarify which virus has close association with development of aCL. Subjects and Methods: Subjects consisted of 62
Int Conf AIDS 1996 Jul 7-12; 11:60 (abstract no. We.A.3018)
Kojima A, Nakatsu F, Iwata T, Tachibana Y, Sairenji T, Oka S, Kurata T; Dept. of Pathology, NIH, Tokyo, Japan. Fax: (81)-3-5285-1189.
Objective: To find serological diagnostic markers relating with the progression of HIV infection, which are detectable by a quick, easy and low-cost assay method, ELISA. Methods: Recombinant Gag p17, p24, p7 or p6 proteins of HIV-1 (BH10) and ZEBRA protein of EBV were expressed as a fusion protein to GST in E. coli and
Objective: To quantitate the number of B-cells in lymphiod tissue and peripheral blood producing antibodies against the HIV-1 proteins gp 120 and p24, and to correlate antibody production to surrogate markers commonly used in HIV infection. Materials and methods: Peripheral blood (PB) and tonsillar tissue (TT) were obt
Int Conf AIDS 1996 Jul 7-12; 11:60 (abstract no. We.A.3020)
Petchclai B, Khupulsup K, Tanprasert S, Kurimura T; Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand. Fax: (66) (2) 2468271.
Objective: To determine the immunoglobulin classes of anti-HIV in blood donors showing early seroconversion and the results used as a guide for the development of screening test for anti-HIV. Methods: The presence of both p24 antigen and anti-HIV in a plasma specimen were used as evidence of early seroconversion. Plasm
Int Conf AIDS 1996 Jul 7-12; 11:60 (abstract no. We.A.3021)
Ahmad S, Giavedoni L, Jones L, Yilma T; International Lab. Of Mol. Biology, Uni. of California, Davis, CA, USA. Fax: 916-752-3349. E-mail: guillen@ingen.cigb.edu.cu.
Objective: The nef gene product has been implicated to play a role in viral pathogenesis. We expressed the nef gene of SIVmac239 and SIVmaclAll in insect cells. The recombinant nef protein was used to determine the level of anti-nef antibody response in macaques infected with SIV. Methods: The nef gene of SIVmac239 or
Int Conf AIDS 1996 Jul 7-12; 11:61 (abstract no. We.A.3023)
Mabondzo A, Rouvier P, Le Naour R, Raoul H, Courpotin C, Herve F, Parnet-Mathieu F, Lasfargues G, Dormont D; CEN-FAR, DSV/DRM/SNV, Fontenay aux Roses, France. Fax: (33-1) 46 54 77 26.
Objective: HIV burden of the mother, maternal immune factors and the integrity of the placental barrier are likely to play major roles in HIV-1 vertical transmission. In this view, we sought to determine whether the presence of antibodies in sera from 47 HIV-1 infected mothers that include 30 non transmitting (NT) and
Int Conf AIDS 1996 Jul 7-12; 11:61 (abstract no. We.A.3024)
Turbica I, Besnier JM, Simon F, Choutet P, Goudeau A, Barin F; Laboratoire de Virologie, Universite F Rabelais, Tours, France. Fax: (33) 47473610.
Objective: To study the prevalence, kinetics of development, biological significance and prognostic value of CD4BS Ab during HIV-1 infection. Methods: Detection and titration of CD4BS Ab was done using an enzyme immunoassay in which serum antibodies compete with the labeled F105 human monoclonal antibody for binding to
Int Conf AIDS 1996 Jul 7-12; 11:61 (abstract no. We.A.3026)
Gripp CB, Guimaraes ML, Neves I, Costa CI, Santos VG, Linhares de Carvalho MI, Galvao-Castro B, Bongertz V, Morgado MG; Dept. of Immunology/IOC/FIOCRUZ, Rio de Janeiro, Brazil.
Objectives: The aim of this work is to assess whether the polymorphism in this region could also restrict T cell antigenic response to the synthetic peptides corresponding to the V3 loop of distinct subtype B isolates, including the Brazilian B . Methods: We have evaluated the lymphoproliferative response (LR) of asymp
Int Conf AIDS 1996 Jul 7-12; 11:61 (abstract no. We.A.3027)
Beaulieu R, Vanhems P, Letendre F, Monte M, Belanger D, St-Louis J; Hotel-Dieu de Montreal, Montreal, QC, Canada. Fax: 514-843-2708. E-mail: beaulier@ere.umontreal.ca.
Objective: A prospective study was undertaken on 250 HIV-infected patients between January 89 and June 93 in order to find out if peripheral blood lymphocytes as measured by the spontaneous incorporation of tritium labelled thymidine in short term cultures were activated. Methods: All the patients were asymptomatic and
Int Conf AIDS 1996 Jul 7-12; 11:61 (abstract no. We.A.3028)
L'Homme C, Beaulieu R, Vanhems P, Roy L, Bernier-D'Astous M, Lalonde R; Hotel-Dieu de Montreal, Montreal, Quebec, Canada. Fax: 514-843-2748. E-mail: lhommec@ere.umontreal.ca.
Objective: To assess the association between the immunological status and the occurrence of opportunistic complications in HIV-infected patients in order to identify those which were the best predictors. Methods: We studied retrospectively 251 asymptomatic HIV-infected patients (class II and III [CDC]) within one year
Objective: To study the pathogenesis of the CD8 lymphocytic pseudotumoral infiltration that unfrequently occurs in AIDS patients presenting with a severe erythroderma exhibiting some of the clinical and anatomical features of epidermotropic cutaneous T cell lymphomas (CTCL). Methods: Immunophenotypic and molecular gene
Int Conf AIDS 1996 Jul 7-12; 11:62 (abstract no. We.A.3030)
Harrer T, Schmitt M, Harrer E, Low P, Weber C, Kalden JR; Department of Medicine III, University of Erlangen, Erlangen, Germany. Fax: 49-9131-856448.
Objective: An important issue in the development of an HIV-vaccine is the question whether all patients with identical HLA alleles can recognize the same HLA-I-restricted CTL-epitopes or whether additional factors restrict the recognition of epitopes. Therefore we studied the pattern of recognition of three defined HLA
Int Conf AIDS 1996 Jul 7-12; 11:62 (abstract no. We.A.3031)
Shin Yo, Kee MK, Choe BS, Min BS, Shin DY, Maeng SH; Center for AIDS Research, National Institute of Health, Seoul, Korea (South). Fax: 82-2-382-6542.
Objective: To determine the level of immunity among Korean with HIV/AIDS with time after their infection and compare CD4+ T lymphocyte numbers with disease progression. Methods: Three hundred and fourteen persons with HIV/AIDS in Korea were selected for the study and surveyed for zidovudine use and disease progression.
Objective: To analyse HIV antigen-stimulated cytokine production in HIV-infected individuals, health care workers (HCW) exposed to HIV-infected or uninfected blood/body fluids and presumably unexposed HIV seronegative individuals. Methods: Cytokine production in response to HIV envelope (env) peptides and a gp 120 depl
Objective: Describe the lymphocyte subpopulations in genital tract samples from HIV-infected women and the clinical correlates associated with lymphocyte shedding. Study design: Genital tract samples of HIV-1 infected women were processed for immunophenotyping analysis using a FACScan flow cytometer. Immunological and
Int Conf AIDS 1996 Jul 7-12; 11:62 (abstract no. We.A.3034)
Kannagi M, Yamada T, Fujii M, Iwamoto A, Oka S, Harada S; Department of Immunotherapeutics, Tokyo Medical and Dental University, Tokyo, Japan. Fax: 81-3-5803-0235.
Objective: To clarify the mechanisms of the CD8+ T lymphocyte-mediated suppression of HIV-1 replication in peripheral blood mononuclear cells (PBMC) of asymptomatic HIV-1 carriers. Methods: Immunological aspects of this suppression were investgated by using an experimental system with in vitro infection by a laboratory
Int Conf AIDS 1996 Jul 7-12; 11:62 (abstract no. We.A.3035)
Miyamoto K, Sugiura W, Okamoto Y, Yoshizaki H, Watanabe K, Yosino N, Seriyama M, Kitamura K, Meguro T, Yamada K, Yoshida K, Ishida N, Yamazaki S, Honda M; NIH, Tokyo, Japan. Fax: 03-5285-1183.
Objective: Recent observations have been pointed out that HIV-1 specific cytotoxic T lymphocytes (CTLs) in HIV-1 infected individuals may play major role to suppress the virus production in some infected individuals, and consequently regulate infection and HIV-induced diseases. In addition, Thai type virus were prevale
Int Conf AIDS 1996 Jul 7-12; 11:63 (abstract no. We.A.3036)
Yang OO, Johnson RP, Kalams S, Trocha A, Walker BD; Infectious Disease Unit, Massachusetts General Hospital, Boston, MA, USA. Fax: 617-726-5411.
Objective: To examine the ability of HIV-1 specific, class I restricted CTL to inhibit viral replication and to investigate the contributions of cytotoxicity and soluble inhibitory factor(s) in this inhibition. Methods: HIV-1 permissive cell lines were acutely infected with HIV-1 strain IIIB and viral replication was q
Int Conf AIDS 1996 Jul 7-12; 11:63 (abstract no. We.A.3037)
Pezzella M, Ferrazzi M, Russo M, Rosci MA, Miceli M, Mercurio P, Marinelli L, Sturchio E, Vonesch N, Mannella E; University "La Sapienza", Rome, Italy.
Objective: To study the HIV-1 inhibitory effect of cytoplasmatic molecules in peripheral blood lymphocytes (PBMCs) of seronegative high risk subjects, but repeatedly positive for HIV-1 genome by DNA:DNA/ DNA:RNA in situ hybridization. Methods: Dialyzable cytoplasmatic uncultured leucocyte extracts of two seronegative s
Int Conf AIDS 1996 Jul 7-12; 11:63 (abstract no. We.A.3038)
Carini C, Fratazzi C; Harvard School Publ Health, Boston, MA, USA.
Objective: To gain insights into the mechanisms involved in the destruction of HIV-infected cells by gamadelta CTL and the role played by integrin and adhesiveness among T cell subsets. Methods: Ten seropositive asymptomatic HIV-1 infected subjects and 5 HIV-negative healthy subjects have been studied for HIV specific
Int Conf AIDS 1996 Jul 7-12; 11:63 (abstract no. We.A.3039)
de Larranaga G, Harris N, Pierangeli S, Alonso B; Hemostasia, Hospital "F. J. Muniz", Buenos Aires, Argentina. Fax: (54-1)432-6625.
Objective: Autoimmune anticardiolipin antibodies (aCL) are phospholipid binding antibodies (aPL) and have been associated with arterial and venous thrombosis, recurrent fetal losses and low platelet counts and a positive lupus anticoagulant test (LA). In addition, utilizing cardiolipin as antigen, most ELISA assays ava
Int Conf AIDS 1996 Jul 7-12; 11:63 (abstract no. We.A.3040)
Donadi EA, Lopes I, Machado AA; University Hospital, School of Medicine of Ribeirao Preto, SP, Brazil. Fax: 55 016 633 6695.
Objective: To determine auto- and allosensitization to lymphocyte antigens in homosexual and intravenous drug addiction (IVDA) AIDS patients, with no previous history of blood transfusions. Methods: Fifty-one HIV+, group IV, male patients were studied; subset A: 31 IVDA patients, aged 20 to 39 years (median = 29), with
Int Conf AIDS 1996 Jul 7-12; 11:64 (abstract no. We.A.3041)
Chia WK, Read S, Freedman J, Li X, Wright F; St. Michael's Hospital, Department of Immunohaematologty, Toronto, Ontario. Fax:(905)849-3853.
Objective: To study the presence of antibodies reactive to vaccinia virus elicited by HIV infection. Methods: Serum specimens collected from HIV-infected individuals (34 adults and 16 children) were examined for the presence of antibodies reactive to vaccinia virus (vSC-8) by immunofluorescent (IF) microscopy. Western
Int Conf AIDS 1996 Jul 7-12; 11:64 (abstract no. We.A.3042)
Derancourt C, Mole C, Leroy J, Drobacheff C, Laurent R, Vuitton D; Department of Dermatology, University-Hospital, Besancon, France.
Objective: To determine whether increased serum levels of secretory immunoglobulins occur in HIV infection, and constitute a predictor of evolution towards AIDS. Methods: - The serum levels of secretory (S) IgA, S-IgM and secretory component (SC) were assayed using an ELISA in 46 patients (CDC groupe A: 17; CDC groupe
Int Conf AIDS 1996 Jul 7-12; 11:64 (abstract no. We.A.3043)
Aries SP, Schaaf B, Kaschinski D, Mueller C, Weyrich K, Dennin RH, Dalhoff K; Dept. of Internal Medicine, Medical University of Luebeck, Germany. Fax: 0049-451-314 83.
Objective: Several lines of evidence suggest a dysregulation of the complement system in HIV infection. Methods: We investigated the expression of complement receptors (CD35,CD21,CD11b,CD11c) and complement regulatory proteins (CD46,CD55,CD59) on bronchoalveolar lymphocytes from 19 HIV+ individuals (all CDC III) and 7
Int Conf AIDS 1996 Jul 7-12; 11:64 (abstract no. We.A.3044)
Neilsen GA, Bodsworth NJ, Watts N; Indonesia HIV/AIDS & STD Prevention and Care Project, Jakarta, Indonesia. Fax: +62-21-350 5564. E-mail: 100236.137@compuserve.com.
Objectives: To examine the influence of HIV infection; HIV-related immune depression; and vaccine schedule on the immunogenicity of an inactivated hepatitis A vaccine, (HAVRIX, SmithKline Biologicals). Design and methods: Open, randomised, prospective, multi-centre study. 90 HIV-infected homosexual men were randomised
Objective: To assess the effect of coinfection with HIV in patients (pts) with mixed cryoglobulinemia (cryo) induced by hepatitis C virus (HCV). Methods: One-hundred-and-eigthy-two HCV-infected pts were studied: 120 men (73 HIV-positive, 47 HIV-negative, mean age 35 and 38 yrs, respectively) and 62 women (45 HIV-positi
Int Conf AIDS 1996 Jul 7-12; 11:64 (abstract no. We.A.3046)
Piu G, Merella W, Liguori M, Piro S, Palomba S, Garau MG, Crociani C, Spissu A; S. Michel Hospital, Cagliari, Italy. Fax: 070-531717.
Objective: We evaluated the intratecal production of IgG by seeking the oligoclonal bands into CSF from HIV+ patients, to get some indications about the evolution stage of HIV infection. Methods: We examined the CSF of 15 patients (12o - 3o),aged on average 28. Just about. every patient was included in the Walter Reed
Int Conf AIDS 1996 Jul 7-12; 11:65 (abstract no. We.A.3047)
Sasaki Y, Lecoeur H, Blanchard A, Montagnier L, Gougeon ML; NIH, Tokyo, Japan. Fax: 81-425-65-3315. E-mail: yuko@nih.go.jp.
Objective: HIV infection is characterised by a progressive depletion of CD4+T lymphocytes. Both CD4+ and CD8+ T lymphocytes from HIV-infected individuals have been shown to undergo spontaneous apoptosis in vitro. In order to analyse molecular mechanisms of apoptosis in CD4+ and CD8+ T cell subsets, Fas/APO-1 (CD95) exp
Int Conf AIDS 1996 Jul 7-12; 11:65 (abstract no. We.A.3048)
Garcia R, Aceituno E, Castanon S, Gorgolas M, Fernandez-Guerrero M, Ortiz F; Dpt. of Immunology, Fundacion Jimenez Diaz, Madrid, Spain. Fax: 34-1-549 47 64.
Objective: Recently, immune complexes of rgp120-anti-gp120 were known to induce apoptosis of normal lymphocytes. The present paper try to demostrate that naturally occurring circulating immune complexes from HIV-1 + patients can induce apoptosis of normal human lymphocytes. Methods: Circulating immune-complexes (CIC) o
Int Conf AIDS 1996 Jul 7-12; 11:65 (abstract no. We.A.3049)
O'Gorman MR, Kleeberger C, Gange S, Peng Y, Margolick J, Farzadegan H, Phair J; Children's Memorial Hospital, Chicago, IL, USA. Fax: (312) 880-3739. E-mail: mogorman@nwu.edu.
Objective: To compare the levels of immunoglobulin (Ig) classes G, A and M as well as the IgG subclasses, IgG1, IgG2, IgG3 and IgG4 in the sera of rapid vs. non-rapid progressors to AIDS. Methods: The 2 comparison groups were selected from men enrolled in the Multicenter AIDS Cohort Study (MACS): 10 men who had progres
Int Conf AIDS 1996 Jul 7-12; 11:65 (abstract no. We.A.3050)
Giovannetti A, Ricci G, Pierdominici M, Guerra EC, Quinti I, Cassone A, Aiuti F; Dept. Clinical Medicine, University "La Sapienza", Rome, Italy,.Fax: +396 44 54621.
Objective: Mucosal candidiasis is one of the first opportunistic diseases in HIV-infected subjects. We have already demonstrated that cultured PMBC from HIV-1 infected subjects manifested an early decreased ability for proliferative as well differentiative cytotoxic responses to immunodominant candidal mannoproteins (M
Introduction: Before 1985 when routine screening for HIV in blood products commenced, 133 individuals became infected and were subsequently traced by the NSW Red Cross Blood Transfusion Service Lookback Program. The identification of specific donors and time of donation for 108 of these recipients contributed to the di
Int Conf AIDS 1996 Jul 7-12; 11:65 (abstract no. We.A.3052)
Biti RA, Williamson P, Stewart GJ; Dept. Clinical Immunology, ICPMR, Westmead Hospital, Westmead, NSW, Australia. Fax: 61-2-891 3889. E-mail: ROBYNB@westmed.wh.su.edu.au.
Objective: To develop quantitative reverse transcription-polymerase chain reaction (QRT-PCR) assays for measurement of interleukin-2 ( IL-2 ) and IL-2 receptor (IL-2R)alpha mRNA, to study (i) the loss of T helper cells ability from HIV+ individuals to respond to antigen and (ii) the effect of Nef and Gag on CD28 signal
Int Conf AIDS 1996 Jul 7-12; 11:66 (abstract no. We.A.3053)
Trickett A, Dwyer J; Haematology, Southpath, St George Hospital, Kogarah, Australia. Fax: +61-2-350-3942.
Objective: To determine the proportions of naive and memory CD4 and CD8 lymphocytes during longitudinal assessment of initially asymptomatic HIV-infected patients. Methods: Peripheral blood samples collected at yearly intervals from 32 initially asymptomatic HIV-infected patients were stained with conjugated antibodies
Objective: To check cell-mediated immunity/CMI/ in HIV-1 infected persons in different stages of infection and to look for correlation between parameters of CMI and disease progression. Methods: 18 bulgarian HIV-1 infected persons in different stages of infection were followed-up at 3-6 months intervals for a two years
Int Conf AIDS 1996 Jul 7-12; 11:66 (abstract no. We.A.3055)
Asad S, Petsche D, Read S; Division of Invfectious Diseases and Allergy/Immunology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. Fax: 416-813-5032.
The CD4 molecule is the usual receptor for HIV. However, replication in non-CD4 bearing cells has been reported. We have studied the phenotypic expression of surface markers on B lymphocytes following HIV infection. Methods: A B-lymphocyte line established from a patient (P) with HIV and EBV infection and also Daudi ce
Int Conf AIDS 1996 Jul 7-12; 11:66 (abstract no. We.A.3056)
Eugen-Olsen J, Andresen L, Nielsen JO, Hofmann B; Department of Infectious Diseases, Hvidovre Hospital, Denmark. E-mail: Jeo@biobase.dk.
Objectives: To investigate the mechanism by which HIV Gag p17 protein impairs proliferation and modulates cytokine gene expression in normal T cells. Methods: We have previously shown that HIV proteins impair T-cell proliferation in response to mitogens by a mechanism involving the inhibitory cAMP/PKA pathway (Hofmann,
Int Conf AIDS 1996 Jul 7-12; 11:66 (abstract no. We.A.3057)
Peceny J, Tkaczuk J, Massip P, Bonnet E, Marchou B, Ohayon E, Auvergnat JC; Dept of Infectious Diseases, Hospital Rangueil, Toulouse, France.
Objective: The peripheral T gamadelta lymphocyte (T gamadelta L) count is high in HIV-1 seropositive individuals. The Vdelta1 subtype is frequently predominant. The aim of our study was to detect the variation of the T gamadelta L count in various clinical and biological situations during a 12 months period. Methods: T
Int Conf AIDS 1996 Jul 7-12; 11:67 (abstract no. We.A.3058)
Buisson O, Dighiero G, Scott-Algara D; Immunohematology and Immunopathology Service, Institut Pasteur, Paris, France. Fax: (33) 1 45 68 89 51. E-mail: Scott@pasteur.fr.
Objective: To determine the role of HIV-1 p24 protein during in vitro allogeneic response. Method: Mismatched peripheral blood mononuclear cells from normal donors were put in culture in the presence or absence of recombinant p24 or gp120. The proliferation, secretion of cytokines or TCR-Vbeta usage were measured 6 day
Int Conf AIDS 1996 Jul 7-12; 11:67 (abstract no. We.A.3059)
Ledrue DS, Lembele M, Zoubga A, Dahourou H, Fumoux F, Gougeon ML; Unite d'Oncologie Virale, Department SIDA et Retrovirus Institut Pasteur, Paris, France. Fax: 33 1 45 68 89 09.
Objectives: Tuberculosis is the major cause of death in West-African patients with HIV infection. Vg/Vgcells, recently shown to react with mycobacterial non-peptidic antigens, could have a central role in immune surveillance of intracellular pathogens. Expression of this VT cell subset was analysed in TB+ patients, whe
Int Conf AIDS 1996 Jul 7-12; 11:67 (abstract no. We.A.3060)
Hartmann P, Romer J, Franzen C, Hegener P, Diehl V, Fatkenheuer G; Department of Internal Medicine I, University Clinics of Cologne, Germany. Fax: 49-221-478 6456.
Objective: Aim of this study was to determine whether production of oxygen radicals by PMN of HIV-infected Patients is dependent on the stage of disease and if impairment of oxygen burst could be compensated by the administration of GCSF in vitro. Subjects and Method: We measured oxygen radical production of PMN derive
Int Conf AIDS 1996 Jul 7-12; 11:67 (abstract no. We.A.3061)
Choremi-Papadopoulou H, Viglis V, Gargalianos P, Kordossis T, Samouilidou E, Kosmidis J; Immunology Department, Laiko General Hospital, Athens, Greece. Fax: 01-7757442.
Objective: In a previous study we demonstrated downregulation of CD28 surface antigen in both CD4+ and CD8+ T cell subsets in HIV-1 infection. It has been also reported that T cell function as measured by responses to CD3 MAb is a prognostic marker for development to AIDS. CD28 surface antigen is a costimulatory signal
Int Conf AIDS 1996 Jul 7-12; 11:67 (abstract no. We.A.3062)
Viora M, Pugliese O, Camponeschi B, Giacomini E, Giordani L, Di Genova G, Fattorossi A, Boirivant M, Luzzati AL; Lab.of Immunology, Istituto Superiore di Sanita Viale, Roma Italy.
Objective: To study the role of HIV structural (p24, gp120) and regulatory (nef) proteins as causative agents of some immunological impairments in AIDS and to study the effects of antiretroviral drugs on different immune functions in view of their use in immunocompromised HIV-infected patients. Methods: The experimenta
Int Conf AIDS 1996 Jul 7-12; 11:67 (abstract no. We.A.3063)
Piazza C, Gilardini MM, Cundari E, Moretti S, Piccolella E; Department of Cellular and Developemental Biology, University of Rome "La Sapienza", Rome, Italy. Fax: 39-6-49917594.
The observation that both CD4+ and CD8+ T cells from HIV-infected individuals undergo abnormal programmed cell death by apoptosis, raises the question of the mechanisms responsible for the development of apoptosis in CD8+ T cells. Although it is highly unlikely that apoptosis mediated by the HIV glycoprotein, gp120, ca
Int Conf AIDS 1996 Jul 7-12; 11:68 (abstract no. We.A.3064)
Sakaida H, Kawamata S, Hattori T, Uchiyama T; Institute for Virus Research, Kyoto University, Kyoto, Japan. Fax: 81-75-751-4049.
Objective: We investigated the effect of the third variable loop (V3 loop) of HIV-1 gp120 on IL-2-dependent T cell growth and found that (1) V3 loop markedly suppressed IL-2-induced cell proliferation and (2) produced G1 arrest of IL-2-dependent Kit 225 cell line. In this study, we have examined the effect of V3 loop o
Int Conf AIDS 1996 Jul 7-12; 11:68 (abstract no. We.A.3065)
Tuset Ruiz C, Pedro F, Carbonell-Uberos F, Mir A, Ferrer C, Lopez-Santovena F, Herrera A; Section of Immunology, Hospital General Univ., Tres Cruces, Valencia (Spain).
Objective: An analysis was made of the presence of the alpha subunit of the IL-2 cellular receptor, represented by antigen CD25, in certain cell populations of HIV-infected patients. Methods: Clinico-biological controls were made every three months for two years in 55 HIV-infected patients (26 belonging to Group A, 15
Int Conf AIDS 1996 Jul 7-12; 11:68 (abstract no. We.A.3066)
Benito JM, Zabay JM, Gil J, Bermejo M, Escudero A, Carbone J, Rodriguez C, Fernandez-Cruz E; Division of Immunology, Hospital General "Gregorio Maranon", Madrid, Spain. Fax: 34-1-5868018.
Objective: To determine the representation of naive and memory subsets of CD4+ and CD8+ T cells, suppressor and cytotoxic subsets of CD8+ T cells, and the activated populations of all of these subsets in the HIV infection. Methods: The subsets of CD4+ and CD8+ T cells have been quantitated by three-colour flow cytometr
Int Conf AIDS 1996 Jul 7-12; 11:68 (abstract no. We.A.3067)
Siegal FP, Shodell M, Robins T, Sevall JS; Long Island Jewish Medical Center (AECOM), New Hyde Park, NY, USA.
Objective: To define the relationship of virus burden of HIV-1 to mononuclear cell interferon-alpha generation (IFN-alphaGN) in response to Herpes simplex virus, and its relative correlation with CD4 lymphocyte count. IFN-alphaGN is a natural, T cellindependent functional marker of non-T blood mononuclear cells (MNC) h
Int Conf AIDS 1996 Jul 7-12; 11:68 (abstract no. We.A.3068)
Patki AH, Lederman MM; Center for AIDS Research, University Hospitals of Cleveland, Cleveland, OH, USA. Fax: (216) 368-5415. E-mail: ahp3@po.cwru.edu.
Objectives: To ascertain the relationships among CD4+ T cell count, spontaneous apoptosis and Fas expression in PBMC obtained from HIV-1-infected subjects. Methods: Heparinized blood was obtained from 56 HIV-1-infected subjects with circulating CD4+ T cell counts from 0 to 990/mL and from 12 healthy controls. PBMC were
Int Conf AIDS 1996 Jul 7-12; 11:69 (abstract no. We.A.3069)
Tumietto F, Valet G, Costigliola P, Marinacci G, Ganesh S, Di Bari MA, Borderi M, Colangeli V, Dentale N, Chiodo F; Institute Of Infectious Diseases, University of Bologna, Bologna, Italy.
Introduction and Background. Many Authors have described defective capacity in the phagosome formation and /or in the O2-dependent killing (oxidative burst) in course of the HIV infection. Recently, flow cytometry has been used to better analyse these immune functions, offering more advantages. Moreover, the availabili
Int Conf AIDS 1996 Jul 7-12; 11:69 (abstract no. We.A.3070)
Medrea DP, Paunescu V, Tatu CA, Stanescu D, Costa R; University of Medicine, Timisoara, Romania.
Objective: To investigate the CD69, CD25 and HLA-DR molecules expression on leukocyte surface, as immune activation markers in HIV infection Methods: Flow-cytometric assessement was performed on whole lysed peripheral blood, from 35 HIV-infected children. Monoclonal antibodies coupled with FITC or PE, with specificites
Int Conf AIDS 1996 Jul 7-12; 11:69 (abstract no. We.A.3071)
Nokta MA, Nichols J, Pappas T, Rosenbaum M, Pollard R; University of Texas Medical Branch, Galveston, TX. Fax: 409-747-1857.
Objective: Apoptosis (AP) is associated with the pathogenesis of HIV disease. In this study the objective is to determine if the tumor suppressor gene p53 is involved in the regulation of spontaneous and activation induced AP in cells from patients with HIV-infection. Methods: Peripheral blood mononuclear cells from HI
Int Conf AIDS 1996 Jul 7-12; 11:69 (abstract no. We.A.3072)
Zekeng L, Sadjo A, Babiel R, Kaptue L, Hess; AIDS Control Program, Yaounde, Cameroon. Fax: 237 23 02 96.
Objective: To establish baseline means of the absolute CD4+ (ACD4), CD8+ (ACD8) T lymphocyte and the CD4/CD8 ratio among healthy HIV seronegative Cameroonians adults. Methods: Randomly selected visitors and guardians of patients admitted in 4 biggest hospitals in yaounde were enrolled. Verbal informed consent was obtai
Int Conf AIDS 1996 Jul 7-12; 11:69 (abstract no. We.A.3073)
Raoul H, Blond D, Le Naour R, Mabondzo A, Dormont D; CEN-FAR, DSV/DRM/SNV, Fontenay aux Roses, France. Fax: (33-1) 46 54 77 26.
Objective: We studied: 1) the effects of HIV-1 in vitro infection of cultured human macrophages on the MnSOD, Cu/ZnSOD, and iNOS gene expression, 2) the potential regulation of these genes by the inflammatory cytokines, and 3) the effect of NO production on the HIV replication. Methods: Human monocytes were isolated fr
Int Conf AIDS 1996 Jul 7-12; 11:70 (abstract no. We.A.3074)
Carlesimo M, Varani AR, Bernardi ML, Guerra EC, Mezzaroma I, D'Offizi G, Pontesilli O, Paganelli R, Aiuti F; Department of Allergology and Clinical Immunology, University of Roma, Rome, Italy. Fax: +39-6-445-4621.
Objective: To study the effect of CD28 mediated costimulation on lymphoproliferation to anti-CD3 monoclonal antibody (mAb) in patients at different stages of HIV infection. Methods: Blood was collected from 6 long term non progressor (LTnP) subjects ( Documented seropositivity from at least 7 years, asymptomatics with
Int Conf AIDS 1996 Jul 7-12; 11:70 (abstract no. We.A.3075)
Yoshino N, Okamoto Y, Someya K, Nakasatomi T, Miyamoto K, Yoshizaki H, Watanabe K, Ando S, Takizawa M, Meguro T, Takamatsu J, Kayagaki N, Yagita H, Ueno Y, Honda M; AIDS Res. Cent. NIH, Tokyo, Japan. Fax: 03-5285-1183.
Objective: CD4 cell population in HIV-infected patients markedly decreases followed by progression of HIV/AIDS pathogenesis. This is one of the difficulties in understanding the complex pathology of HIV/AIDS. It may be crucial for its understanding to study the role of apoptosis in HIV pathogenesis. Methods: In this st
Int Conf AIDS 1996 Jul 7-12; 11:70 (abstract no. We.A.3076)
Paunescu V, Medrea DP, Tatu CA, Stanescu D, Costa R; University of Medicine, Timisoara, Romania.
Objective: To reveal a possible correlation between the levels of gamadelta T cells and CD4+ T cells, in HIV-infected children and possible implications in the pathogenesis of the immunodepression Methods: The study was performed on 35 HIV horizontally infected children, in different stages of the disease. Flow-cytomet
Int Conf AIDS 1996 Jul 7-12; 11:70 (abstract no. We.A.3077)
Lu SS, Chen W, Kotler DP; St. Lukes-Roosevelt Hosp. Center, New York, NY, USA.
Objective: To quantitate mucosal apoptosis along the length of the intestine. Previous studies had demonstrated variation in apoptosis during disease progression. Methods: Retrospective analysis of upper and lower intestinal biopsies in 15 HIV+ patients and 4 controls. Peripheral blood CD4+ lymphocyte counts ranged fro
Int Conf AIDS 1996 Jul 7-12; 11:70 (abstract no. We.A.3078)
Boyer JD, Wang B, Ugen K, Baggarazi M, Chattergoon M, Javadian A, Agadjanyan M, Higgins T, Carrano RA, Coney L, Weiner DB; University of PA, Philadelphia, PA, USA. Fax: 215-573-9436.
An efficacious prophylatic vaccine has the ability to eventually eliminate HIV-1 infection. Project: In vivo injection of DNA expression vectors, which code for foreign proteins, have proven to express active proteins in vivo and induce both a cellular and humoral immune response. In smaller animal models this i
Int Conf AIDS 1996 Jul 7-12; 11:70 (abstract no. We.A.3079)
Ffrench R, Clarkson J, Marshall P, Kelleher A, Smith D, Patou G, Gow I, Cooper D, Stewart G, Benson E; Department of Immunology, Westmead Hospital, NSW, Australia.
Cytotoxic T cells are now considered to be critical in the immunopathogenesis of HIV infection. We are evaluating whether HIV-specific CTL activity can be increased by the administration of an immunotherapeutic agent. Individuals participating in the trial were randomised to one of 3 arms; p24-VLP alone, zidovudine alo
Int Conf AIDS 1996 Jul 7-12; 11:71 (abstract no. We.A.3080)
De Lucca FL, Sales VS, Lucchiari MA, Watanabe MA, Silva JS, Voltarelli JC; Dept. Biochem., Sch. Medicine Univ., Sao Paulo, Brazil. Fax: 55-16-6336840. E-mail: fldlucca@fmrp.usp.br.
Objective: It is known that exogenous RNAs are incorporated into eukaryotic cells and are able to exert various biological effects. One of the most interesting biological properties of exogenous RNA is its ability to transfer cellular immunity to a variety of antigens. We examined the ability of exogenous RNA to induce
Int Conf AIDS 1996 Jul 7-12; 11:71 (abstract no. We.A.3081)
Kinchington D, Ng T, Mathews N, Ayuko W; Dept. Virology, St. Bartholomew's Hopital, London, UK.
A number of analogues of benzoic acid were evaluated as putative immunomodulators. Several compounds, in the presence of an anti-CD3 activating antibody, costimulated human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner (p=0.001). This effect was accompanied by the induction of tyrosyl phosphoryla
Int Conf AIDS 1996 Jul 7-12; 11:71 (abstract no. We.A.3082)
Ullum H, Victor J, Katzenstein T, Geerstoft J, Gotzsche PC, Bendtzen K, Skinhoj P, Pedersen BK; Department of Infectious Diseases, Rigshospitalet, Copenhagen, N. Denmark. Fax: (45) 35457644.
Objectives: Tumor necrosis factor-alpha (TNF-alpha) and interleukin 1beta (IL-1beta) stimulate the replication of HIV and may cause weight loss and fever in patients with HIV infection. This study was performed to test the ex vivo production and the plasma-levels of IL-1beta and TNF-alpha and their relation to immunolo
Int Conf AIDS 1996 Jul 7-12; 11:71 (abstract no. We.A.3083)
Taoufik Y, Wallon C, Delfraissy JF; Universite Paris Sud, Le Kremlin Bicetre, France. Fax: 33 (1) 49596753.
Introduction: Interleukin-12 (IL-12 or P70) is a heterodimeric cytokine formed by two covalently linked chains P40 and P35. IL-12 is mostly produced by activated monocytes and macrophages and has potent biological effects on NK and T cells. It has been recently shown that mononuclear cells from patients with HIV infect
Int Conf AIDS 1996 Jul 7-12; 11:71 (abstract no. We.A.3084)
Rimaniol AC, Zylberberg H, Zavala F, Viard JP; INSERM, Clinical Immunology Department Hospital Necker, Paris, France. Fax: 33-1-43-06-23-88.
Objective: The aim of this study was to determine circulating levels of IL-1Ra and other markers of immune activation in HIV-infected patients, and their changes during disease progression. Methods: Sixty-one HIV patients were classified into CDC groups A (n=14), B (n=14) and C (n=33). Blood was collected and serum lev
Objective: We observed a very low spontaneous mortality rate in lymphoid cells from HIV+ subjects defined as Long-Term non Progressors (LTnP). Since some cytokines, as IL-2 , protect from apoptosis, we have studied the pattern of cytokine production in T cell clones from LTnP patients in comparison to HIV+ subjects at
Int Conf AIDS 1996 Jul 7-12; 11:72 (abstract no. We.A.3086)
Mastroianni CM, Paoletti F, Valenti C, Folgori F, Santopadre P, Forcina G, Vullo V; Dept. Infectious and Tropical Diseases, La Sapienza University, Rome, Italy. Fax: 39 6 4453760.
Objective: To evaluate the production of tumor necrosis factor alpha (TNFalpha) and soluble TNF receptors (sTNF-Rs) in AIDS-associated cryptococcosis. Methods: Cerebrospinal fluid (CSF) samples from 22 AIDS patients with cryptococcal meningitis and 44 AIDS patients with other neurological HIV-related diseases were eval
Int Conf AIDS 1996 Jul 7-12; 11:72 (abstract no. We.A.3087)
Okamoto M, Makino M, Kitajima I, Maruyama I, Baba M; Center for Chronic Viral Diseases, Faculty of Medicine, Kagoshima University, Kagoshima, Japan. Fax: 81-99-275-5932.
Objective: To determine whether Fas (CD95) antigen is involved in the programmed cell death (apoptosis) of OM10.1 cells (a promyelocyte cell line latently infected with HIV-1). Methods: OM10.1 cells were cultured in the presence of various concentrations of either anti-Fas monoclonal antibody, TNF-alpha, or both. After
Int Conf AIDS 1996 Jul 7-12; 11:72 (abstract no. We.A.3088)
Tsuchie H, Detorio MA, Hossain MM, Ohwatari S, Zhang J, Taniguchi K, Nishimoto A, Shirono H, Koga J, Kurimura T; Research Institute for Microbial Diseases, Osaka University, Osaka, Japan. Fax: 06-875-3894. E-mail: tsuchie@biken.osaka-u.ac.jp.
Objective: To determine whether the inhibitory effect of cytokine(s) produced by CD8+ T cells from HIV-infected individuals on HIV transcription is type-specific. Methods: HIV-1 or HIV-2 LTR directing the chloramphenicol acety ltransferase gene (CAT) in transient transfection assays using a human T cell line of CEM wer
Int Conf AIDS 1996 Jul 7-12; 11:72 (abstract no. We.A.3089)
Tateyama M, Hattori M, Oishi T, Miyasaka S, Ohmoto Y, Fukutake K; Tokyo Medical College, Tokyo, Japan. Fax: 81-3-3340-5448.
Objective: We investigated the effect of gp120 and p24 on the release of soluble TNF receptor (sTNFR) and TNF-alpha in mononuclear cells (PBMCs) from healthy subjects. Methods: PBMCs were obtained from six healthy subjects. PBMCs were cultured for 48h in the presence or absence of recombinant gp120 (rgp120) which was d
Int Conf AIDS 1996 Jul 7-12; 11:72 (abstract no. We.A.3090)
Tanaka Y, Tanaka R, Nishimura T, Koyanagi Y, Yamamoto N; Sch. Science, Kitasato University, Kanagawa, Japan. Fax: +467-78-9480.
Objective: To determine replication potential of macrophage/primary T cell (M/T)-tropic HIV-1 in Th1-like CD4+T cells in which primary T cell/T cell line (T/T)-tropic HIV-1 cannot replicate Methods: Purified human CD4+ T cells were resuspended in 12% FCS-RPMI with 100 U/ml IL-2 and either 100 U/ml IL-12 or IL-4 at
Int Conf AIDS 1996 Jul 7-12; 11:72 (abstract no. We.A.3091)
Kaneko H, Sekigawa I, Takeda N, Neoh LP, Ogasawara H, Yamaguchi K, Hishikawa T, Takasaki Y, Iida N, Hashimoto H, Yamamoto N, Hirose S; Dept. of Rheumatology, Juntendo Univ., Tokyo, Japan. Fax: +81-(3)-5800-4893.
Objective: HIV-1 infected patients have T cell dysregulation including T cell activation and decline of IL-2 production. We showed these T cell dysregulation induced by gp120 and investigated this mechanism. Vesnarinone (Otsuka Pharmaceutical. Co., Japan ) has been known to reduce the replication of HIV-1
Int Conf AIDS 1996 Jul 7-12; 11:73 (abstract no. We.A.3092)
Gray CM, Morris L, Murray J, Shalekoff S, Sonnenberg P, Martin DJ; Center for AIDS Research, Division of Infectious Diseases and of Geographical Medicine, Stanford University Medical Center, Stanford, CA, USA. E-mail: cgray@leland.stanford.edu.
Objective: To identify the cellular source of endogenous cytokines in HIV-1 infected lymph nodes. Methods: Lymph node biopsies were collected from 3 HIV- and 4 HIV+ patients, including a patient undergoing seroconversion illness. Cells were liberated after collegenase digestion and assessed for total cytokine mRNA expr
Int Conf AIDS 1996 Jul 7-12; 11:73 (abstract no. We.A.3093)
Gurbindo MD, Obregon E, Navarro J, Fdez-Cruz E, Munoz-Fdez MA; Division Of Pediatrics, Division Of Immunology, H. Gregorio Maranon, Madrid, Spain.
Objective: To evaluate serum levels of TNF-alpha and circulating intercellular adhesion molecule-1 (cICAM-1) in 52 HIV-1 infected children. Methods:The study subjects included 52 children (34 females, 18 males, mean age of 46.6 plus or minus 6.6 months) admited to our Division of Pediatrics who were born to HIV-infecte
Int Conf AIDS 1996 Jul 7-12; 11:73 (abstract no. We.A.3094)
Grutzmeier S, Gerstoft J, Boje Hansen P, Sandstrom E; Gay Men's Health Clinic, The South Hospital, Stockholm, Sweden.
Objectives: Leukopenia in AIDS-patients is common. Causes can be HIV-infection, mycobacterial ( MAC ) infection, cytomegalovirusinfection ( CMV ), antibiotics, antiviral medications or cytostatic therapy for Kaposis sarkoma (K S) Treatment with G-CSF is succesfull in reversing the leukopenia but its effects on survival
Int Conf AIDS 1996 Jul 7-12; 11:73 (abstract no. We.A.3095)
Schifitto G, Kieburtz K, Fitzgerald T, Soucier H, Evans T; University of Rochester, Rochester, NY. Fax: 716-273-1074.
Objective: To assess the relationship between autonomic nervous system (ANS) deficits and the production of cytokines by peripheral blood mononuclear cells (PBMC) in HIV-positive subjects. Background: The ANS innervates primary and secondary lymphoid organs; furthermore, PBMC express adrenergic receptors. In animal mod
Int Conf AIDS 1996 Jul 7-12; 11:73 (abstract no. We.A.3096)
Dezube BJ, Lederman MM, Chapman B, Georges DL, Dogon A, Mudido P, Silberman SL, Crumpacker CC; AIDS Clinical Trials Unit, Cleveland, OH. Fax: (216) 844-5523. E-mail: MXL@po.cwru.edu.
Objectives: Tenidap, a structurally and functionally novel antirheumatic antiinflammatory drug decreases proinflammatory cytokine (IL-6, TNF-alpha, IL-1beta) production in vitro and decreases plasma levels of IL-6 in rheumatoid arthritis patients. This study was designed to ascertain if tenidap treatment decreases leve
Int Conf AIDS 1996 Jul 7-12; 11:74 (abstract no. We.A.3097)
Patke CL, Green C, Shearer W; Texas Children's Hospital, Baylor College of Medicine, Houston, TX. Fax: 713-770-1260.
Objective: Binding and infection by HIV, independent of CD4 and without viral penetration has been observed in human B cells. TNFalpha, and IL6 which are secreted by B cells of HIV-infected individuals known to be important regulators of HIV production, whereas IL2 and IL4 are potent regulators of B cell responses. The
Int Conf AIDS 1996 Jul 7-12; 11:74 (abstract no. We.A.3098)
Lee BN, Li S, Popek E, Hammill H, Erickson N, Helfgott A, Shearer W, Reuben J; University of Texas, Houston, TX. Fax: 713-792-4296. E-mail: blee@odin.mdacc.tmc.edu.
Objective: Cytokines, IL-1beta, IL-6 and TNF-alpha, have been associated with increased expression of HIV in experimental systems. To address the possible roles of cytokines in vertical transmission of HIV, we measured the transcription and production of inflammatory cytokines and the level of HIV-gag sequences in trop
Int Conf AIDS 1996 Jul 7-12; 11:74 (abstract no. We.A.3099)
Reuben J, Lee BN, Ordonez N, Shen DY, Paul M, Popek E, Hammill H, Shearer W; University of Texas, Houston, TX, USA. Fax: 713-792-4296. E-mail: blee@odin.mdacc.tmc.edu.
Objective: Vertical transmission of HIV from mother to infant occurs at a rate of less than 30%. To investigate the potential anti-viral mechanisms in the micro-environment of maternal-fetal interface, we determined the constitutive production of interferon-g (IFN-g) and the level of interferon-beta1 (IFN-beta1) transc
Int Conf AIDS 1996 Jul 7-12; 11:74 (abstract no. We.A.3100)
Adams JM, Hu J, D'Ambrosio R, Morse GD; SUNY at Buffalo, Buffalo, NY, USA. Fax: 716-898-3279.
HIV results in a deregulation of a number of cytokines and also leads to cytopenias in many patients. A potentially important one in these patients is Interleukin-1 (IL-8) due to its chemotactic influence on PMNs. Objectives: To validate an ELISA for IL-8 and utilize it in the assessment of IL-8 concentrations in HIV-i
Int Conf AIDS 1996 Jul 7-12; 11:74 (abstract no. We.A.3101)
Portmore AC, Haga-Rice J, Pesano RL, McShane DJ, Lipil WH; URSUS Medical Group, Palo Alto, CA.
STUDY: Ten (10) HIV-infected pts with CD4 counts greater than 200, high motivation and ability to make an informed decision, were treated with 2 Million International Units/M2 body surface area of IL-2 SC bid for 5 sequential days once a month for up to 5 months. Study is ongoing. Baseline mean CD4 counts =356 (range 2
Int Conf AIDS 1996 Jul 7-12; 11:75 (abstract no. We.A.3102)
Breen EC, Salazar-Gonzalez JF, Shen LP, Kolberg JA, Urdea M, Martinez-Maza O, Fahey JL; Dept. of Microbiology & Immunology, UCLA School of Medicine, Los Angeles, CA, USA. Fax: (310) 206-1318. E-mail: ebreen@ucla.edu.
Objective: To characterize the cell type(s) which contribute to increases in interferon gamma (IFNg) gene expression in HIV infection, and to determine if the IFNg-expressing cell(s) are the same or different in non-infected individuals. Methods: Peripheral blood mononuclear cells (PBMC) were isolated from fresh whole
Int Conf AIDS 1996 Jul 7-12; 11:75 (abstract no. We.A.3103)
Auci D, Anderson V, Feldman J, Zevallos E, Durkin H, Landesman S, Mendez H, Gu J; SUNY Health Science Center Brooklyn (SUNY HSCB), Brooklyn, NY, USA. Fax: 718-270-3313.
Objective: To study trophoblast exfoliation as a placental defense mechanism against HIV. Method: Cell cycle analysis, (flow cytometry) was performed on 8 HIV exposed placentae and compared with 9 control term placentae. Results: The G2/M1 phase of HIV exposed placentae ranged from 0.5 to 4.3% as compared to 4.5% to 16
Objective: To study IL-1ra and IL-8 production in HIV-infected patients Methods: We have investigated the production of IL-1ra and IL-8 by isolated monocytes and unfractionnated peripheral blood mononuclear cells (PBMC) from HIV-seropositive patients (n=30) and HIV-seronegative controls (n=30). Levels of both cytokines
Objective: We investigate 26 healthy persons and 37 patients subsequently during a year TNF plasma level and mononuclear cells (MNC) spontaneuos and induced of lypopolysacharid (LPS) Methods: For investigation TNF plasma level and MNC spontaneuos and induced of LPS using ELISA. Results: (table: see text) Conclusion: In
Int Conf AIDS 1996 Jul 7-12; 11:75 (abstract no. We.A.3107)
Dereuddre-Bosquet N, Clayette P, Martin M, Fretier P, Jaccard P, Benveniste O, Lebeaut A, Dormont D; CEA, DSV-DRM-SNV, IPSC, Fontenay aux Roses, France. Fax: (33-1) 46 54 77 26. E-mail: BOSQUET@DSVIDF.CEA.FR.
Objective: Interleukin-10 (IL-10) is a pleiotropic cytokine which was first described as a product of TH2 lymphocytes. In HIV-infected patients, IL-10 may participate to T cell dysfunctions. Monocytes/macrophages (MM) are potential producers of IL-10 and MM proinflammatory functions are susceptible to be decreased by I
Int Conf AIDS 1996 Jul 7-12; 11:75 (abstract no. We.A.3108)
Cinque P, Bernasconi S, Vicenzi E, Sozzani S, Ceresa D, Lazzarin A, Poli G, Mantovani A; Division of Inf Diseases, San Raffaele Hospital, Milan, Italy. Fax: 39-2-26437989.
Objective: To assess chemokine levels in the cerebrospinal fluid (CSF) of AIDS patients with neurological complications. Methods: CSF and plasma samples from 51 patients with HIV infection and neurological disorders, including cytomegalovirus ( CMV ) encephalitis (n=12), progressive multifocal leukoencephalopathy (PM
Int Conf AIDS 1996 Jul 7-12; 11:126 (abstract no. We.A.3398)
Bruckova M, Jedlicka J, Mruskovicova L, Maly M, Vojtechovsky K, Stankova M, Rozsypal H; NRL AIDS, National Institute of Public Health, Prague, Czech Republic.
Objective: To follow up the changing trends in HIV transmission categories and to study the impact of HIV infection on women in the Czech Republic . Methods: Statistical data from HIV tests performed by standard serological screening and confirmatory methods in the Czech Republic in 1985-95 were analysed and male/femal
Int Conf AIDS 1996 Jul 7-12; 11:75 (abstract no. We.B.3115)
Zheng NN, Delaney SF, Law MG, Cooper DA, McQueen PW; Centre for Immunology, University of New South Wales, Darlinghurst, Sydney, NSW, Australia. Fax: 02 361 2391. E-mail: p.mcqueen@cfi.unsw.edu.au.
Objective: To determine changes in CD4 cell count, viral load, drug sensitivity and reverse transcriptase sequence associated with combined ddI and 935U83 (5-chloro-2 ,3 -dideoxy-3 -fluorouridine) therapy. Methods: Eight patients, whose CD4 cell counts were between 200 and 500 cells/mm3, were enrolled in a phase I/II t
Int Conf AIDS 1996 Jul 7-12; 11:76 (abstract no. We.B.3116)
Adams L, Conway B, Montaner JS, O'Shaughnessy MV, Freimuth WW; B.C. Centre for Excellence in HIV/AIDS, Vancouver, B.C. Fax: 631-5527. E-mail: lyadams@unixg.ubc.ca.
Introduction: There is a need for rapid, inexpensive and accurate phenotypic anti-retroviral drug susceptibility assays. Our project was undertaken to develop a 14-day culture-based method for screening for high-level resistance of clinical HIV isolates to delavirdine , a non-nucleoside reverse transcriptas
Int Conf AIDS 1996 Jul 7-12; 11:76 (abstract no. We.B.3117)
Palmer RW, Rachlis AR, Peter AM; HIV Project Centre, Toronto, Ontario, Canada. Fax: (416) 480 6060. E-mail: 102114.3046@compuserve.com.
Objective: To determine the effect of different HIV treatment strategies on survival time. Methods: From November 1986 the Ontario Drug Distribution Program distributed ZDV, ddI and ddC to over 8000 patients in the province of Ontario, Canada .
Int Conf AIDS 1996 Jul 7-12; 11:76 (abstract no. We.B.3118)
Rachlis AR, Palmer RW, Peter AM; Sunnybrook Health Science Centre, Toronto, Ontario, Canada. Fax: (416) 480 6060. E-mail: a.rachlis@utoronto.ca.
Objective: To describe trends in the utilization of licensed anti-retrovirals (ZDV, ddI and ddC ) by HIV patients in Ontario, Canada . Methods: The Ontario Drug Distribution Program distributes licensed antiretrovirals (ZDV, ddI and ddC) for all HIV pat
Int Conf AIDS 1996 Jul 7-12; 11:76 (abstract no. We.B.3119)
Kupfer B, Rockstroh J, Schneweis KE, Theisen A, Matz B, Kaiser R; University of Bonn, Bonn, Germany. Fax: 01149-228-2874433.
Objective: To investigate the efficiency of antiretroviral therapy with lamivudine in combination with other antiretroviral drugs in a cohort of anti-HIV-seropositive patients with advanced HIV-1 infection. Methods: Longitudinal blood samples from 30 individuals with advanced HIV-1 infection, treated with lamivudine (
Int Conf AIDS 1996 Jul 7-12; 11:76 (abstract no. We.B.3120)
Pascucci R, Wolf E, Virgin G, Poppinger J, Jaegel-Guedes E, Jaeger H; KIS, Curatorium for Immunedeficiency, Munchen, Germany. Fax: 0049-89-5328651.
Objective: To validate the efficacy as well as to monitor for toxicity and adverse effects of d4T . Methods: N= 113 patients who did not effectively respond to or were intolerant of other antiretroviral drugs were administered d4T in dosages of 40-120 mg (0.5-2.25 mg/kg body weight/day). All patients were in advanced s
Int Conf AIDS 1996 Jul 7-12; 11:77 (abstract no. We.B.3121)
Jager H, Virgin G, Pascucci R, Poppinger J, Jaegel-Guedes E, Wolf E; KIS, Curatorium for Immunedeficiency, Munich, Germany. Fax: +49-89-5328651.
Objective: The primary objective is to evaluate virostatic efficacy of combination therapy AZT + 3TC in advanced HIV patients who experienced either failure of or an intolerance to the other conventionally used therapi
Int Conf AIDS 1996 Jul 7-12; 11:77 (abstract no. We.B.3122)
Lopez-Martinez C, Guarner J, Teran X, Varela C, Rangel A, Hernandez G, del Rio C; CONASIDA (National AIDS Council), Mexico City, Mexico. Fax: (525) 528.4220.
Objective: To evaluate the possible benefit of switching to ZDV + ddI after treatment with ZDV alone in terms of CD4+ cell counts in asymptomatic HIV+ patients as well as toxicity assessment. Methods: We conducted a cohort study of asymptomatic HIV+ patients with CD4+ cell counts between 200 and 500 cells/microliter wi
Int Conf AIDS 1996 Jul 7-12; 11:77 (abstract no. We.B.3123)
Sirera R, Bayona A, Oltra A, Bueno C, Postigo A, Sebastia M, Mesa E, Gonzalez-Molina A; Inmunologia Exp., Centro de Investigacion, Hospital "La Fe", Valencia, Spain.
Objective: To evaluate the in vitro effects of ddI on PHA-induced secretion of cytokines in whole blood cell (WBC) cultures, since some synthetic nucleoside analogues in addition to their antiretroviral capacity, are likely to have adverse effects on DNA, RNA and protein synthesis. Methods: 38 healthy human adults were
Int Conf AIDS 1996 Jul 7-12; 11:77 (abstract no. We.B.3124)
Antela A, Casado JL, Perez-Elias MJ, Moreno A, Redondo E, Martin-Davila P, Frutos B, Guerrero A; Enfermedades Infecciosas, Hospital Ramon y Cajal, Madrid, Spain. Fax: 34-1-3.36.86.72.
Objective: To evaluate the efficacy of additive antiretroviral therapy (AAT), in patients previously treated with zidovudine (ZDV) for more than two years, or presenting progression of HIV disease. Methods: Retrospective review of 135 patients in whom DDI, DDC or 3TC was added to ZDV from Jan/92 to
Int Conf AIDS 1996 Jul 7-12; 11:77 (abstract no. We.B.3125)
Phanuphak P, Sirivichayakul S, Ruxrungtham K, Ubolyam S, Hanvanich M, Grayson ML, Wanke C, Hammer SM; Thai Red Cross Society, Program on AIDS, Bangkok, Thailand. Fax: 66-2-254-7577.
Objective: To compare the clinical & immunologic efficacy of ZDV 100mg tid + 200mg H/S (ZDV-A) to 250mg bid (ZDV-B) in an adult Thai population. Methods: 196 HIV-infected Thai adults with early ARC & CD4 cts less than 400/mm3 (100 ZDV-A; 96 ZDV-B) were enrolled in a 24 mth randomized, open-label trial. Analysis
Objective: To estimate the medical care costs averted if ritonavir is added to current antiretroviral therapy for patients in the U.K. and in U.S.A. Methods: Using Markov assumptions, modeling of outcomes and cost of medical care based on 4 months CD4 data from 1090 AIDS patients with baseline CD4 counts less than 101
Int Conf AIDS 1996 Jul 7-12; 11:78 (abstract no. We.B.3127)
Heath-Chiozzi M, Leonard J, Sun E, Lehman L, Henry D, Kravcik S, Mills R, Potthoff A; Abbott Laboratories, Abbott Park, IL, USA. Fax: 847-938-3711.
Objective: An intensive substudy of virologic and immunologic surrogate markers of anti-HIV activity was conducted in an ongoing international, randomized, placebo-controlled clinical trial of ritonavir 600 mg twice daily. Methods: The study enrolled 1090 patients. The 16 week substudy evaluated the first 159 patients
Int Conf AIDS 1996 Jul 7-12; 11:78 (abstract no. We.B.3128)
Scheibel SF, Saget B, Elbeik T, Guthries J, Drews B; San Francisco, CA, USA. Fax: 415-864-5117. E-mail: bssstt@aol.com.
Objective: To determine the efficacy of aggressive combination antiretroviral therapy (CAT) in HIV+ subjects using a 4, 5, or 6 drug regimen. Methods: Seventeen HIV+ men were treated using aggressive CAT with either 4 drugs: zidovudine ( AZT ), dida
Int Conf AIDS 1996 Jul 7-12; 11:78 (abstract no. We.B.3129)
Wortel CH, McKinlay M, Chancellor T, Sonderfan A, Jenson J, Profy A; Procept, Inc., Cambridge, MA, USA. Fax: 617-491-9019.
Objective: To determine the tolerability and preliminary pharmacokinetics of the HIV-1 binding/fusion inhibitor PRO 2000 following administration of single intravenous doses to healthy, HIV-negative volunteers. Methods: Thirty-six normal, healthy adult male volunteers who tested negative for antibodies to HIV-1 and
Int Conf AIDS 1996 Jul 7-12; 11:78 (abstract no. We.B.3130)
Sirivichayakul S, Hammer S, Gillis J, Ruxrungtham K, Hanvanich M, Phanuphak P; Division of Infectious Diseases, Deaconess Hospital, Boston, MA, USA. Fax: 617-632-0766.
Objective: To characterize HIV-1 isolates from Thailand on the basis of their subtype, syncytium-inducing (SI) or non-syncytium-inducing (NSI) phenotypes, cytotropism, and zidovudine (ZDV) susceptibility. Methods: HIV-1 isolates were obtained from Thai subjects with CD4 counts less than 400/mm3. An ACTG macrococultivat
Int Conf AIDS 1996 Jul 7-12; 11:78 (abstract no. We.B.3131)
Para M, Morse G, Fischl M; Ohio State University, Columbus, OH, USA. Fax: 614-293-5240.
Delavirdine mesylate is a highly protein bound, nonnucleoside reverse transcriptase inhibitor with activity against HIV-1. Plasma samples from eighty-one HIV-infected patients receiving delavirdine mesylate monotherapy in ACTG 260 were studied to determine delavirdine and N-DLV protein binding characteristics.
Int Conf AIDS 1996 Jul 7-12; 11:79 (abstract no. We.B.3132)
Morse GD, Hu J, Ingalls E, Bartos L, D'Ambrosio R; SUNY at Buffalo, Buffalo, NY, USA. Fax: 716-645-2001. E-mail: phmgene@ubvm.cc.buffalo.edu.
Delavirdine mesylate is a highly protein bound, nonnucleoside reverse transcriptase inhibitor with activity versus HIV-1. This in vitro study was performed to examine potential drug-drug displacement interactions for delavirdine mesylate and agents which are commonly prescribed to patients with HIV infection.
Int Conf AIDS 1996 Jul 7-12; 11:79 (abstract no. We.B.3133)
Heredia A, Soriano V, Vallejo A, Mas A, Garcia-Lerma G, Bravo R, Martinez M, Valencia E, Moreno V, Gonzalez-Lahoz J, Hewlett I; Lab. Molecular Virology, CBER/FDA/HFM, Rockville, MD, USA. Fax: 594 6989.
Background: The efficacy of zidovudine (ZDV) is lost in many treated individuals after a few weeks or months of monotherapy. The development of resistance by selection of or by new generation of mutated strains seems to explain this adverse event. However, for the last few years several reports have pointed out that so
Int Conf AIDS 1996 Jul 7-12; 11:79 (abstract no. We.B.3134)
Hollister AS, Dunn JM; University of Colorado Health Sciences Center, Denver, CO, USA. Fax: 303-270-3272. E-mail: Alan.Hollister@UCHSC.edu.
Objective: To compare the surrogate marker efficacy, side effects, toxicity, and development of Codon 215 mutation of regular zidovudine (ZDV-C, Retrovir), 200 mg t.i.d., versus sustained-release ZDV (ZDV-SR, AZTec), 300 mg b.i.d. Methods: An 18 week, randomized, double-blind, multicenter comparative clinical trial of
Int Conf AIDS 1996 Jul 7-12; 11:79 (abstract no. We.B.3135)
Myoung-Don OH, Merrill D, Hirsch M; Infectious Disease Unit, Massachusetts General Hospital, Boston, MA, USA. Fax: 617-726-7416.
Objective: Previous studies have suggested that simultaneous(Sm) combination regimens are more effective than alternating combination regimens in inhibiting HIV-1 replication. In this in vitro study, we evaluated Sm combination regimens vs regimens in which drugs were sequentially added(Sq) at weekly intervals. Methods
Objective: To evaluate the durability of effect of nevirapine (NVP) on immunologic and virologic markers in ZDV experienced patients treated for 12 months in a placebo controlled trial. To explore the relationship between surrogate marker response and emergence of drug resistance. Methods: Sixty patients with 200-500 C
Int Conf AIDS 1996 Jul 7-12; 11:80 (abstract no. We.B.3137)
Rouleau D, Conway B, Raboud J, Patenaude P, Schechter MT, O'Shaughnessy M, Montaner JS; Pacific Region, Canadian HIV Trials Network, Vancouver, BC, Canada. Fax: (604)631-5412.
Objectives: To assess the short term antiviral effect and tolerability of d4T / 3TC in patients who show intolerance to zidovudine (ZDV) or disease progression despite ZDV. Methods: This is a pilot, open label and non randomized study.
Int Conf AIDS 1996 Jul 7-12; 11:80 (abstract no. We.B.3138)
de Lima LA, Neto PG, Pacheco AG, Faccio MR, Neto JS, Moulton LH, Harrison LH, Schechter M; Hospital Universitario, Universidade Federal do Rio de Janeiro, Brazil. Fax: 55(21) 590-1615. E-mail: MauroSch@Omega.LNCC.Br.
Objective: To evaluate the effectiveness of antiretroviral treatment for mortality reduction in a large cohort of HIV- infected patients in Rio de Janeiro, Brazil . Methods: We prospectively collected data on participants of a cohort study whose objective is to validate the World Health Organization
Int Conf AIDS 1996 Jul 7-12; 11:80 (abstract no. We.B.3139)
Simonelli C, Comar M, Zanussi S, Nasti G, Vaccher E, De Paoli P, Giacca M, Tirelli U; Div. Medical Oncology and AIDS, Centro di Riferimento Oncologico, Aviano, Italy. Fax: 434/659531.
Objective: Evaluation of feasibility and activity of combination therapy with ddI + HU in HIV-positive pts and comparison with mono-therapy with ddI. Methods: HIV-positive pts were alternatively enrolled to receive ddI alone or in combination with HU if they met the following entering criteria: failure and/or intolera
Int Conf AIDS 1996 Jul 7-12; 11:80 (abstract no. We.B.3140)
Garcia-Lerma G, Ruiz I, Soriano V, Altisent C, Ocana I, Gonzalez-Lahoz J; CIC, Instituto de Salud Carlos III, Madrid, Spain. Fax: 733 6614.
Introduction: Direct quantitative measurement of HIV viremia has become a clinical practical tool for the study of HIV-infected patients, providing a useful marker for monitoring response to antiretroviral therapy. Lamivudine ( 3TC ) is one of the most promising
Int Conf AIDS 1996 Jul 7-12; 11:80 (abstract no. We.B.3141)
Nfila BF; Nfila BF
Botswana is in the grip of an HIV epidemic. It is estimated that there are currently about 3110 AIDS Patients and 125,000 people living with HIV infection in Botswana. It has been noted that 50% Hospital beds are now being occupied by patients with HIV related illnesses. Project: Ten AIDS patients for home based
Int Conf AIDS 1996 Jul 7-12; 11:81 (abstract no. We.B.3142)
Colombrini MR, Paiva MC, Barcella I, Moraes MJ, Caraccio MB, Velho P, Monteiro DT, Oliveira AC, Aoki FH; Nurse Care Division & Inf. Dis. Div., Hosp. of Clinics and Faculty of Medical Science, State University of Campinas, Brasil.
Introduction: The rapid apread of HIV/AIDS cases in the world and subsequently in Brazil ,specially in the southeastern region of this country have determined serious reflex in the assistance structure of patients with HIV/AIDS. In this hospital there are exiguo us beds disposable for necessity of patients in general (
Int Conf AIDS 1996 Jul 7-12; 11:81 (abstract no. We.B.3143)
Heath KV, Montaner JS, Hogg RS, Singer J, O'Shaughnessy MV, Schechter MT; BC Centre for Excellence in HIV/AIDS, HIV Clinical Trial Network and UBC, Vancouver, BC, Canada.
Objective: To assess the degree of heterogeneity of therapeutic management of HIV infection among physicians in British Columbia (BC) and to identify physician characteristics associated with increased knowledge as assessed by level of agreement with contemporary therapeutic guidelines. Methods: A 51 item questionnaire
Int Conf AIDS 1996 Jul 7-12; 11:81 (abstract no. We.B.3144)
Klein A, Rachlis AR, Peter AM, Throop RG, Hettiarchchi D; Mount Sinai Hospital Toronto, Ontario, Canada. Fax: (416) 964-2300. E-mail: alexk@ican.net.
Background: Primary care physicians are providing a rapidly increasing proportion of HIV/AIDS care in Canada . Building on the success of a provincial program in Ontario, Canada, a national steering committee was formed to create CHAMP, a peer education project. Program Description: The program uses experienced primary
Int Conf AIDS 1996 Jul 7-12; 11:81 (abstract no. We.B.3145)
Bugler C, Moulin P, Vincent I, D'Herouville D, Fraval J, Marmagne V, Mallet D, Berki Z, Hervier S, Gabriel C, Salamagne M, Vilde JL, Leport C, Jodelet D; Infectious and Tropical Diseases Unit (Pr. Vilde), Hopital Bichat-C. Bernard, Paris, France.
Objectives: A prospective multidisciplinary study was undertaken to compare the modalities and the consequences of the development of palliative care practices for advanced HIV-infected pts, in 2 different care units: (1) an Infectious and Tropical Diseases Unit (ITDU), (2) a Palliative Care Unit (PCU). The objectives:
Int Conf AIDS 1996 Jul 7-12; 11:81 (abstract no. We.B.3146)
Vincent I, D'Herouville D, Moulin P, Bugler C, Fraval J, Marmagne V, Mallet D, Berki Z, Hervier S, Gabriel C, Salamagne M, Vilde JL, Jodelet D, Leport C; Infectious and Tropical Unit (PrVilde), CHU Bichat-Claude Bernard, Paris, France. Fax: 33-1-40-25-88-60.
Objective: To assess in parallel the modalities of care in advanced AIDS patients in an Infectious and Tropical Diseases Unit (ITDU) and in a Palliative Care Unit (PCU). Methods: Prospective pluridisciplinary research: physicians, psychosociologists, nurses and psychologists (oct 94-jan 95: oct 95-dec 95). All hospital
Int Conf AIDS 1996 Jul 7-12; 11:82 (abstract no. We.B.3147)
Shah RM, Mehrul A; Kandivli Medical Association A.I.D.S. Cell, Bombay, India.
Objective:- To compare the HIV + patients referrals by pvt. physicians & surgeons to pvt.& muncipal HSP. STD & HIV O.P.D. & to determine duties & responsibilities of pvt. physicians & surgeons. Method:- Referrals of HIV+ pts. by pvt. physicians & surgeons in pvt. STD-HIV Clinic (GROUP-A)
Int Conf AIDS 1996 Jul 7-12; 11:82 (abstract no. We.B.3148)
Monolo G, Edo S, Lopez S, Sanbartolomeo P, Vitali R, Barbarini G; Clinic of Infectious and Tropical Diseases IRCCS, S. Matteo University of Pavia, Pavia, Italy. Fax: 39-382-423320.
Background and objective: Lombardy has the largest population of AIDS patients in Italy , about one third of all cases. Today the number of living P.W.A.s. in our region is about 3500 and 1500 of them need a continuous care. In our Country about 65% of all AIDS cases are or were drug addicts and the most of them are fo
Int Conf AIDS 1996 Jul 7-12; 11:82 (abstract no. We.B.3149)
Lucchini A, Gola E, Salomoni A, Edo S, del Buono G, Barbarini G; Clinic of Infectious and Tropical Diseases IRCCS, S. Matteo University of Pavia, Pavia, Italy. Fax: 39-382-423320.
Objective: To determine if methadone maintenance therapy is a key strategy within the philosophy of harm reduction among HIV+ and HIV-I.V.D.A. Methods: During the period January 1990 to December 1995 we followed for almost 12 months 520 I.V.D.A. (390 Males, 130 Females) treated with Methadone therapy; 230 (175 Males, 5
Int Conf AIDS 1996 Jul 7-12; 11:82 (abstract no. We.B.3150)
Weinstein M, Thompson C, Farthing C, Stidham D, Portillo C; AIDS Healthcare Foundation, Los Angeles, CA. Fax: 213-962- 8513.
Economic pressures are driving both private and publicly funded care in the United States into capitated programs or managed care. HIV disease is relatively expensive and typically problematic for mainstream managed care programs. Project: The AIDS Healthcare Foundation has launched Positive Healthcare, a divisi
Int Conf AIDS 1996 Jul 7-12; 11:82 (abstract no. We.B.3151)
Clark PJ, Woods Byrne M; Columbia University, Incarnation Children's Center, New York, NY. Fax: 212-928-5077.
Issues: Unique and innovative solutions for the care of HIV-infected children and their families are urgently needed. Project: The Incarnation Children s Center is the only transitional foster care residence for HIV-infected children in New York City. It has created a flexible, cost effective, high quality program to m
Int Conf AIDS 1996 Jul 7-12; 11:82 (abstract no. We.B.3152)
Singh P, Policar M, Masci J; Elmhurst Hospital Center, Elmhurst, NY.
Objectives: To contrast the attitudes and practices of Infectious Disease (ID) physicians (MDs) towards Advance Directives (AD) for patients (pts) with AIDS. Methods: We reviewed the charts of a randomly selected sample of pts with AIDS, in order to calculate the percentage of pts with AD s. All were outpatients follow
Int Conf AIDS 1996 Jul 7-12; 11:82 (abstract no. We.B.3153)
Shi JM, O'Connor P; APT Foundation and Yale University, School of Medicine, New Haven, CT, USA. Fax: 203-781-4654.
Background: Development of effective substance abuse and primary care services for HIV-infected drug users (DU) are essential for their comprehensive care. Project: In July, 1994 APT Foundation initiated a new methadone maintenance program (MMP)-Holistic Maintenance Services (HMS)-to facilitate entry of HIV-infected DU
Int Conf AIDS 1996 Jul 7-12; 11:83 (abstract no. We.B.3154)
Acosta AM, Levy D, Thar W; Corning Franklin Health, Inc., Upper Saddle River, NJ, USA. Fax: 201-934-4953.
AIDS-related medical care expenses may generate substantial costs for indemnity-type health insurance plans and may consume the life time dollar maximum benefit for HIV-infected beneficiaries. Project: A voluntary, intensive, coordinated case management program (CCM) was offered to indemnity health insurance pla
Int Conf AIDS 1996 Jul 7-12; 11:83 (abstract no. We.B.3155)
Guillemi S, Phillips P, Craib KJ, Montaner JS, Heath KV, Hogg R, O'Shaughnessy MV; BC Centre for Excellence in HIV/AIDS and University of British Columbia, Vancouver, BC, Canada. Fax: 604-631-5464. E-mail: Kevin@hivnet.ubc.ca.
Objective: To examine trends in therapeutic management of HIV infection and related conditions among HIV experienced physicians in British Columbia (BC) between 1993 and 1995. Methods: During the period 12/92 to 05/93, a 35-item, anonymous questionnaire was mailed to all physicians in British Columbia. In November of 1
Int Conf AIDS 1996 Jul 7-12; 11:83 (abstract no. We.B.3156)
Negishi M, Ajisawa A, Masuda G, Minamitani M; Department of Infectious Disease, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan. Fax: 81-3-3824-1552.
Objective: To determine the role of our clinic on the activities for HIV-testing, care, support for infected persons, and HIV prevention. Method: We analyzed the data of persons who got HIV-tests at the HIV-Clinic in Komagome Hospital for these ten years, from October 1985 to September 1995. Results: We had 7,939 visit
Int Conf AIDS 1996 Jul 7-12; 11:83 (abstract no. We.B.3157)
Landau R, Coker R, Weber J, Touquet R, Fothergill J, Poznansky M; Dept. of Accident and Emergency Medicine, St Mary's Hospital, London, UK.
Objective: The study of the presentation and management of patients presenting with an AIDS defining illness (ADI) to the Emergency Room (ER) at St. Mary s Hospital in London, during 1994. Methods: The Genito-Urinary (G-U) Medicine Department at St. Mary s Hospital registered 133 patients with new AIDS diagnoses during
Int Conf AIDS 1996 Jul 7-12; 11:83 (abstract no. We.B.3158)
Halley A, Bazin B, Fiolet M, Aboulker JP; INSERM, Villejuif, France. Fax: 33(1)45595180.
An error on initial drug allocation and/or drug accountability during a clinical trial is a major protocol deviation. Here we propose two ways of guaranteeing the highest quality in the drug dispensing management: (1) a computer system for drug allocation and distribution; (2) a model of prescription form. Proje
Int Conf AIDS 1996 Jul 7-12; 11:84 (abstract no. We.B.3159)
Hedge B, Riddell L, Parkin JM; Andrewes Unit, King George V Block, St Bartholomew's Hospital, London, UK. Fax: 0171 601 8057.
Objective: To identify physical and psychological side effects and personality changes which accompany participation in the Immukin-placebo drug trial and to assess factors participants use in deciding whether they are receiving active drug or placebo. Methods: As part of a longitudinal study 13 patients in the Immukin
Objective: To share a simple, practical tool for clinicians who screen patients for HIV/AIDS clinical trials. This visual aid assists clinicians in quickly identifying the studies for which a patient may be eligible. Methods: A table was developed and is used to present concise study information to staff and referring
Int Conf AIDS 1996 Jul 7-12; 11:84 (abstract no. We.B.3161)
Mooney K, Lambert J, Fakhry R, Deisinger G, Sippel L, McMillen L, Vallier W, MacArthur RD; The Terry Beirn Community Programs For Clinical Research On AIDS (CPCRA), Wayne State University, Detroit, MI. Fax: 313-745-9173. E-mail: kmooney@oncgate.roc.wayne.edu.
Timely reporting of quality indicators (clinical events, adverse events, deaths, and vital status) is an essential aspect of community based clinical trials. A standardized, inclusive quality assurance plan needs to be integrated into community based research programs in compliance with CPCRA/ FDA
Int Conf AIDS 1996 Jul 7-12; 11:84 (abstract no. We.B.3162)
Lubin B, Sherer R, Cohen M, Pulvirenti J, Weber K, Orange E, Goodwin E, Zimmerman S, Straight C, Booth C, Cohen G, Jasek J, Pearson K; Cook County HIV Primary Care Center, Cook County Hospital (CCH), Chicago, IL, USA. Fax: (312)738-3102. E-mail: blubin@hektoen.org.
Cook County HIV Primary Care Center, Cook County Hospital (CCH), Chicago, Il USA Objective: To determine the cost and effort required to achieve recruitment targets and 90+ retention rates for longitudinal clinical studies with a minority population at Cook County Hospital, Chicago in 1994 and 1995. Methods: We correla
Objectives: To describe accrual, retention, compliance, and preliminary safety and pharmacokinetics in AIDS Clinical Trials Group (ACTG) protocol 185, a randomized controlled trial of HIV-IGin HIV-infected pregnant women with CD4+ less than 500/microgram on zidovudine (ZDV). Methods: Cumulative data on patient characte
Int Conf AIDS 1996 Jul 7-12; 11:85 (abstract no. We.B.3164)
Pearson LD, Abrams L, St Louis D, Loriz-Lim L; Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, USA. Fax: 301-762-7460. E-mail: dpearson@pasteur.hjf.org.
Data accuracy and management are crucial elements of any clinical drug trial research program. Quality assurance (QA) programs ensure the integrity of the data by ensuring proper execution of clinical trials, compliance with requisite study procedures and data collection. Project: We developed an integrated appr
Int Conf AIDS 1996 Jul 7-12; 11:85 (abstract no. We.B.3165)
Coakley D, Fry J, Holland G, Owens S, Hurwitz S, Feinberg J; Glaxo Wellcome Research and Development USA/UK, Durham, NC. Fax: 919-315-8513. E-mail: Coakley_Dion@us.wfl.com.
Objective: To describe the processes involved in confirming CMV endpoints in a cohort of 1227 HIV/CMV co-infected patients participating in an international collaborative trial of valaciclovir for CMV prophylaxis. Methods: As the diagnosis of CMV end-organ disease can be elusive, strict definitions for confirmed CMV sy
Int Conf AIDS 1996 Jul 7-12; 11:85 (abstract no. We.B.3166)
Neaton JD, Hogan CH, Chaloner KM, Forsgren J, Hare DA, Larntz KF, Louis TA, Roane R, Wentworth DN; Division of Biostatistics, University of Minnesota, Minneapolis, MN. Fax: (612) 626-8892. E-mail: jim@blueox.ccbr.umn.edu.
Objectives: Community based clinical research in AIDS offers unique challenges and opportunities. Patient involvement in all phases of research planning, execution, and interpretation assure research that is relevant, attractive and timely. In depth seminars can help improve communications between patients and investig
Int Conf AIDS 1996 Jul 7-12; 11:85 (abstract no. We.B.3167)
Bouzas MB, Zapiola I, Juncos G, Wainstein C, Muchinik G; Unidad de Virologia, Hospital Francisco J. Muniz, Buenos Aires, Argentina. Fax: (54-1)1 806-2078.
Objective: To investigate the presence of IgA antibodies to HIV-1 in patients during the seroconversion period. Materials: Sequential serum samples were obtained from 5 patients, 3 specimens from each of them were collected. Samples from HIV-negative and HIV-positive individuals were included in this study. Methods: Al
Int Conf AIDS 1996 Jul 7-12; 11:85 (abstract no. We.B.3168)
Gobbers E, Hilgers P, Fransen K, van de Wiel P, van der Groen G; Organon Teknika, Turnhout, Belgium. Fax: 014/43.62. 58.
Objective: HIV RNA seems to be a promising marker for early diagnosis of HIV-infection and for the measurement of viral load. The HIV1 NASBA-system (Organon Teknika) is a novel primer-dependent, isothermal amplification technique capable of amplifying RNA based on the activity of reverse transcriptase, RNaseH and T7RNA
Int Conf AIDS 1996 Jul 7-12; 11:86 (abstract no. We.B.3169)
Malloch L, Beaudoin F, Macpherson S, Calder-Kent B, Rud EW; Health Canada, LCDC, National Laboratory for HIV Reference Services, Tunney's Pasture, Ottawa, Ontario, Canada. Fax: 613-957-7258. E-mail: lmalloch@hpb.hwc.ca.
Objective: To determine if a selection of HIV testing laboratories in Canada were able to correctly identify a panel of HIV-1, HIV-2 or control serum or plasma. Methods: A serology proficiency panel was sent to 25 laboratories currently testing for HIV including 24 Canadian laboratories and one laboratory outside of Ca
Int Conf AIDS 1996 Jul 7-12; 11:86 (abstract no. We.B.3170)
Brignoli E, Foussadier A, Pretis C, Pascual F, Morel C, Vernet G, Jolivet M, Ly TD; Biomerieux, Marcy L'etoile, France. Fax: 78 87 21 01. E-mail: Vernetg@Bmx.Dedal.Fr.Net.
Objective: To evaluate the performance of a new automated screening test for the VIDAS analyser, which simultaneously detects p24 antigen as well as anti-HIV1 and anti-HIV2 antibodies. Methods: 300 random negative sera and the various commercial panels available (BBI,NABI) were tested using the VIDAS HIV DUO reagent. T
Int Conf AIDS 1996 Jul 7-12; 11:86 (abstract no. We.B.3171)
Icardi GC, Della Pietra P, Gaino M, Wicks R, Venturino V, Gabutti G; Institute of Hygiene and Preventive Medicine, University of Genoa, Italy. Fax: 39-10-3538533.
Objective: To evaluate a new fully-automated strip immunoblot assay for the confirmation of specimens repeatedly reactive to licensed screening tests for anti-HIV-1 and/or HIV-2. Methods: The new test CHIRON RIBA HIV-1/HIV-2 SIA (distributed by Ortho Diagnostics System) is a qualitative enzyme immunoassay which utilize
Int Conf AIDS 1996 Jul 7-12; 11:86 (abstract no. We.B.3172)
Martinez P, Ortiz de Lejarazu R, Eiros JM, Inglada L, Orduna A, Rodriguez-Torres A; Dpto. Microbiologia. Facultad de Medicina, Valladolid, Spain. Fax: 83-423022.
Objective: To determine reactivity patterns of HIV antibodies by means of a Western blot (WB) in saliva and urine samples in order to asess the usefulness of this method to confirm HIV infection. Methods: One hundred eighty seven paired samples of urine and saliva were obtained from HIV-infected individuals (106 stage
Int Conf AIDS 1996 Jul 7-12; 11:86 (abstract no. We.B.3173)
Farmer D, Clewley G, Griffiths P, Johnson M; Royal Free Hospital, London, UK.
Objective: The objective of this study was to compare saliva collection and testing with the routine blood sample. We examined patient preference, staff preference and laboratory reliability. Methods: Over a seven month period, all patients who tested for HIV antibodies, under supervision of their counsellor, were aske
Int Conf AIDS 1996 Jul 7-12; 11:86 (abstract no. We.B.3174)
Cochran KP, Bain B, Eskes N, Ramsay DH, Eldemire D; Pediatric Dentistry, Children's Hospital of Buffalo, Buffalo, NY, USA. Fax: (716) 878-7611. E-mail: Ken_Cochran@sdm.buffalo.edu.
Objectives: This international collaborative study set out (a) to assess the practicability of collecting saliva with the Omni-SAL (Saliva Diagnostic Systems, Inc.) collection device in a group of Jamaican children born to women with HIV/AIDS and (b) to compare the results of HIV antibody (HIV-Ab) tests completed on th
Int Conf AIDS 1996 Jul 7-12; 11:87 (abstract no. We.B.3175)
Frederick WR, Leverette C, Hunte D, Delapenha R, Mcneil J, Greaves W; Howard University Hospital, Washington, D.C., USA. Fax: 202-865-4607.
Objective: To report our experience with HIV testing at an inner city hospital retrovirology laboratory between 1986-1995. Methods: Commercially available ELISA(E) HIV-1 antibody kits from Ortho Diagnostics 1986-88 and from Cambridge Biotech 1989-95 were used to screen serum samples. Western blot(WB) kits from Cambridg
Int Conf AIDS 1996 Jul 7-12; 11:87 (abstract no. We.B.3176)
Hanson IC, Pitt J, McIntosh K, Sherrieb K, Diaz C, Rich K, Mendez H, Moye J, Fowler MG; New York, NY, USA. Fax: 212-305-7338. E-mail: pitt.jane@karloff.fstrf.org.
Objective: To assess HIV-exposed infants with limited follow-up and IND infection status. Methods: Infants (n=885) born to HIV-infected women in a natural history study of vertical HIV transmission (WITS) were evaluated for infection status using the WITS working definition (infected- greater than or equal 2 positive H
Int Conf AIDS 1996 Jul 7-12; 11:87 (abstract no. We.B.3177)
Delapenha RA, Leverette C, Hunte D, McNeil J, Greaves W, Frederick W; Howard University Hospital, Washington, D.C.
Objective: To determine characteristics and trends in HIV testing among minority women at an inner city teaching hospital over the last 10 years. Methods: Records from the clinical retrovirology laboratory for the period June 1986 - Dec. 1995 were reviewed and the following data collected: age, sex, HIV results, year o
Int Conf AIDS 1996 Jul 7-12; 11:87 (abstract no. We.B.3178)
Krutzik SR, Choi DP, Chung S, Krutzik SR, Nguyen M; Trinity Biotech Inc., Irvine, CA.
Objective: To develop a one step assay for determination of anti HIV-1 and HIV-2 antibodies in biological fluids based on the antigen sandwich principle. Methods: Synthetic peptides representing highly conserved, immunodominant regions of the transmembrane (gp41) and envelope (gp120) proteins of HIV-1 and transmembrane
Int Conf AIDS 1996 Jul 7-12; 11:88 (abstract no. We.B.3179)
Zapiola I, Bouzas MB, Mathov I, Sordelli N, Cattaneo A, Fallo A, Lopez E, Wainstein C, Muchinik G; Virologia, IDEFI, Buenos Aires, Argentina. Fax: (54-1)1 806-2078.
Objective: The aim of the study was to examine the performance of a HIV-1/HIV-2 enzyme immunoassay (EIA), which has been modified in order to make it suitable to be used to detect HIV-IgA antibodies as a diagnostic tool for early diagnosis of pediatric HIV infection. Methods: Serum samples from 71 pediatric patients bo
Int Conf AIDS 1996 Jul 7-12; 11:88 (abstract no. We.B.3180)
Vieillard V, Hadida F, Rozenbaum R, Debre P, De Maeyer E, Lauret E, Autran B; Institut Curie, Centre Universitaire, Orsay, France. Fax: 69 07 83 21. E-mail: ural343@curie.u-psud.fr.
We are developing a somatic cell gene therapy of HIV infection based on enhancing the antiviral resistance of primary lymphocytes through the constitutive low production of interferon beta (IFN-beta). Lymphocytes from HIV-infected patients at different clinical stages of infection were transduced, with an efficacy rang
Int Conf AIDS 1996 Jul 7-12; 11:88 (abstract no. We.B.3181)
Cremer I, Vieillard V, De Maeyer E, Lauret E; Institut Curie, Centre Universitaire, Orsay, France. Fax: 69 07 83 21. E-mail: ura1343@curie.u-psud.fr.
Interferon-beta (IFN-beta) exerts its antiretroviral activity at several stages of the HIV infectious cycle, and we are exploring the use of low constitutively expressed IFN-beta production for conferring a permanent antiviral state. To this purpose, we have constructed the HMB-KbHuIFN-beta retroviral vector, carrying
Int Conf AIDS 1996 Jul 7-12; 11:88 (abstract no. We.B.3182)
Ovsiannikov v, Sizova N; D.V. Efremov Scientific Research Institute Of Electrophysical Apparatus, St. Petersburg, Russia. Fax: 812-314-33-60. E-mail: victor@movs.ioffe.rssi.ru.
Objective: To develop the new method of the HIV-patient s treatment in the stage of acute attack of a disease or in the AIDS-stage. Methods: The treatment has been carried out by means of laser through-skin action on blood, blood-production or immune-responsible areas of an organism. On the basis of our previous succes
Int Conf AIDS 1996 Jul 7-12; 11:88 (abstract no. We.B.3183)
Zaia JA, Yam P, Yee JK, Li S, Sniecinski I, Forman S, Ito J; City of Hope National Medical Ctr, Duarte, CA. Fax: 818-301-8458. E-mail: jzaia@smtplink.coh.org.
Objective: To determine 1) the safety and effectiveness of granulocyte-colony stimulating factor (G-CSF) for mobilization of peripheral blood stem cells (PBSC) in HIV-1 infected persons and 2) the transduction efficiency of retrovirus vectors in these cells. Methods: HIV-1 infected persons with greater than 200 CD4 cel
Int Conf AIDS 1996 Jul 7-12; 11:88 (abstract no. We.B.3184)
Arthur-Nouel A; Universidad Autonoma de Santo Domingo, Instituto Dermatologico y Cirugia de Piel, Santo Domingo, Rep. Dominicana. Fax: (809) 221-4361. E-mail: infocomp@aaar.net.
Patients present genital lesions produced by the Sexually Transmitted Diseases, although extragenital sex or general manifestations of the diseases produce characteristical lesions in the mouth and other parts of the human body. The participation of the dental practitioner is of great importance, if complete ora
Int Conf AIDS 1996 Jul 7-12; 11:89 (abstract no. We.B.3185)
Varkonyi V, Tisza T, Horvath A, Takacsy T, Balazs E, Nagy K; National Institute for Dermato-Venereology, Budapest, Hungary. Fax: 36-1-1340566.
Objective: To evaluate the data of HIV-positive patients screened out from STD patients in the National Institute for Dermato-Venereology (NIDV). Methods: The screening laboratory of the NIDV is one of the most important ones in the hungarian HIV screening network testing among others the blood samples of the patients
Int Conf AIDS 1996 Jul 7-12; 11:89 (abstract no. We.B.3186)
Sule Rajiv R, Tolat Sunil N, Manjarekar H; Department of Skin & STD, B.J. Medical College & Sassoon General Hospitals, Pune, India.
Objectives: 1) Study clinical bacteriological and serological profile of early syphilis amongst STD patients in tertiary level General Hospital. 2) Assess HIV positivity in early syphilis. 3) Study effect of HIV infection on presentation, bacteriology and serology of early syphilis. Methods: 5430 STD patients were inve
Int Conf AIDS 1996 Jul 7-12; 11:89 (abstract no. We.B.3188)
Thongkrajai P, Pengsaa P, Pakarasang M, Thongkrajai E; Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. Fax: 66-43-243064,348375. E-mail: pratho@kku1.kku.ac.th.
Objective: To investigate the prevalence, type and distribution of non-HIV, glynaecological diseases and STD in rural women of the northeast Thailand . Methods: To work in villages, a mobile gynaecological clinic was set up so that physical examination could be done. Demographic variables were collected by questinaires
Int Conf AIDS 1996 Jul 7-12; 11:89 (abstract no. We.B.3189)
Cu Uvin S, Warren D, Mayer K, Peipert J, Anderson J, Klein RS, Schoenbaum E, Schuman P, Holmberg S, Vlahov D; The Miriam Hospital Immunology Center, Providence, R.I. Fax: 401-272-5082.
Objective: To determine the prevalence of genital tract infections among HIV seropositive women and high risk HIV seronegative women. Methods: Women enrolled in a multi-site cohort study (HER Study) were interviewed and underwent a physical examination (study visits not symptom drive). Gonorrhea was diagnosed by cultur
Int Conf AIDS 1996 Jul 7-12; 11:89 (abstract no. We.B.3190)
Williams AB, Frankel R, Andrews S, Cummings N, Mezger J, Winfry J, Dos Santos K; Yale School of Nursing, New Haven, CT. Fax: 203-785-6455. E-mail: ann.williams@yale.edu.
Objective: To describe the characteristics of a cohort of HIV-infected women enrolled in a prospective clinical trial of prophylaxis for vulvovaginal candidiasis (VVC). Methods: Cross-sectional analysis data from history, physical examination, microscopic exam and fungal studies of vaginal secretions for 121 HIV+ women
Int Conf AIDS 1996 Jul 7-12; 11:89 (abstract no. We.B.3191)
Mellon LR, Theodore H, Grand'Pierre R, Pape JW, Liautaud B; Division International Medicine, Cornell University Medical College, New York, NY.
Objectives: To determine the association between vaginal discharge (Vdisch.) and hygienic practices in Haitian women and to evaluate the effect of a hygienic intervention on the incidence of Vdisch. comparing two groups of HIV-seronegative females, by providing menstrual pads to one group, over a 12-month period, after
Int Conf AIDS 1996 Jul 7-12; 11:90 (abstract no. We.B.3192)
Redini L, Ortega G, Garcia Messina O, Maranzana A, Oliva SM, Santucho E, Benetucci J; Hospital De Infecciosas Muniz, Buenos Aires, Argentina.
AIMS: To study the incidence of sexually transmitted diseases (STD) in a population of patients tested for HIV, relating the seropositiveness and the different risky behaviours. MATERIAL AND METHOD: The STD were studied within a population of 18373 people examined in an AIDS Assistance Center from May 1987 to December
Objective: To determine the effect of Interferon alpha (IFN) and Zidovudine (ZDV) on HIV 1 viral load and the course of CD4-positive (CD4+) cells in HIV-seropositive (HIV+) individuals with rapidly declining CD4+ cell counts, who were already Zidovudine treated for at least three months. Methods: In a randomized, prosp
Int Conf AIDS 1996 Jul 7-12; 11:90 (abstract no. We.B.3195)
Li YK, Li M, Wang K; Yung Kong Chinese Traditional Medicine Hospital of Wuhan, China, Hubei Province of China. Fax: 86-027-2861984.
Objective: To determine the effect and effective mechanism of the Extract Spring of Life (SOL) for treating AIDS and ARC. Methods: Forty two cases of AIDS and ARC were divided into a therapeutic group and control group according to odd number and even number. The 27 cases of therapeutic group took SOL 15g Bid for 3 mon
Int Conf AIDS 1996 Jul 7-12; 11:90 (abstract no. We.B.3196)
Bainbridge D, Lowdell MW, Hannet IM, Strauss KW, Karpas A; Dept. of Haematology, University of Cambridge, Cambridge, UK. Fax: 01223 214788.
Objective: To study the long term effects of repeated plasma donation by healthy HIV-infected individuals with a CD4+T-cell count of greater than 400, for passive immunotherapy (PIT). Methods: Approximately 800ml of plasma were taken monthly. 25 peripheral blood measurements were examined on the day of each donation on
Int Conf AIDS 1996 Jul 7-12; 11:90 (abstract no. We.B.3197)
Pickus O, Ollila-Pickus G, Nadeau C; Fallbrook Medical Assoc, Chiron Therapeutics, Apria Health Care, Portland, ME, USA. Fax: 207-878-5508.
Objective: Interleukin 2, a T cell derived lymphokine, has several immunomodulatory effects including stimulation of helper and cytotoxic T cell proliferation and augmentation of cytolytic T cell activity. These findings provide basis for evaluating the effects of IL2 on CD4 counts and viral replication. Methods: 21 HI
Int Conf AIDS 1996 Jul 7-12; 11:91 (abstract no. We.B.3198)
Lange M, Maitra U, Inada Y, Stauder G, Klein EB; St. Luke's-Roosevelt Hospital, New York, NY, USA. Fax: 212- 523-3931.
Objective: To determine the effect of WOBENZYMR, an oral pharmaceutical preparation of 7 enzymes, (trypsin, chymotrypsin, papain, bromelain, pancreatin, lipase, amylase), and the flavinoid rutin with known immunomodulating and anti-inflammatory properties, in HIV seropositive subjects with CD4 counts of 200 to 500, on
Int Conf AIDS 1996 Jul 7-12; 11:91 (abstract no. We.B.3199)
Sapse AT, de Moraes HB, Bensabat S, Mosman T; Steroidogenesis Inhibitors, Inc., Las Vegas, NV, USA. Fax: (702)733-9505, 737-7016.
Objective: To continue the evaluation of ANTICORT, an anti-cortisol/steroidogenesis inhibitor drug, in the treatment of HIV+ and AIDS patients. The use of ANTICORT, a high dose, complexed form of procaine, in oral form, is based upon the following: 1. Evidence that, with the exception of terminal cases, cortisol is oft
Int Conf AIDS 1996 Jul 7-12; 11:91 (abstract no. We.B.3200)
Heimlich HJ, Chen XP, Xiao BQ, Liu SG, Lu YH, Spletzer EG, Yao JL; Heimlich Institute, Cincinnati, OH, USA. Fax: (513) 221-0003.
In one study, 71 patients with AIDS had a 35% mortality; during the same period, none of 41 patients with both AIDS and malaria died. Weakened immunity renders HIV + patients susceptible to fatal secondary infections. Studies show malaria, unlike opportunistic diseases, does not adversely affect AIDS patients, nor does
Int Conf AIDS 1996 Jul 7-12; 11:91 (abstract no. We.B.3201)
Barrick B, Vogel SE, Dugan FA, Engle JE, Lane HC, Kovacs JA; Warren Grant Magnuson Clinical Center, NIH, Bethesda, MD, USA. Fax: 301-402-1137. E-mail: bbarrick@nih.gov.
Objective: Intermittent Interleukin-2 ( IL-2 ) therapy can result in substantial increases in CD4+ lymphocyte counts in some patients with HIV infection, especially those with CD4+ counts greater than 200 cells/mm3. The purpose of this study was to evaluate symptom distress during administration of IL-2 and the impact
Int Conf AIDS 1996 Jul 7-12; 11:91 (abstract no. We.B.3202)
Moss RB, Jensen F, Ferre F, Trauger R, Daigle A, Theofan G, Richieri S, Carlo D; The Immune Response Corporation, Carlsbad, CA, USA. Fax: (619) 431-8636. E-mail: shotdoc@imnr.com.
Objective: To determine the clinical utility of a gp120-depleted, inactivated HIV-1 virus preparation in Incomplete Freund s Adjuvant (HIV-1 Immunogen) to treat HIV-1 infection. Methods: Previous studies have revealed a stabilization in viral load and CD4 percent in subjects inoculated with the HIV-1 Immunogen. A doubl
Int Conf AIDS 1996 Jul 7-12; 11:91 (abstract no. We.B.3203)
Reiter WM, Gomatos PJ, Keller RH, Tomaka F, Uribe MR, Giannetti B; Center for Special Immunology, Ft. Lauderdale, FL, USA. Fax: 954-462-4077.
Objective: To determine changes in clinical and laboratory parameters in late-stage AIDS patients after monthly transfusion (TR) of human IVIG and cross-matched (X-matched) peripheral blood mononuclear cells (PBMC). Methods: Patients with late-stage AIDS received monthly TR of 12-15g IVIG followed by 1-4 x 109 X-matche
Int Conf AIDS 1996 Jul 7-12; 11:92 (abstract no. We.B.3204)
Bouvet E, Lambotte O, Fleury L, Joly Guillou ML; Hopital Bichat, Paris, France. Fax: 40 25 88 40.
Objectives: To determine the role of peripheral venous catheters (PVC) as a source of bacteriemia in HIV-infected patients. Methods: A retrospective study concerning all cases of bacteremia in HIV-infected patients admitted in our infectious diseases unit during 1993 and 1994 was performed. Results: Fifty three episode
Int Conf AIDS 1996 Jul 7-12; 11:92 (abstract no. We.B.3205)
Tumbarello M, Tacconelli E, Pittiruti M, Cauda R, Ortona L; Istituto Clinica Malattie Infettive, Universita Cattolica, Roma, Italy. Fax: + 39-6-3051343.
Objectives: to evaluate the incidence, type and outcome of central venous catheter (CVC) related complications in HIV-infected patients. Methods: all HIV-infected patients admitted at our ward from Jan-1994 to Dec-1995, who had central venous polyurethane catheters implanted, were entered into this study. CVC were impl
Int Conf AIDS 1996 Jul 7-12; 11:92 (abstract no. We.B.3206)
Cruceta A, Miro JM, Gatell JM; Infectious Diseases Unit, Hospital Clinic, Barcelona, Spain. Fax: Int+34+3+2275454. E-mail: miro@medicina.ub.es.
Objective: 1. To describe the incidence and clinical characteristics of 1529 episodes of infective endocarditis (IE) in Spanish IV drug addicts (IVDAs) diagnosed between 1977 to 1993; 2. To identify prognostic factors associated with higher mortality; and 3. To compare the clinical characteristics and the prognosis of
Int Conf AIDS 1996 Jul 7-12; 11:92 (abstract no. We.B.3207)
Chantry CJ, Patnaik M, Diaz C; University of Puerto Rico, Pediatric Hospital, San Juan, Puerto Rico, USA. Fax: (809) 767-4798. E-mail: actg_uprch@fstrf.org.
INTRODUCTION: Bartonella quintana (B. quintana) is a gram negative bacterium causing clinical illness (e.g. bacillary angiomatosis , endocarditis) which is closely related and cross reacts on immunofluorescence assays to Bartonella henselae (B. henselae), a recently described organism which has been associated with var
Int Conf AIDS 1996 Jul 7-12; 11:92 (abstract no. We.B.3208)
Berman SM, Mulligan M, Ho M, Ma C; Department of Veterans Affairs Medical Center, Long Beach, CA, USA.
Objective: To describe the characteristics and epidemiology of AIDS patients with Clostridium difficile associated diarrhea (CDAD). Methods: Retrospective case analyses of HIV-positive patients who developed diarrhea that was attributed to C. difficile. The presence of C. difficile was confirmed by either positive stoo
Int Conf AIDS 1996 Jul 7-12; 11:93 (abstract no. We.B.3209)
Zachariah J, Mateo N, Saravolatz L; Infectious Diseases Division, Henry Ford Hospital, Detroit, MI. Fax: (313) 876-2993.
Introduction: Pulmonary infections caused by Rhodococcus equi (RE) in AIDS patients are being increasingly recognized. There is increased potential for hematogenous spread in immunosuppressed patients. Objective: To present a case and review the literature on brain abscess caused by RE, discuss risk factors, diagnosis
Int Conf AIDS 1996 Jul 7-12; 11:93 (abstract no. We.B.3210)
Patey O, Breuil J, Fosse T, Prazuck T, Chaplain C, Meynard JL, Christmann D, Bentata M; Service des Maladies Infectieuses, Centre Hospitalier St. Georges, France. Fax: 33 1 43 86 22 98.
Patients with AIDS and AIDS related conditions are at increased risk of bacteremia. Most isolates are aerobic bacteria with a predominance of Gram positive (Staphylococcus and Streptococcus pneumoniae) versus Gram negative bacteria (Salmonella, Pseudomonas). Despite many predisposing conditions to develop anaerobic inf
Int Conf AIDS 1996 Jul 7-12; 11:93 (abstract no. We.B.3211)
Zamora L, Guelar A, Mallolas J, Miro JM, Soriano E, Gatell JM; Hospital Clinic, Barcelona, Spain.
We present a case of R. equi disseminated infection in a patient with advanced HIV infection, with retinal and central nervous system involvement and good response to long-term antibiotic treatment. Case: Thirty-two years old male patient with HIV infection. He started zidovudine and PCP primary prophylaxis on Augu
Int Conf AIDS 1996 Jul 7-12; 11:93 (abstract no. We.B.3212)
Bourez JM, Valette M, De La Tribonniere X, Ajana F, Senneville E, Chidiac C, Mouton Y; Service Des Maladies Infectieuses, Tourcoing.
Objectives: To assess the level of surrogate markers at the first occurence of CMV .R in PWH. Method: Retrospective chart review of PWH presenting a first occurence of CMV.R between January 1988 and December 1994 in the north of France AIDS medical reference center. For each patient, CD4 count, p24 antigenemia were per
Int Conf AIDS 1996 Jul 7-12; 11:93 (abstract no. We.B.3213)
Merl S, Emminger C, Karwat M, Spiegl F, Jager U, Eichenlaub D; Municipal Hospital Munich-Schwabing, Munich, Germany. Fax: 01149/89/3071301.
In long term surviving patients with AIDS, CMV-disease becomes an increasing clinical problem. Findings at autopsy confirm clinicians suspicion, that CMV-disease exceeds far the known manifestations: retinitis and gastrointestinal tract involvement. The value of different diagnostic tests to confirm the disease is uncl
Int Conf AIDS 1996 Jul 7-12; 11:93 (abstract no. We.B.3214)
Danise A, Cinque P, Vergani A, Racca S, Candino M, Castagna A, Lazzarin A; Division of Inf. Diseases, San Raffaele Hospital, Milan, Italy. Fax: 39-2-26437030.
Objective: To evaluate the polymerase chain reaction (PCR) from aqueous humor for diagnosis of Toxoplasma gondii and varicella-zoster virus (VZV) retinitis and to differentiate retinitis with atypical lesions in HIV-infected patients. Methods: From February 1994 to November 1995, 820 HIV-infected patients were evaluate
Int Conf AIDS 1996 Jul 7-12; 11:94 (abstract no. We.B.3215)
Perez-Elias MJ, Casado JL, Antela A, Ciancas E, Suarez M, Redondo E, Pintado V, Guerrero A; Infectious Diseases Unit, Hospital Ramon y Cajal, Madrid, Spain. Fax: 341-3368672.
Objective: To assess the safety and efficacy of oral Ganciclovir (O-GCV) as maintenance theraphy in a compassionate programme. Methods: Patients with stable cytomegalovirus retinitis (CMV-R) and with contraindications, intolerance or voluntary refusal to intravenous catheter maintenance therapy, were included in a open
Int Conf AIDS 1996 Jul 7-12; 11:94 (abstract no. We.B.3216)
Orellana J, Lieberman R, Velez W, Dauhajre R, Adelson K; Mount Sinai School Of Medicine, New York, NY, USA.
Objective: To assess the efficacy of high dose intravitreal foscarnet in patients with poor vision (less than 20/200) secondary to recurrent posterior pole CMV retinitis. Methods: 19 eyes of 16 patients presenting with poor visual acuity (less than 20/200) and recurrent CMV retinitis in the posterior pole were treated
Int Conf AIDS 1996 Jul 7-12; 11:94 (abstract no. We.B.3217)
Chaisson RE, Keruly JC, Gallant JE, Moore RD; Johns Hopkins University School Of Medicine, Baltimore, MD. Fax: rchaiss@welchlink.welch.jhu.edu.
Objective: To identify predictors of cytomegalovirus ( CMV ) disease in patients with advanced HIV infection. Methods: We studied 869 patients with HIV and CD4 counts less than100 in a prospective cohort. We analyzed the association of demographic and clinical features with the occurrence of CMV disease by univariate a
Int Conf AIDS 1996 Jul 7-12; 11:94 (abstract no. We.B.3218)
Stalder N, Olmari M, Opravil M, Gabriel V, Sudre P, Sansonetti A, Von Overbeck J, Herbort K, Hirschel B; Division of Infectious Diseases, Departments of Ophthalmology, HCU, Geneva, Switzerland. Fax: +41 22 372 98 20.
Background: Cytomegalovirus ( CMV ) retinitis may be treated systemically, or intravitreally with foscarnet or ganciclovir. Systemic treatment may prevent spread of CMV from one eye to the other. Patients and Methods: We reviewed retrospectively all charts of patients with AIDS and initially unilateral CMV retinitis di
Int Conf AIDS 1996 Jul 7-12; 11:94 (abstract no. We.B.3219)
Lopardo GD, Bonvehi P, Falco A, Temporiti E, Relloso S, Cassetti L, Ruttimann R, Herrera F, Smayevsky J, Stamboulian D; CEMIC, Buenos Aires, Argentina.
Factors predisposing to candidemia include long term granulocytopenia, organ transplantation, surgical procedures, burns, intravascular catheters, total parenteral nutrition, chemotherapy and radiotherapy. Previous exposure to steroids and broad spectrum antibiotics are also associated with this disease. Notably, HIV-p
Int Conf AIDS 1996 Jul 7-12; 11:95 (abstract no. We.B.3220)
Williams KE, Tan B, Martin T; Royal University Hospital, Saskatoon, Saskatchewan, Canada. Fax: 306-975-0383.
Objectives: 1. To describe the occurrence of disseminated histoplasmosis in an HIV-infected man in a non-endemic area. 2. To describe the incidental isolation of H. capsulatum on mycobacterial media. Methods: A 46 year old HIV-positive man with 50 CD4 cells x106/L. presented with 1 month of fevers, copious diarrhea, my
Objective: To dermine clinic presentations, radiographic findings and clinical outcomes of pulmonary nocardiosis in HIV seropositive patients at tertiary referral chest hospital in Thailand . Methods: Medical records of registered HIV seropositive patients in Central Chest Hospital from January 1994 to December 1995 we
Int Conf AIDS 1996 Jul 7-12; 11:95 (abstract no. We.B.3222)
Denning DW, Hood SV, Moore CB; Department of Infectious Diseases and Tropical Medicine, North Manchester General Hospital (NMGH), Manchester, UK. Fax: 00 44 161 720 2562.
Abstract Previously uncommon or unreported fungal infections are becoming increasingly recognised in patients following the advent of the HIV pandemic. We report the first documented case of infection with Neurospora sitophila. A 48 yr old HIV-positive man, presented initially with pneumocystis carinii pneumonia in
Int Conf AIDS 1996 Jul 7-12; 11:95 (abstract no. We.B.3223)
Maenza JR, Merz W, Romagnoli M, Moore R, Keruly J, Gallant J; Johns Hopkins University School Of Medicine, Baltimore, MD, USA. Fax (410) 955-7889.
Objectives: To determine if treatment of oral thrush is associated with decreased fluconazole susceptibility of fungal isolates during and immediately after a course of antifungal therapy. Methods: To date, oral fungal cultures have been obtained from 30 HIV-infected patients who presented with thrush. Cultures were re
Int Conf AIDS 1996 Jul 7-12; 11:95 (abstract no. We.B.3224)
Lacaz CS, Alves KS, Del Negro GB, Ninomiya A, Melhem MS, Wagon BB, Oyafuso LK, Franca LC; Instituto de Medicina Tropical de Sao Paulo, Sao Paulo, Brazil. Fax: 55 11 3061-3900.
Objective: Two paracoccidioidomicosis cases report in HIV patients. Methods: Files, histopatology, mycology and serology review. Results: Case # 1 - F.S.R., male, 31 years old, HIV-positive, originally from Bahia, living in Sao Paulo, Brazil , with 38-39 C fever, dry cough, abdominal pain, swelling of the lymph nodes a
Int Conf AIDS 1996 Jul 7-12; 11:95 (abstract no. We.B.3225)
Del Bianco R; Instituto De Infectologia Emilio Ribas, Sao Paulo, Brazil.
Objective: To describe uncommon manifestations of Paracoccidiordomycosis in AIDS. Methods: 1) Identification of cases through: a) computer search of discharge diagnosis of Paracoccidiordomycosis b) review of infections disease consult service and pathology records for the period 1989-1994 in Sao Paulo c) Retrospective
Int Conf AIDS 1996 Jul 7-12; 11:95 (abstract no. We.B.3226)
Verdier RI, Pape JW; Division International Medicine, Cornell University Medical College, New York, NY.
Objectives: To evaluate the response of Isospora belli and Cyclospora species in a comparative open trial using Trimetoprim/Sulfamethoxazole (TMP/SMX) versus Ciprofloxacin. Materials and Methods: During a 6 month period, patients referred to our HIV Referral Center in Port-au-Prince and complaining of chronic/intermitt
Int Conf AIDS 1996 Jul 7-12; 11:96 (abstract no. We.B.3227)
Murro HH, Bezares RF, Arra A, Pzsenni V, Cueva F; Policlinico Bancario, Buenos Aires, Argentina. Fax: 54-1-8553204.
Background: CF1 strain mice experimentally infected with Toxo die within 3-4 days after infection. Objectives: To evaluate the effects of GM-CSF in mice infected with Toxo. Material and Methods: 5 mice infected with 2x10 Toxo intraperitoneally day 1 and treated with GM-CSF 5ugr/kg/day, days 2 to 10. Five mice infected
Int Conf AIDS 1996 Jul 7-12; 11:96 (abstract no. We.B.3228)
Lefevre-Elbert V, Ciraru-Vigneron N, Garin JF, Derouin F, Ravina JH; Dep. of Obstetrics and Gynecology, CHU Lariboisiere, Paris, France. Fax: 33 1 49 95 62 15.
Objectives: To confirm absence of clinical toxoplasmosis in asymptomatic mothers even when pregnancy immunosuppression is combined with HIV-positive status. To evaluate potential risk of congenital toxoplasmosis and necessity of prophylactic treatment. Methods: Toxoplasmosis antibodies cinetic and parasitemia were perf
Int Conf AIDS 1996 Jul 7-12; 11:96 (abstract no. We.B.3229)
Bourdillon F, Raffif, Pradier C; Mission Sida Direction des Hopitaux, Paris, France. Fax: 033 40 56 58 30.
Objective: To determine the principal situations giving rise to cerebral toxoplasmosis in HIV-infected patients in France . Methods: A prospective study by questionnaire was conducted in 100 public hospitals, between 15 April and 14 July 1995, to record all first episodes of cerebral toxoplasmosis. Results: 149 cases o
Int Conf AIDS 1996 Jul 7-12; 11:96 (abstract no. We.B.3230)
Arici C, Finazzi MG, Minola E, Quinzan GP, Tambini R, Rizzi M; Divisione di Malattie Infettive, Ospedali Riuniti di Bergamo, Bergamo, Italy. Fax 39-35-269286.
Introduction: Trimethoprim (TMP; 160mg) plus sulfamethoxazole (SMX; 800 mg) is routinely prescribed for primary and secondary prophylaxis of Pneumocystis carinii pneumonia. According to preliminary results, this regimen seems to be also effective in preventing toxoplasmic encephalitis. Objective: To verify the effectiv
Int Conf AIDS 1996 Jul 7-12; 11:39 (abstract no. We.B.3231)
Roca B, Saez-Royuela A, Teruel C, Uso J, Simon E; Medicine Department, Hospital General of Castellon, Spain.
Objective: To determine the rate of HIV infected patients with positive serology against Toxoplasma gondii (a risk factor for developing cerebral toxoplasmosis), in the province of Castellon, Spain . Methods: The medical records of all 323 HIV seropositive patients, attended for the first time from April 1991 to April
Int Conf AIDS 1996 Jul 7-12; 11:96 (abstract no. We.B.3232)
Poizot-Martin I, Giovannini M, Rosello R, Viallat JR, Dalmas AM, Sauniere F, Gastaut JA; Institut Paoli-Calmettes, Marseille, France.
Ojectives: To evaluate the efficacy and safety of TLC D-99 in HIV-infected patients with cutaneous and/or visceral KS. Methods: Twelve HIV-infected male patients (mean CD4 count = 136/ mm3(range, 5 to 587/mm3) participated in the study. Seven subjects presented with visceral KS (lung, pericardium, stomach, colon, and/o
Int Conf AIDS 1996 Jul 7-12; 11:97 (abstract no. We.B.3233)
Saillour M, Risbourg M, De Truchis P, Valance A, Sarrazin E, Perronne C; Hopital R. Poincare, Garches, France. Fax: (33)-1-47107767.
Ojective: HHV8, a gamma-herpes virus, has been identified by Chang et al in AIDS-associated Kaposi s sarcoma. There are aneCDotal reports of remission of KS following foscarnet (PFA) therapy. We studied wether anti- CMV agents could be efficient for the treatment of KS. Methods: Retrospective study of all HIV-infected
Int Conf AIDS 1996 Jul 7-12; 11:97 (abstract no. We.B.3234)
Mendel I, Prevost M, Collandre H; Virologie, Centre Hospitalo-Universitaire de Rouen, Rouen, France. Fax: 35.88.58.49.
Objective: To determine the incidence of the Kaposi s sarcoma associated herpesvirus (KSHV) in biopsies from patients with AIDS associated Kaposi s sarcoma (KS). Methods: We screened for the presence of KSHV DNA sequences in various KS biopsies and PBMCs from 22 HIV-positive patients with or without KS. DNA was directl
Int Conf AIDS 1996 Jul 7-12; 11:97 (abstract no. We.B.3235)
Cazorla C, Dabis F, Dupon M, Ragnaud JM, Geniaux M, Pellegrin JL, Journot V, Salmi LR; CISIH, Hopital Saint Andre, Centre Hospitalier Universitaire, Bordeaux, France. Fax: (33) 56.79.58.22.
Objectives: To study in a systematic fashion behavioural risk factors of Kaposi s sarcoma (KS) among HIV-infected homosexuals in Bordeaux, southwest France . Methods: A case-control study was performed within the Aquitaine Cohort. Cases of KS surviving in 1995 and homosexuals were systematically enrolled. For each case
Int Conf AIDS 1996 Jul 7-12; 11:97 (abstract no. We.B.3236)
Cagni A, Quirino T, Bestetti G, Cremoni L; Dep Infect. Diseases, Luigi Sacco Hospital, Milan, Italy.
DNA sequences of a new herpes-like virus (HHV-8) have been recently found in KS biopsies obtained from patients with AIDS-related and classical Kaposi s sarcoma (KS). Although the way of infection of this novel human herpesvirus is unknown, epidemiologic features indicate a likely sexual transmission. We report the cas
Int Conf AIDS 1996 Jul 7-12; 11:97 (abstract no. We.B.3237)
Uccini S, Sirianni MC, Vincenzi L, Stoppacciaro A, Capuano M, Masini C, Lesnoni La Parola I, Cerimele D, Ruco LP, Baroni CD; Department of Experimental Medicine and Pathology, Rome, Italy. Fax: 011 39 6 494 0896.
Objective: To investigate the possibility that PB of KS patients contains circulating KS precursor cells. Methods: PBMC from 5 AIDS-KS and 11 classic KS patients, from 30 healthy volunteers, 5 HIV-1+ patients without KS, and from 15 patients affected by chronic dermatitis were cultured in 20% conditioned medium from PH
Objectives: To evaluate the efficacy and toxicity of a therapeutic scheme with ABV in association with rHuG-CSF for the treatment of poor risk AIDS - related KS. Methods: HIV-positive patients were enrolled in the study if they had biopsy-proven KS with either visceral involvement or tumor associated edema and/or ulcer
Int Conf AIDS 1996 Jul 7-12; 11:98 (abstract no. We.B.3239)
Kravtchenko A, Gruzdev BM, Yurin O, Parkhomenko Y, Gorbacheva E; Moscow City AIDS Centre, Moscow, Russia. Fax: 7-095-365-2488.
Objective: To study clinical manifestations of Kaposi s sarcoma (KS) in Russian HIV-infected patients (pts.). Methods: Disseminated KS was diagnosed in 20 pts., mean age = 39.2 y., M/F = 17/3. Clinical, immunological and morphological methods were used. Results: 80% pts. had count of CD4-cells less than 100/mm3 (mean =
Int Conf AIDS 1996 Jul 7-12; 11:98 (abstract no. We.B.3240)
Warren DR, Ng C, Sepkowitz K, Jacobs J; The New York Hospital, Center for Special Studies, NYC, NY, USA. Fax:(212)746-8415. E-mail: DRobertW@AOL.COM.
Objective: To add 2 cases to the literature and analyze demographic, clinical and survival data of HIV-positive (HIV+) women with Kaposi s Sarcoma (KS). Methods: Demographic, clinical and survival data for 2 HIV+ women with KS and 56 HIV+ women with KS from 11 case reports identified by MEDLINE from January 1985 throug
Int Conf AIDS 1996 Jul 7-12; 11:98 (abstract no. We.B.3241)
Leoung GS, Aboulafla D, Millikan L, Duvic M, MacGregor RR, Gill G, Truglia J, Yocum R; St. Francis Memorial Hosp, San Francisco, CA. Fax: (415) 353-6594.
Objective: To assess the safety and efficacy of a new topical retinoid gel, Targretin (LGD1069) on KS lesions. Methods: Fifty-nine patients with biopsy proven KS were randomized at 5 study sites in an unblinded fashion to either 0.5% vs. 1.0% gel, BID and increasing to 1.0% QID or the maximum dose tolerated. Patients w
Int Conf AIDS 1996 Jul 7-12; 11:98 (abstract no. We.B.3242)
Anthony K, Stool E, Gathe J Jr, Holder P; Park Plaza Hospital, Houston, TX. Fax: (713) 522-6954.
Objectives: To point out occult Kaposi s Sarcoma (KS) must be considered in the differential diagnosis of unexplained abdominal crisis and/or bone marrow suppression. Method: Retrospective chart review of a patient followed prospectively by the authors. Results: A 30 year old man with AIDS for four years complicated by
Int Conf AIDS 1996 Jul 7-12; 11:98 (abstract no. We.B.3243)
Grekin R, Razum N, Trommer R, Doiron D, Snyder A; UCSF, Medical Center, San Francisco, CA, USA. Fax: 415-476-0414.
Objective: To define a clinical PDT drug and light dose to elicit response/remission of cutaneous AIDS-associated KS and to determine the response/remission rate of KS lesions in an expanded population of AIDS patients. Methods: In the UCSF Phase I trial, 11 patients (91 lesions) were treated in a drug escalation proto
Int Conf AIDS 1996 Jul 7-12; 11:99 (abstract no. We.B.3244)
Mary-Krause M, Lievre L, Costagliola D; INSERM, Faculte de Medecine Saint-Antoine, Paris, France. Fax: 33(1)43 07 39 57. E-mail: mmary@b3e.jussieu.fr.
Objective: To evaluate change in incidence of HIV-related diseases and in access to therapy between 1989 and 1994. Methods: The French Clinical Epidemiology Database on HIV seropositive subjects followed in hospitals was started in 1989 in more than 50 hospitals in France . The standardised data collection form include
Int Conf AIDS 1996 Jul 7-12; 11:99 (abstract no. We.B.3245)
Katlama C, Matheron S, Mary-Krause M, Ait-Mohand H, Li T, Ruggeri C, Costagliola D; Service des Maladies Infectieuses, Groupe Hospitalier Pitie-Salpetriere, Paris, France. Fax: 42.16.01.26.
Objective: To estimate the incidence of CMV disease, mycobacterium avium intracellulare ( MAC ), cryptosporidiosis .html cryptosporidium (CRYP) and microsporidium (MICR) infections and the survival in patients with advanced HIV disease in mids 1990.
Int Conf AIDS 1996 Jul 7-12; 11:99 (abstract no. We.B.3246)
Ayensa C, Agud JM, Portu JJ, Aldamiz-e M, Barroso J, Rubio A, Erdozain M; Hospital Txagorritxu. Vitoria, Spain.
Objective: To determine the most frequent opportunistic diseases (OD) in HIV-infected patients. Design: Series of descriptive cases. Methods: 1017 patients treated in a Teritary Hospital in The Basque Autonomous Community (Hospital Txagorritxu, Vitoria-Gasteiz, Spain ) were studied. The evolution of opportunistic disea
Int Conf AIDS 1996 Jul 7-12; 11:99 (abstract no. We.B.3247)
Del Amo J, Petruckevitch A, Phillips A, Stephenson J, Johnson A, Decock KM; UCLMS, London, UK.
Objectives: To compare the distribution of AIDS-defining conditions (ADC) in African and non-African subjects with HIV/AIDS in London. Methods: Case notes for all 1056 Africans seen in 11 HIV/AIDS Units in London and 992 non-African controls, matched for Unit and year of presentation, were analysed for characteristics
Int Conf AIDS 1996 Jul 7-12; 11:99 (abstract no. We.B.3249)
de Chabalier F, Alioum M, Leteneur L, Commenges D, Leroy V, Dabis F, Salamon R; INSERM, Universite de Bordeaux, Bordeaux, France. Fax: 56.99.13.60. E-Mail: hivu330@bordeaux2.fr.
Objectives: Since the beginning of Human Immunodeficiency Virus (HIV) pandemic, the definition of the Acquired Immunodeficiency Syndrome (AIDS) has been revised several times. From the last revision (1993), different options have been taken in Europe and in the USA. The classifying clinical conditions are the same in b
Objective: To evaluate the global impact of therapeutic intervention - antiretroviral therapy prophylaxis of opportunistic infections - on survival in HIV-infected patients. Methods: Retrospective analysis of the survival probability after the first CD4+ cell count greater than or equal 50 and less than 200/microliter
Int Conf AIDS 1996 Jul 7-12; 11:100 (abstract no. We.B.3251)
Romeu J, Paredes R, Tural C, Gimenez G, Morales A, Modol JM, Clotet B; HIV Unit, Hospital Universitari "Germans Trias i Pujol", Badalona, Spain.
Objective: To study the survival rates of a cohort of HIV-infected patients whose CD4 cell counts fall below 50/mm3 and to identify which variables are associated with a better outcome. Patients and methods: Medical records of 3130 HIV-infected individuals seen at our institution since 1984 were reviewed in order to id
Int Conf AIDS 1996 Jul 7-12; 11:100 (abstract no. We.B.3252)
Barkan S, Melnick S, Stonis L, Preston-Martin S, Weber K, Sacks H, Marx E, Padian N, Feldman J; Office of AIDS Research, NIH, Bethesda, MD. Fax: 301/402-7769. E-mail: SM33k@nih.gov.
Objective: To investigate in women (WM) the spectrum of AIDS-defining and other HIV-related conditions; predictors of genital infections/cervical disease; immunologic/virologic/clinical correlates of disease progression; substance abuse; sexual behavior; health care utilization; and depression, domestic violence, and q
Int Conf AIDS 1996 Jul 7-12; 11:100 (abstract no. We.B.3253)
Moorman A, Holmberg S, Fuhrer J, Loveless M, Von Bargen J, Marlowe S, Fisher D; CDC, Atlanta, GA. Fax:(404)639-6018.
Objective: To evaluate the changing demographic characteristics, symptoms, risks for, and incidence of HIV-related conditions and therapies of HIV-infected patients seen out-of-hospital in the United States . Methods: Analysis of prospectively collected data abstracted and electronically charted from 11, 755 visits of
Int Conf AIDS 1996 Jul 7-12; 11:100 (abstract no. We.B.3254)
Sinicco A, Fora R, Sciandra M, Bechis G, Calvo MM, Raiteri R; Institute of Infectious Diseases, University of Turin, Turin, Italy. Fax: +39117761757.
Objective: To assess the possibility of a change in the natural history of HIV infection. Methods: From September 1985 to December 1995, all seroconverters to HIV with a negative test within 12 months before the first positive, first follow-up visit within 6 months after the seroconversion and at least a 6-month follow
Int Conf AIDS 1996 Jul 7-12; 11:100 (abstract no. We.B.3255)
Vovk AD, Shcherbinska AM, Antonyak SN; Research Institute of Epidemiology & Infectious Diseases, Kiev, Ukraine. Fax: 044-277-24-00.
Objective: To determine patters of infection transmission, clinical manifestations and opportunistic infections frequency. Methods: 160 HIV-infected persons were followed up to 2-3 years. Among them: 38 AIDS patients, 34 AIDS-AC, 72 - generalized lymphoadenopathia and 16 AIDS virus carriers. Results: Till lately
Objectives: To determine the nutritional habits of HIV-infected patients prior and after the diagnosis/annoucement of their status. Methods: HIV-positive patients were interviewed annonymously on Knowledge, Attitude and Behaviour questionnaire, with their verbal consent in 3 hospitals in Yaounde, from September to Dece
Int Conf AIDS 1996 Jul 7-12; 11:101 (abstract no. We.B.3257)
Lalonde RG, McDermid JM, Kubow S, Gray-Donald K; Immunodeficiency Service, Montreal Chest Institute, Montreal, Quebec, Canada. Fax: 514-843-2092. E-mail: rlalonde@is.rvh.mcgill.ca.
Objective: To evaluate the association between oxidative stress and the dietary intake of ascorbic acid, vitamin E, beta-carotene, selenium and zinc in a cross-sectional study of HIV-seropositive men and women. Methods: Consenting persons at all stages of HIV infection were screened by a physician and recruited if they
Objective: To describe the dietary intake and supplementation practices of five antioxidant micronutrients, protein and energy in a cross-sectional study of HIV-seropositive men and women. Methods: Consenting persons at all stages of HIV infection were screened by a physician and recruited if they were free of active i
Int Conf AIDS 1996 Jul 7-12; 11:101 (abstract no. We.B.3259)
Denotter DM, Strathdee SA, Craib KJ, Cornelisse PG, Hogg RS, Rabound JM, O'Shaughnessy MV, Schechter MT; BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada.
Objective: To examine the potential relationship between dietary vitamin and mineral intake, particularly vitamin A, and progression of HIV infection within the Vancouver Lymphadenopathy-AIDS Study (VLAS). Methods: The dietary intake of 158 seropositive (SP) men was evaluated utilizing a self-administered 24-hour dieta
Objective: To better define the amino acid requirements in order to prevent muscle protein wasting in AIDS. Methods: Seven male AIDS patients (median age 37 yr, median CD4 count 59 mm-3, no evolutive opportunistic infection on the week before experiment) were intravenously infused with a complete amino acid mixture (Pr
Int Conf AIDS 1996 Jul 7-12; 11:102 (abstract no. We.B.3261)
Tassie JM, Bessou J, Perez M, Berard A, Cuzin L, Marchou B, Auvergnat JC; Dept. Of Infectious Diseases, Hospital Purpan, Toulouse, France. Fax: (33) 61 77 21 38.
Objective: To evaluate the relationship between vitamins, trace elements, and disease progression in HIV-infected patients. Methods: Outpatients were systematically proposed a nutritional consultation between 06/94 and 10/95; no patient has had previous nutritional counselling. We analysed the initial serum levels of v
Int Conf AIDS 1996 Jul 7-12; 11:102 (abstract no. We.B.3262)
Schwenk A, Kremer G, Becker K, Breidenbach M, Steuck H, Fatkenheuer G, Diehl V, Schrappe M; HIV & Nutrition Study Group, Klinik I fuer Innere Medizin, Universitaet Koeln, Koeln, Germany.-4175, Fax: +49221 478 -6456. E-mail: achim.schwenk@uni.koeln.de.
Objectives: In patients (pts) with severe cachexia, feasibility and tolerance of enteral nutrition was evaluated. The effect of dietary fiber in enteral nutrition on the course of diarrhea was investigated.Study design and intervention: prospective double-blind controlled pilot study, comparing polymeric diet without f
Int Conf AIDS 1996 Jul 7-12; 11:102 (abstract no. We.B.3263)
Liss MI, Chan RS, McKinley M, Ilaria G, Jacobs J; New York Hospital, Center for Special Studies, New York, NY, USA. Fax: (212)746-8415.
Individuals with HIV are challenged with maintaining both adequate nutritional intake and home management independence. Project: An innovative outpatient cooking group combining the disciplines of nutrition and occupational therapy was implemented. A registered dietitian and an occupational therapist, specialize
Int Conf AIDS 1996 Jul 7-12; 11:102 (abstract no. We.B3264)
Knox TA, Speigelman D, Gorbach S; New England Medical Center, Boston, MA. Fax: (617)636-6407.
Objective: To measure vitamin levels in a cohort of HIV-infected persons and correlate them with vitamin supplementation and gastrointestinal function. Methods: We performed a cross-sectional analysis of folate, vitamin B6 and vitamin B12 levels in participants in a longitudinal study of HIV and nutrition. Gastrointest
Int Conf AIDS 1996 Jul 7-12; 11:102 (abstract no. We.B.3265)
Di Franco MG, Woods M, Spiegelman D, Knox T, Gorbach S; Tufts University School of Medicine, Boston, MA, USA. Fax: (617) 636-5810. E-mail: mdifranc@opal.tufts.edu.
Objective: To determine the correlation between nutritional parameters in HIV-infected individuals and their CD4 counts. To compare estimated caloric needs and energy intake in the same population. Methods: We performed a cross-sectional analysis of 73 HIV-infected subjects, 57 males and 16 females enrolled in a longit
Int Conf AIDS 1996 Jul 7-12; 11:102 (abstract no. We.B.3266)
Bowers JM, Ampel NM, Scott RW, Dols CL, Campbell S; Veterans Affairs Medical Center (VAMC), Tucson, AZ.
Objective: The Harris-Benedict equation (HBE) is routinely used as a method of calculating energy needs, and incorporates weight, height, gender, and age as primary factors. For patients with trauma, surgery or sepsis, additional stress factors have been applied to the HBE to better estimate their caloric requirements.
Int Conf AIDS 1996 Jul 7-12; 11:103 (abstract no. We.B.3267)
Bork JM; Loma Linda University, Loma Linda, CA, USA. Fax: (909) 824-4184.
Objective: To determine if the clinical finding of lettuce craving in the pediatric AID s patient is a form of PICA (unnatural food craving) and an indicator of a nutritional deficiency. Method: A dietary survey was conducted on a pilot group of 15 HIV-positive children to determine their dietary habits and basic nutri
Objective: to determine if baseline vitamin A (VA) status, as determined by serum retinol concentration, was associated with mortality or the development of active tuberculosis (TB) in HIV-infected Haitians. Methods: Persons greater than or equal 16 years of age who were HIV seropositive and had a positive (greater tha
Int Conf AIDS 1996 Jul 7-12; 11:103 (abstract no. We.B.3269)
Daniel V, Hollister AS, Almada AL; Myogenix, Palo Alto, CA, USA. Fax: (408) 662-9602.
Objective: To assess the tolerability of a nutrient/biochemical enteral formula, and its effects on subjects sense of well-being and total body mass in non-wasting seropositive males. Methods: Ten HIV+ men (18-45 years old) were recruited into an open trial and received a powdered nutrient/biochemical formula (Somatoga
Int Conf AIDS 1996 Jul 7-12; 11:103 (abstract no. We.B.3270)
Cimoch PJ, Hoppe JB; FACP Center for Special Immunolgy, Irvine, CA.
Objective: Hypovitaminosis A may contribute to impaired humoral and cell-mediated immunity in HIV-infected patients. It is reported to span the spectrum of HIV disease even occurring in patients with dietary intakes above the RDA s. We investigated whether plasma vitamin A (vitA) deficiencies correlated with the degree
Int Conf AIDS 1996 Jul 7-12; 11:103 (abstract no. We.B.3271)
Mooney M, Vergel N; Program for Wellness Restoration (PoWeR), Houston, TX. Fax:(713) 526-5883. E-mail: mmoony@ao1.com.
Wasting is one of the main causes of death in PWA s. Research has shown that increased lean body mass (LBM) and improved nutritional status are correlated to survival in HIV disease. However, it is very difficult and frustrating for an HIV + person to access consolidated and comprehensive information about effec
Int Conf AIDS 1996 Jul 7-12; 11:103 (abstract no. We.B.3272)
Gorbea RM, Flores LM, Martinez RH, Garcia Gonzalez ER, Torres GF; Infectology Hospital "Dr Daniel Mendez" "La Raza" Medical Center Mexican Instituto for Social Security, Mexico City.
Objective: Investigate the efficacy of a complete specialized diet formulated with proteins of high density and fatty acid omega 3 - designed specially for patients with AIDS vs traditional Mexican - nutrition in children with AIDS in any stage of disease; over nutritional condition and immunological competence. Patien
Objective: To determine the frequency of nutritional status assessment in early HIV infection and to describe the frequency and types of interventions recommended. Methods: Charts of 31 (M=25 F=6) HIV+ patients with CD4 counts greater than 200 cumm at first visit were reviewed retrospectively for nutritional assessment
Int Conf AIDS 1996 Jul 7-12; 11:104 (abstract no. We.B.3274)
Leyria C, Fridman E, Ricci S, Wainstein C; Hospital Muniz, Buenos Aires, Argentina. Fax: (541) 807-0428.
Objective: To evaluate the main pathologies at the lower genital tract in HIV-positive women. Methods: we studied 185 HIV-positive women during 18 months (Jan 1, 1994/July 1, 1995). Age group 16- 50 a$os, (X:27+/-6), 71% were intravenous drug user, 78% with multiples partner and 57% with HIV+ partners. Was also perform
Int Conf AIDS 1996 Jul 7-12; 11:104 (abstract no. We.B.3275)
Amaral E, Ribeiro FA, Cristoforo FF, Villarroel MC, Faundes A; State University of Campinas Campinas, SP, Brasil. Fax: (0192) 393687. E-mail: rhama@dglnet.com.br.
Objective: To study the epidemiological profile and lower genital tract diseases in Brazilian HIV (+) women. Methods: Data on sociodemographic factors, sexual practices, lifestyle, HIV, syphilis and hepatitis B serologies, CD4 count, colposcopy, vulvoscopy, Pap smear, N. gonorrhoea culture, Chlamydia immunofluorescence
Int Conf AIDS 1996 Jul 7-12; 11:104 (abstract no. We.B.3276)
Ruiz I, Centeno C, Ocana I, Ribera E, Perez-Morato X, Xercavins J; Unidad de Enfermedades Infecciosas, Hospital General, Barcelona, Spain.
Objective: To estimate the prevalence and the evolution of cervical intra-epithelial neoplasia (CIN) in HIV-infected women. Methods: From June to December 1995, 103 women with HIV infection and gynecologically asymptomatic were examined. The study included: pelvic exam, PAP smear, bacterial sampling, colposcopy and, if
Int Conf AIDS 1996 Jul 7-12; 11:104 (abstract no. We.B.3277)
Taliana M, Byrne M, Mikou P, Morse A, Weber J; St Mary's Hospital, London, UK. Fax: 01144 171 402 0401.
Objective: To examine whether HIV-1 antigens were routinely detectable in material from cervical samples from HIV-positive women. Methods: Cervical scrapings, endocervical brushings and cervical biopsy material were obtained from 14 HIV-positive and 14 HIV-negative women. Positive cells were identified using monoclonal
Int Conf AIDS 1996 Jul 7-12; 11:104 (abstract no. We.B.3278)
Eason JV, Masci J, Policar M, McDonald A, Gibbons P; Elmhurst Hospital Center, Mount Sinai School of Medicine Elmhurst, NY.
Objectives: To determine the impact of establishing a Gynecology (GYN) clinic specifically and solely for the care of HIV-infected women, as opposed to referring these women to a general GYN or Sexually Transmitted Disease (STD) clinic for evaluation. Methods: In a large New York City hospital, records were reviewed fr
Int Conf AIDS 1996 Jul 7-12; 11:105 (abstract no. We.B.3279)
Cheung TW, Cohen S, Gurtman A, Sacks HS; Mount Sinai Medical Center (MSMC), New York, NY, USA. Fax: (212) 860-4607.
Objective: To determine the prevalence and risk factors for cervical dysplasia among HIV seropositive women of an inner city primary care clinic. Methods: The HIV Clinic of MSMC serves over 1,500 HIV-infected persons mostly from the East Harlem area and South Bronx. 378 women were seen by a trained nurse practitioner f
Int Conf AIDS 1996 Jul 7-12; 11:105 (abstract no. We.B.3280)
Leyria C, Fridman E, Ricci S, Wainstein C; Hospital Muniz, Buenos Aires, Argentina. Fax: (541) 807-0428.
Objective: to evaluate the association of HPV manifestations as the lower genital tract in HIV-positive women. To compare the incidence among a control group of HIV-negative women. Methods: we studied 317 women during 18 months (01/01/94, 07/01/95), age group:15-51. The patients were followed by colposcopy examination,
Int Conf AIDS 1996 Jul 7-12; 11:105 (abstract no. We.B.3281)
Daniel-Ribeiro AF, Giraldo PC, Simoes JA, Amaral E, Polli CH; State University Of Campinas Campinas, SP, Brazil. Fax: 55.192.395935.
Objective - To determine the probability of correct clinical diagnosis of vulvovaginitis in women infected with HIV. Methods - A hundred and fifty two women (75 HIV -, 46 HIV + and 31 with AIDS) who attended the sexually transmmited disease outpatient clinic during the year of 1995, had a vaginal smear collected at the
Int Conf AIDS 1996 Jul 7-12; 11:105 (abstract no. We.B.3282)
Li A, Cook D; Casey House Hospice, Toronto, ON. Fax: (416) 962-5147.
Objective: To describe clinical profile and course of disease progression in AIDS patients with PML. Method: Retrospective chart review on patients admitted to Casey House AIDS Hospice (464 total admissions) between 1990 to 1995 was carried out. Thirty-three patients with a definitive diagnosis of PML were identified a
Objective: To identify genetic and biological characteristics of HIV-1 isolates associated with the presence of AIDS dementia complex. Methods: Analysis of both V3 sequence variability (PCR, cloning and sequencing) and SI/NSI phenotype (MT-2 test) of HIV-1 isolates derived from plasma and cerebrospinal fluid (CSF) of f
Objective: a) to define the evolution of the early signs of AIDS dementia complex, shown by neuropsychological test and SPECT (Single Photon Emission Computed Tomography), at base line observation (AIDS, Volume 6 No. 11-1992), in asymptomatic HIV-1 infected subjects. We also aimed b) at defining the effect of antiretro
Int Conf AIDS 1996 Jul 7-12; 11:106 (abstract no. We.B.3285)
Burns BT, Couch DA, Katner HP, Smith MU; Mercer University School of Medicine, Macon, GA, USA. Fax: (912) 749-9119.
Objective: To describe the clinical manifestations of PML in 2 African American females that presented atypically. Methods: Chart reviews were done on cases of two African American females with AIDS and PML, one presenting with Anton s syndrome and another presenting with aseptic meningitis. Review of the literature wa
Int Conf AIDS 1996 Jul 7-12; 11:106 (abstract no. We.B.3286)
MacArthur RD, Nandi P, McMillen L, Crane L; Wayne State University, Detroit, MI. Fax: (313) 745-9173. E-mail: crane@oncgate.roc.wayne.edu.
Objective: To review the pathologic findings from all CT guided stereotactic brain biopsies performed on hospitalized HIV-infected persons at the Detroit Medical Center from 6/1993-6/1995, and to correlate these findings with clinical and radiologic data collected on the same persons. Methods: Retrospective chart revie
Int Conf AIDS 1996 Jul 7-12; 11:106 (abstract no. We.B.3287)
Lanier ER, McClernon D, Stocum M, Nance-Sproson L, St Clair MH, Rooney J, McArthur JC; Dept of Molecular and Cellular Virology, Glaxo-Wellcome, Research Triangle Park, NC, USA. Fax: (919) 315-5243.
Background: HIV-associated neurological disease affects 20-30% of individuals with advanced HIV infection; however the association with increasing viral load remains unclear. Using customized PCR systems, plasma HIV RNA copy number has been shown to correlate with neurologic dysfunction (Conrad AJ, JAIDS 1995); however
Int Conf AIDS 1996 Jul 7-12; 11:106 (abstract no. We.B.3288)
Huengsberg M, Gompels M, Round RA, Winer J, Shahmanesh M; Department of GU Medicine, Whittall Street Clinic, Birmingham, UK. Fax: (44)121 233 9810.
Introduction: Abnormalities in amino-acid metabolism have been reported in HIV infection. Abnormal tryptophan metabolism has been correlated with dementia and neuropathy. There is evidence of activation of alternative pathway of tryptophan metabolism with increased production of neurotoxic metabolites. Aim: to determin
Int Conf AIDS 1996 Jul 7-12; 11:106 (abstract no. We.B.3289)
Merighi M, Gambina G, Teresi G, Luzzati R, Martini MC, Di Perri G, Mirandola M, Ferrari G, Concia E; Immunology and Infectious Diseases and Neurology, University and Hospital of Verona, Italy. Fax: 39 45 8340223.
Objective: the aim of this cross-sectional study is to establish risk factors for AIDS-related dementia (ARD) in a group of italian HIV-infected patients. Methods: we studied 36 consecutive male patients (pts) (homo-bisexuals, 76% heterosexuals, 24%) affected by symptomatic HIV infection (CDC 1986, group IV). No patien
Int Conf AIDS 1996 Jul 7-12; 11:107 (abstract no. We.B.3290)
Ensoli F, Wang H, Zeichner SL, Fiorelli V, Luzi G, Aiuti F, Thiele CJ; Dept. of Clinical Medicine, Allergy and Immunology, University of Rome "La Sapienza", Rome, Italy. Fax: 39-6-4463328.
Neurological abnormalities are common in HIV-1 infected patients and often represent the dominant clinical manifestation of pediatric AIDS. The neurological dysfunction has been directly related to the CNS invasion by HIV-1, however, its severity often appear unrelated to the extent of the CNS histopathology. Thus, the
Int Conf AIDS 1996 Jul 7-12; 11:107 (abstract no. We.B.3291)
Nebuloni M, Vago L, Mainini F, d'Arminio Monforte A, Grassi MP, Sala E, Costanzi G; L.Sacco Hospital, University of Milan, Italy. Fax: +39-2-38200385.
Objective: To correlate the viral replication in the CNS of AIDS patients indirectely evaluated by immunohistochemical reactivity for HIV p24 core protein with AZT treatment. Methods: Immunochemical evaluation was performed on paraffin-embedded sections of the deep gray nuclei in 56 AIDS patients randomly sampled from
Int Conf AIDS 1996 Jul 7-12; 11:107 (abstract no. We.B.3292)
Fogaa H, Belo M, Huang L, Pimentel ML, Elia P, Drummond M Jr, Guimaraes M, Elia C; University Hospital of the Federal University of Rio de Janeiro, Brazil. Fax: 5521-2702193.
Objective: To evaluate the prevalence and the features of AIDS-related diarrhea. Methods: We reviewed a total of 355 medical records of HIV-infected inpatients (pts), enrolled in the AIDS Program of the Federal University Hospital of Rio de Janeiro, in the last two years. Epidemiological and clinical data of diarrhea i
Int Conf AIDS 1996 Jul 7-12; 11:107 (abstract no. We.B.3293)
Belo M, Fogaa H, Dutra S, Giordani ML, Souza MJ, Elia C; University Hospital of the Federal University of Rio de Janeiro, Brazil. Fax: (5521) 2702193.
Objective: Protein calorie malnutrition is common in AIDS patients and may lead to further immune dysfunction. The aim of this study is to evaluate the effects of oral nutritional support in HIV disease. Methods: Six patients with AIDS between 26 and 47 years old, with at least 10% of weight loss, received oral support
Int Conf AIDS 1996 Jul 7-12; 11:107 (abstract no. We.B.3294)
Helen ML, Lim SG, Chew SK; Department of Medicine, Toa Payoh Hospital, Toa Payoh Rise, Singapore. Fax: 65-2527149.
Objective: To evaluate the frequency and etiology of diarrhoea in AIDS patients. Methods: 123 AIDS patients treated at the Communicable Disease Centre, Singapore , from January 1985 to March 1995 were included in the study. Diarrhoea was defined as 2 or more loose or watery stools per day for more than 2 consecutive da
Objective: to test the hypothesis that symptoms suggestive of disturbed upper GI function in HIV+individuals are related to delayed gastric emptying, associated with autonomic dysfunction and/or the presence of opportunistic pathogens. Methods: 14 HIV+ subjects with small intestinal (SI) protozoal infections and 24 HIV
Int Conf AIDS 1996 Jul 7-12; 11:108 (abstract no. We.B.3296)
Balano KB; San Francisco General Hospital, San Francisco, CA, USA. Fax: (415) 476-3454. E-mail: kbalano@itsa.ucsf.edu.
Problem: Intractable nausea and vomiting from various causes, including gastrointestinal disease and drug induced emesis, is a major source of morbidity for many patients with AIDS and contributes to significant weight loss. Ondansetron, a selective serotonin antagonist, is a highly effective therapy for preventing nau
Int Conf AIDS 1996 Jul 7-12; 11:108 (abstract no. We.B.3297)
Hii JH, Guccion JG, Benator DA, Gibert CL, Soltyk A, Brunton JL; Veterans Affairs Medical Center, Washington, DC. Fax: (202) 745-8284. E-mail: jhhii@gwis2.circ.gwu.edu.
Objective: Chronic diarrhea is a significant contributor to morbidity and mortality anong HIV-infected patients and oftentimes after extensive evaluation, a pathogen cannot be identified. To describe an unusual enteroadherent eaeA-positive Escherichia coli organism associated with chronic diarrhea in an HIV-infected in
Int Conf AIDS 1996 Jul 7-12; 11:108 (abstract no. We.B.3298)
Anton P, Miller M, Lewin D, Wagar E, Horgan K, McGowan I; Section of Mucosal Immunology, Division of Digestive Diseases, UCLA School of Medicine, Los Angeles, CA. Fax: (310) 825-7067. E-mail: panton@med1.medsch.ucla.edu.
Objectives: The purpose of this study was to compare histological and immunohistochemical evidence of CMV infection with viral cell culture (CC), shell vial assay (SVA) and DNA PCR amplification of intestinal biopsy homogenates from HIV-infected patients. Methods: Intestinal tissue biopsies were processed for CC, SVA a
Int Conf AIDS 1996 Jul 7-12; 11:108 (abstract no. We.B.3299)
Chalmers A, Horgan K, Anton P, McGowan I; Section of Mucosal Immunology, Division of Digestive Diseases, UCLA School of Medicine, Los Angeles, CA. Fax: (310) 825-7067. E-mail: achamers@med1.medsch.ucla.edu.
Objective: Substance P (SP) is a neuropeptide widely distributed in the central and peripheral nervous system. Reduced levels of SP immunoreactivity have been described in the HIV-infected intestine and more recently SP has been shown to inhibit lymphocyte proliferation in AIDS patients. Relatively little is known abou
Int Conf AIDS 1996 Jul 7-12; 11:108 (abstract no. We.B.3300)
Alfonzo R, Vainrub B, Bronstein M, Ponte A, Azcarate H, Vurgait A; Departamento de Cirugia y Enfermedades Infecciosas Hospital de Clinicas, Caracas, Venezuela. Fax: (582) 587.6664.
Objective: To prove that anoplasty is an effective treatment in order to decrease the pain of non specific perianal ulcers refractory to medical treatment in HIV (+) male patients. Method: During the years 1992 to 1995, anoplasties were performed on 31 HIV (+) patients diagnosed by ELISA and confirmed by Western Blot.
Int Conf AIDS 1996 Jul 7-12; 11:109 (abstract no. We.B.3301)
Tai H, Suzuki T, Yoshie H, Jeannel D, Fournier S, Dupont B, de The G, Hara K; Niigata University School of Dentistry, Niigata, Japan. Fax: (+81) 25 223 3761. E-mail: periodon@dent.niigata-u.ac.jp.
Objectives: To assess the relationship between clinical and immunobiological parameters and analyze potential diagnostic criteria of HIV-related periodontitis (HIV-P) in stage IV AIDS patients. Design: Of the 91 CDC stage IV AIDS patients screened 44 had HIV-P (48.355%), of which 38 underwent complete clinical periodon
Int Conf AIDS 1996 Jul 7-12; 11:109 (abstract no. We.B.3302)
Suzuki T, Tai H, Yoshie H, Jeannel D, Fournier S, Dupont B, de The G, Hara K; Niigata University School of Dentistry, Niigata, Japan. Fax: (+81) 25 223 3761. E-mail: takashi@dent.niigata-u.ac.jp.
Objectives: To assess the mechanism through which an important p24+ macrophage fraction infiltrates into periodontal lesions of stage IV AIDS patients (AIDS, 1996) and compare blood to oral mucosal compartment. Design: Twenty-three CDC stage IV AIDS patients participated to the study. Leukocyte infiltrates in gingival
Int Conf AIDS 1996 Jul 7-12; 11:109 (abstract no. We.B.3303)
Usami T, Ohsuka S, Niimi N, Ueda M; Dept of Oral Surgery, Nagoya Univ. School of Med., Nagoya, Japan. Fax: 81-52-741-3021.
Objective: To investigate secretory immunogulobulin A (S-IgA) in saliva and to estimate the influence of S-IgA on oral Candida albicans carriage in HIV-infected patients. Methods: The study population consisted of 30 HIV-positive hemophiliacs with a mean age of 25 years. Unstimulated whole saliva were collected from al
Int Conf AIDS 1996 Jul 7-12; 11:109 (abstract no. We.B.3304)
Kline MW, Carter AB, Simon C, Cron S, Demmler GJ, Rossmann SN, Hicks MJ, Flaitz CM; Baylor Oral Manifestations of Pediatric HIV Study Group, Dept. of Pediatrics, Baylor College of Medicine, Texas Children's Hosp., Houston, TX. Fax: (713) 770-1260.
Objective: To determine the prevalence of oral manifestations, and examine recovery of oral fungi and viruses, among infants and children with vertical HIV infection. Methods: Thirty-seven children (median age, 2.6 years; range, 6 months to 8.4 years) with vertical HIV infection who are enrolled in a longitudinal study
Int Conf AIDS 1996 Jul 7-12; 11:109 (abstract no. We.B.3305)
Vazquez JA, Vaishampayan J, Arganoza MT, Richards S, Boikov D, Sobel JD; Wayne State University School of Medicine, Detroit, MI. Fax: (313) 993-0302.
New alternative treatments for refractory oropharyngeal candidiasis (OPC) in AIDS patients (Pts) are needed. Melaleuca Oral Solution (M) (Breathaway) is an over the counter mouthwash preparation with known in-vitro activity against yeast and fungi. We present our experience with M for the treatment of OPC in adult AIDS
Int Conf AIDS 1996 Jul 7-12; 11:109 (abstract no. We.B.3306)
Hiroyuki M, Nagata Y, Iwamoto A, Suda H; Tokyo Medical and Dental University, Tokyo, Japan. Fax: 81-3-5803-0197. E-mail: h.matsumoto.endo.@dent.tmd.ac.jp.
Objective: To investigate the association of severity of the human immunodeficiency virus (HIV) -1 disease with decreased saliva and tear production and with other intraoral disease. Patients and Methods: Thirteen patients treated at Institute of Medical Science, University of Tokyo and five control healthy subjects we
Int Conf AIDS 1996 Jul 7-12; 11:110 (abstract no. We.B.3308)
Portas A, Garcia Messina O, Tortora G, Florio L; Hospital Neuropsiquiatrico Borda, Argentina.
Objective: The HIV is a neurotropic virus which can produce different kinds of symptoms on account of the central nervous system (CNS) being affected. These may be caused by casual infections of the CNS, by the direct action of the virus and also by a severe compromise of the immunological system. Within the near psych
Int Conf AIDS 1996 Jul 7-12; 11:110 (abstract no. We.B.3309)
Cohen MA; The Toronto Hospital, Toronto, Ontario, Canada.
Eating disorders (Bulimia and Anorexia Nervosa) are often not identified in men and in HIV-positive men they can worsen nutritional states and the course of illness. Project: Three HIV-positive men with eating disorders were identified from patients referred for psychiatric consultation. They were referred for t
Int Conf AIDS 1996 Jul 7-12; 11:110 (abstract no. We.B.3310)
Skinner CJ, Petrak JA; Ambrose King Centre Royal London Hospital, Whitechapel, London. Fax: 0171-377-7648.
Objective: To examine the impact of ethnicity on perceived psychological morbidity in an inner-city cohort of HIV-positive women. Methods: The case records of all women (53) were reviewed. A standardised proforma was used to collect data on demographics, presenting CDC status and CD4 count, psychological symptoms, medi
Int Conf AIDS 1996 Jul 7-12; 11:110 (abstract no. We.B.3311)
Leclercq P, Bosseray A, Bost-Bru C, Micoud M; Service de Maladies Infectieuses, CHU Grenoble, France. Fax: 76 76 55 69.
Objective: To evaluate the level of consumption and the use of psychotropic agents by HIV patients and the risk factors of this use. Methods: 150 successive HIV-positive out-patients of an infectious unit in France were screened for their psychotropic use; we retained the consumption when the patient regularly use one
Int Conf AIDS 1996 Jul 7-12; 11:110 (abstract no. We.B.3312)
Atkinson JH, Brown SJ, Summers J, Sciolla A, McCutchan A, Grant I; UCSD Department of Psychiatry, La Jolla, CA. Fax: (619) 822-0524. E-mail: jhatkinson@ucsd.edu.
Objective: We wished to determine if transition to AIDS, a stressful life event, were associated with onset or recurrence of major depression, or if major depression, which diminishes immunocompetence, heralded onset of AIDS. Methods: In a two year cohort analytic study 297 HIV+ gay men and 90 HIV- risk group controls
Int Conf AIDS 1996 Jul 7-12; 11:111 (abstract no. We.B.3313)
Getter EV, Sahs J; Village Center for Care - AIDS Day Treatment Program, New York, NY, USA. Fax: (212) 633-6587.
The preponderance of existing literature in psychiatry describes routine treatment guidelines that dutifully warn against boundary violations of role, time, place and touch. However, psychiatrists working with the HIV+ population may find themselves compelled toward crossing these boundaries with little directio
Int Conf AIDS 1996 Jul 7-12; 11:111 (abstract no. We.B.3315)
Albrecht H, Moller R, Stellbrink HJ, van Lunzen J, Greten H; University Clinic Eppendorf, Hamburg, Germany. Fax: xx49-40-47175187.
Objective: To determine whether bronchoscopy has remained a valuable tool in the management of HIV-infected patients after Pneumocystis carinii (PC) prophylaxis has been introduced. Specific questions included: Is bronchoscopy still a reliable method for diagnosing PCP ? How important are transbronchial biopsies? Why d
Int Conf AIDS 1996 Jul 7-12; 11:111 (abstract no. We.B.3316)
Michels B, Rust M, Sedlmeyer I, Moller D, Jansen P, Althoff PH; Medical Department, Medizinische Klinik Buergerhospital Frankfurt, Frankfurt, Germany. Fax: 069-1500-408.
Objective: Description of the management of obstructive tracheobronchitis due to Aspergillus fumigatus infection in a patient with AIDS. Method: Case report. Results: A forty-three years old male homosexual patient with AIDS was admitted with cough, shortness of breath, and problems expectorating sputum. HIV infection
Int Conf AIDS 1996 Jul 7-12; 11:111 (abstract no. We.B.3317)
Ridolfo AL, Sollima S, Santambrogio S, Colombo C, Gervasoni C, Antinori S, Galli M; Clinic of Infectious Diseases, L.Sacco Hospital, University of Milan, Italy. Fax: ++39-2-3560805.
Objective: to evaluate the prevalence, instrumental findings, survival and autopsy data of neoplastic involvement of the lung in HIV-infected patients. Methods: we studied retrospectively 544 HIV patients consecutively cared for and died at our Department from May 1984 to June 1995. Clinical charts, instrumental examin
Int Conf AIDS 1996 Jul 7-12; 11:111 (abstract no. We.B.3318)
Kassim S, Grant AD, Domoua K, Bonnard D, Sylla-Koko F, Dosso M, Yapi A, Maurice C, Whitaker JP, Lucas SB, Hayes RJ, De Cock KM, Wiktor SZ, Greenberg AE; Projet RETRO-CI, Abidjan, Cote d'Ivoire. Fax: (225) 24-29-69.
Objective: To describe the respiratory manifestations of HIV-disease in adults admitted to a Pulmonary Medicine service in Abidjan, CI. Methods: In a cross-sectional study, a systematic sample of patients was recruited at the point of hospital admission. A questionnaire and physical examination were completed for each
Int Conf AIDS 1996 Jul 7-12; 11:112 (abstract no. We.B.3319)
Rimland D, Navin TR, Lennox J, Jernigan J; VA Medical Center, Decatur, GA, USA. Fax: (404) 728-7782. E-mail: drimlan@emory.edu.
Objective: To determine the etiologic agents of community-acquired pneumonia (CAP) in patients with HIV infection and to identify risk factors for the acquisition of specific pulmonary pathogens. Methods: HIV-infected patients admitted to two public hospitals with CAP from 12/94 to 11/95 were tested for a battery of ba
Int Conf AIDS 1996 Jul 7-12; 11:112 (abstract no. We.B.3320)
Mateo NB, Zachariah J; Henry Ford Hospital, Detroit, MI, USA. Fax: (313) 876-2993.
Objective: To present 4 cases of HIV-associated BOOP (Group A) and review the world literature describing other cases (Group B: 9 reports with 11 patients). Methods: Cases were collected from a major urban hospital Infectious Diseases clinic from 1990-1995. The AIDSLINE and MEDLINE databases were queried for articles r
Objective: To describe a case of tracheal rupture caused by biopsy-proven aspergillosis and nocardia in an AIDS patient. Method: Retrospective chart review by the clinician following the patient prospectively. Results: A 39-year old white, male, homosexual, with a diagnosis of AIDS and CD4 count of 7, was hospitalized
Int Conf AIDS 1996 Jul 7-12; 11:112 (abstract no. We.B.3322)
Cheung TW, Estok L, Rose D, Chusid E, Choi K, Sacks H; Mount Sinai School of Medicine, New York, NY, USA. Fax: 212-860-46070. E-mail: tc@academic.mssm.edu.
Objective: To evaluate the natural history and prognostic factors in HIV-positive persons with carcinoma of the lung. Methods: We retrospectively reviewed the tumor registry and medical records of the AIDS Clinic of Mount Sinai Center from 1980 to 1995. Over this period, MSMC took care of over 3,000 HIV-infected person
Int Conf AIDS 1996 Jul 7-12; 11:112 (abstract no. We.B.3323)
Della Negra M, Marques HH, Queiroz W, Yu CL, Sato HK, Aquino MZ, Martins SJ, Veiga AP; Inst. Infectologia Emilio Ribas, Sao Paulo - SP - Brazil. Fax: +55-11-280.3954.
Objectives: To compare the incidence of infectious events and survival among 2 groups of HIV-infected children submitted to 2 different therapeutic regimens: Anti-retroviral therapy (ARVT) and Anti-retroviral therapy plus immunoglobulin (ARVT+IVIG). Methods: A total of 144 HIV-infected children were followed from Janua
Int Conf AIDS 1996 Jul 7-12; 11:112 (abstract no. We.B.3324)
Pellegrino MG, Secord E, Nowakowski M, Bluth M, Kleiner G, Fikrig S, Volsky DJ, Durkin HG; Dept. Pathology, SUNY Health Science Center at Brooklyn, Brooklyn, NY, USA. Fax: (212) 582-5027, (718) 270-3313.
Objective: To ascertain the in vitro efficacy of the HIV-1-specific IgE present in the sera of some healthy HIV-1-infected children (aged 3-12 yrs) in inhibiting HIV-1 replication. Methods: A subset of children (N=7) were studied who acquired HIV-1 through maternal transmission; most had serum levels of IgE greater tha
Int Conf AIDS 1996 Jul 7-12; 11:113 (abstract no. We.B.3325)
Hanekom WA, Heald LM, Yogev R, Chadwick EG; Children's Memorial Hospital, Division of Infectious Diseases, Chicago, IL, USA. Fax: (312) 880-8226. E-mail: whanekom@nwu.edu.
Objective: Description of experience with typhlitis in pediatric HIV infection. Methods: Retrospective review of typhlitis at our HIV clinic (of 120 regular patients) between 1992 and 1995. Typhlitis was defined as a clinical syndrome of fever, abdominal (abd.) pain and tenderness with roentgenographic evidence of righ
Int Conf AIDS 1996 Jul 7-12; 11:113 (abstract no. We.B.3326)
Nishimoto TM, Baptista MR; ASPPE & NIC Nucleo Integrado da Criania Santos, SP, Brazil. Fax: 013-234-3699.
Objective: To determine the relationship between the oral manifestations and the extent of immunological breakdown that will be indicators of the advancement of the disease in HIV-positive and/or AIDS-infected children. Methods: 51 children underwent an extensive clinical exam by 02 medical professionals; their CD4 and
Int Conf AIDS 1996 Jul 7-12; 11:113 (abstract no. We.B.3327)
Rakusan TA, Loechelt B, Brandt C, Schutzbank T, Troy J, Sever J; Children's National Medical Center and The George Washington University School of Medicine and Health Sciences, Washington, DC. Fax: (202) 884-4492.
METHODS The clinical course and CD4 cell counts of children with perinatal HIV infection were classified according to 1994 Revised Classification of Pediatric HIV Infection. HIV viral load was determined by quantitative PBMC coculture, quantitative HIV DNA PCR of PBMC lysates and by quantitation of plasma HIV RNA by NA
Objective: We report virological, biological and clinical analysis of 12 HIV-infected children who have subsequently cleared their HIV specific antibodies despite signs of HIV infection during their first year of life. Design and methods: we have performed a retrospective analysis of the diagnosis in a 7 year old cohor
Int Conf AIDS 1996 Jul 7-12; 11:113 (abstract no. We.B.3329)
Lacoste D, Marimoutou C, Bonarek M, Sire S, Djossou F, Salor Y, Dabis F; CISIH, Hopital Saint Andre, Centre Hospitalier Universitaire, Bordeaux, France. Fax: (33) 56.79.58.22.
Objectives: Continuous intravenous drug use (IDU) has been reported in the literature as reducing HIV disease progression. We looked at the issue of length of IDU in our cohort. Methods: All HIV-infected subjects followed by the participating physicians in the 14 participating wards of the Bordeaux University Hospital
Int Conf AIDS 1996 Jul 7-12; 11:114 (abstract no. We.B.3330)
Maayan S, Pollack S, Galai N, Lang R, Alkan M, Bentwich Z; AIDS Clinic, Hadassah University, Jersalem, Israel. Fax: 972-2-422273.
Objective: To describe the clinical and immunological progression of HIV seropositive Ethiopian immigrants to Israel since their arrival in 1991-1993. Methods: 277 seropositive immigrants (60% males, 40% females) were treated at 5 medical centers in Israel. Patients were seen a 3 to 6 monthly intervals. CD4 were done o
Int Conf AIDS 1996 Jul 7-12; 11:114 (abstract no. We.B.3331)
Rizzardini G, Ruzzante S, Fusi ML, Piconi S, Lulkwiya M, Declich S, Villa ML, Fabiani M, Milazzo F, Clerici M; La Divisione Malattie Infettive, Ospedale Luigi Sacco Via GB Grassi, Milano, Italy. Fax: 39. 2. 3579 9452.
Objective: The concentration of type 1 and type 2 cytokines and soluble APO-1/Fas receptor (sAPO-1/Fas) was analyzed in sera of Ugandan and Italian HIV-1 seropositive (HIV+) and seronegative (HIV-) individuals. The data were compared to determine whether the immunologic status of these groups was different. Methods: Si
Int Conf AIDS 1996 Jul 7-12; 11:114 (abstract no. We.B.3332)
Lee CC, Leo YS, Wong SY; Department of Infectious Diseases, Communicable Disease Centre, Tan Tock Seng Hospital, Singapore.
Objective: To study the epidemiology and natural history of HIV infection in Singapore residents 50 years or older at presentation. Methods: A retrospective analysis of HIV+ patients at or above the age of 50 years who were seen at the Communicable Disease Center, Singapore from 1986 to end of January 1996. Results: By
Int Conf AIDS 1996 Jul 7-12; 11:114 (abstract no. We.B.3333)
Molinero D, Arias JR, Rodriguez J, Garrote E, Tomero JL, Moreno L, Maranon A, Gonzalez-Guilabert I, del Pozo MA; Infectious Diseases Unit, University Clinical Hospital, Valladolid, Spain. Fax: 34-83-257511.
Background: In the Spanish autonomy of Castilla-Leon serological tests (ELISA and Western blot) for HIV infection were currently available late in 1985. But there are few documented large series on HIV infection in our region; to have such information give us the possibility of knowing what was going on in this area, i
Int Conf AIDS 1996 Jul 7-12; 11:115 (abstract no. We.B.3334)
Arias JR, Garrote E, Tornero JL, Rodriguez J, Moreno L, Martin J, Gonzalez-Guilabert I, del Pozo MA; Infectious Diseases Unit, University Clinical Hospital, Valladolid, Spain. Fax: 34-83-257511.
Background: To look for and to describe factors related to progression and survival is a common end point in the studies on large number of patients affected by a disease. And so is happening on HIV-infection. Objective: To investigate in HIV-infected patients the actuarial probability of survival and the clinical and
Int Conf AIDS 1996 Jul 7-12; 11:115 (abstract no. We.B.3335)
Rudin C, Weisser M, Kully C, Battegay M, Egger M; University Children's Hospital, Basel, Switzerland. Fax: 0041-61-692 65 55.
Objective: To prove that pregnancy does not influence the subsequent natural history of HIV-1 infection in women. Patients and Methods: 32 female patients from the Swiss HIV Cohort Study (SHCS) and the Swiss Collaborative Study HIV and pregnancy with an initial CD4-cell count before conception, a complete pregnancy dur
Int Conf AIDS 1996 Jul 7-12; 11:115 (abstract no. We.B.3336)
Veenstra J, Veugelers PJ, Keet IP, Van der Ven AJ, Miedema F, Lange JM, Coutinho RA; Municipal Health Service, Nieuwe Achtergracht, Amsterdam, Netherlands. Fax: + 31-20-5555.533.
Objective: To study the relation between the occurrence of adverse reactions to trimethoprim-sulphamethoxazole (TMP-SMX) prophylaxis and the subsequent course of HIV infection in a cohort of homosexual men. Methods: One hundred and twelve HIV-positives without AIDS started with TMP-SMX prophylaxis. Adverse reactions we
Int Conf AIDS 1996 Jul 7-12; 11:115 (abstract no. We.B.3337)
Petruckevitch A, Del Amo J, Phillips A, Stephenson J, Johnson A, De Cock KM; University College, London School of Hygiene and Tropical Medicine, Royal Free Hospital School of Medicine, London, UK.
Objective: To compare survival and CD4+ lymphocyte decline in HIV-infected Africans and non-Africans in London. Methods: Case notes for all 1,056 African patients attending 11 HIV/AIDS units in London and 992 non-African controls, matched on centre and year of diagnosis, were extracted for use in a retrospective cohort
Int Conf AIDS 1996 Jul 7-12; 11:116 (abstract no. We.B.3338)
Henderson SL, Nesheim SR, Clark WS, Sawyer M, Nahmias AJ; Emory University School of Medicine and School of Public Health, Atlanta, GA, USA. Fax: (404) 659-0129.
Objective: To evaluate the clinical progression and survival of HIV-infected children with very low CD4 cell counts as a potential focus population for antiviral and immune therapy modalities. Methods: A retrospective chart review was performed of children followed from 1987 to 1995. Survival times [from time CD4 count
Int Conf AIDS 1996 Jul 7-12; 11:116 (abstract no. We.B.3339)
Gerbaud L, Laurichesse H, Biolay S, Gourdon F, Marcombes V, Glanddier PY, Beytout J; Service des Maladies Infectieuses et Tropicales, Service d' Epidemiologie, d'Economie de la Sante et de la Prevention - C.H.U. Clermont-Ferrand, France. Fax: (33)-73-31-61-01. E-mail: gerband@clrvax.in2p3.fr.
Objectives: To assess the health related quality of life among HIV patients and to evaluate the changes occuring during a one year period. DESIGN: We used a form translated into French by INSERM, based on the RAND S.F.36 together with the HIV specific items of the HIV-MOS SF30. Each patient receiving ambulatory care is
Int Conf AIDS 1996 Jul 7-12; 11:116 (abstract no. We.B.3340)
Avis NE, Smith K, Mayer K; New England Research Institutes, Watertown, MA, USA. Fax: 617-923-4176. E-mail: nancya%neri@mcimail.com.
Objective: To determine the influence of CD4 count, hemoglobin and symptoms on quality of life domains among a cohort of HIV+ men. Methods: These data are based on sample of 92 HIV+ men who are part of a cohort being studied at a Boston community health center. They were administered questionnaires including measures o
Int Conf AIDS 1996 Jul 7-12; 11:116 (abstract no. We.B.3341)
Gange SJ, Jacobson LP, Kass N, Bing E, Chmiel JS, Zucconi SL, Graham NM; Johns Hopkins University, School of Public Health, Baltimore, MD, USA. Fax: (410) 955-7587. E-mail: sgange@statepi.sph.jhu.edu.
Objective: To compare health related quality of life (QOL) among HIV + homosexual men on either a monotherapy (ZDV, ddI , ddC , d4T ) or combination therapy (ZDV/ddI
Int Conf AIDS 1996 Jul 7-12; 11:116 (abstract no. We.B.3342)
Globe D, Cunningham W, Hays RD; School of Public Health, UCLA, CA, USA. Fax: (805) 253-5016. E-mail: dglobe@ucla.edu.
Objective: To examine the construct of health status in HIV disease, we assessed the associations of HRQOL with utilization and clinical factors. The validity of Health-Related Quality of Life measures (HRQOL) for HIV disease has been supported in some previous studies, but additional information about the association
Int Conf AIDS 1996 Jul 7-12; 11:117 (abstract no. We.B.3343)
Couvaras A, Salvato P, Thompson C; Twelve Oaks Hospital, Houston, TX, USA. Fax: (713) 960-7910.
Objective: To describe the major Opportunistic Infections (OI s) experienced by AIDS patients within twelve (12) months of death. Methods: Of 4,912 HIV-infected individuals followed over an 11-year period (between 1985 - 1996), 2,538 died during follow-up. A complete history of OI s was obtained by chart review of medi
Int Conf AIDS 1996 Jul 7-12; 11:117 (abstract no. We.B.3344)
Revicki DA, Wu AW, Fischer L, Sorensen S; MEDTAP International, Arlington, VA, USA. Fax: (703) 528-8509. E-mail: revicki@medtap.com.
Objective: To develop physical and mental health summary scores based on the MOS-HIV Health Survey to assist in the analysis and interpretation of health-related quality of life outcomes. To evaluate the reliability and validity of the physical and mental health summary scores. Methods: Baseline MOS-HIV Health Survey s
Int Conf AIDS 1996 Jul 7-12; 11:117 (abstract no. We.B.3345)
Garduno J, Vilchis E, Casarrubias M, Sanchez R, Loredo C, Martinez y Zamora R, Barriga B, Munoz O; Unidad de Investigacion en Epidemiologia, Clinica, Centro Medico Nacional, Instituto Mexicano del Seguro Social, Valle, Mexico.
Objective: To evaluate the impact of a delayed diagnosis and therapy in the quality of - life (QL) of patients with HIV infection. Design: Nested case-control study. Setting: 4 General Hospitals in Tamaulipas, SanLuis Potosi and Mexico city. Mexico. Patients: 94 patients with HIV infection either symptomatic (57) or as
Int Conf AIDS 1996 Jul 7-12; 11:117 (abstract no. We.B.3346)
French M, Mallal S, James I; Dept of Clinical Immunology, Royal Perth Hospital, Perth, Western Australia. Fax: (619) 224-2920.
Aim: To determine the value of and indications for measuring cutaneous DTH responses to evaluate cellular immune function in HIV-infected patients. Methods: Data on DTH responses, CD4 T-cell percentages and opportunistic infections (OIs) were analysed from patients in the Western Australian HIV Cohort Study (WAHCS) dat
Int Conf AIDS 1996 Jul 7-12; 11:117 (abstract no. We.B.3347)
Carriere D, Fontaine C, Jansen A, Vendrell JP, Laprade M, Pau B; Sanofil Recherche, Montpellier, France. Fax: 33-67-10-67-67.
Objective: To present an alternative non flow cytometric technology for CD4 and CD8 T cell quantitation. Methods: We designed an ELISA-type immunoassay for CD4 and CD8 lymphocyte determinations. In the assay, anticoagulated whole blood is first reacted with magnetic beads which bind a pan-T antigen on T cell surface. F
Int Conf AIDS 1996 Jul 7-12; 11:117 (abstract no. We.B.3348)
Attia A, Anglaret X, Kone K, Coulibaly S, Gnangbomon J, Dabis F, N'Dri T, Manlan K, Salamon R; Groupe de Recherches sur la Prevention des Infections Opportunistes, Bordeaux, France. Fax: (225) 249206.
Objectives: To evaluate the prevalence rate of HIV infection among patients attending community clinics in Abidjan, Cote d Ivoire . To evaluate the clinical and immunological stage of HIV disease of the HIV-infected (HIV+) subjects diagnosed in these centres. Methods: In July 1995, a consecutive sample of adults was re
Int Conf AIDS 1996 Jul 7-12; 11:118 (abstract no. We.B.3349)
Sullivan MM, Meisner P, Foster K, Steger K, Allen D, Levitz S, Fuller J, Cooley T, Hellinger J, Craven D; Clinical AIDS Program, Boston University & Boston City Hospital, Boston, MA.
Objective: To compare the estimates of CD4/CD8 cell numbers calculated from the TRAx (TR) CD4/CD8 test kit with those obtained by flow cytometry (FC) in splenectomized HIV-infected patients; previous reports have noted a marked discrepancy between absolute number and percentage of CD4 lymphocytes in this population. Me
Objective: To describe CD4 decline in relationship to traditional laboratory markers and newer quantitative viral assays. Methods: Traditional laboratory markers were defined as P24 antigen, Neopterin, Beta2 microglobulin, CD8 count and PMBC Culture. Newer quantitative viral assay was defined as HIV RNA PCR. A retrospe
Objective: To determine a category of strong predictors of disease progression in HIV non-vertical-infected children. Methods: 206 children were followed for different periods of time from 1990 to 1994. They were followed using Cox Regression Model for time independent covariates, the risk of progression to death and t
Int Conf AIDS 1996 Jul 7-12; 11:118 (abstract no. We.B.3352)
Teixeira EG, Selig L, Trajman A, Belo MC, Belo Neto E, Castello Branco MM; Gama Filho and Souza Marques Universities, Santa Casa de Misericordia, Rio de Janeiro, Brazil.
Objectives: To evaluate the acid-fast bacilli (AFB) positivity on sputum smears of patients (pts) with pulmonary Tb with different radiologic patterns, and to assess the influence of HIV infection in AFB smear positivity. Methods: Eighty-nine pts with symptoms suggestive of Tb, including chronic productive cough, in wh
Int Conf AIDS 1996 Jul 7-12; 11:118 (abstract no. We.B.3353)
Selig L, Belo MC, Trajman A, Teixeira EG, Spector N, Belo Neto E; Souza Marques and Gama Filho Universities, Rio de Janeiro, Brazil.
Objectives: To analyze the chest roentgenogram (CXR) findings in tuberculosis (Tb) patients (pts) according to their HIV status. Methods: We analyzed the CXR of 125 pts with Tb diagnosis, according to the Brazilian Ministry of Health criteria. Among them, 100 had pulmonary Tb, 38 had pleural involvement (17 with isolat
Int Conf AIDS 1996 Jul 7-12; 11:119 (abstract no. We.B.3354)
Trajman A, Belo MT, Teixeira EG, Belo Neto E, Selig L, Castello Branco MM; Souza Marques and Gama Filho Universities, Rio de Janeiro, BRAZIL.
Objectives: To assess the HIV prevalence in different clinical forms of TB and compare the clinical presentation of TB in HIV-infected and HIV-negative patients (pts). Methods: A cross-sectional study of 127 pts fulfilling the Brazilian Ministry of Health TB criteria was carried out. All pts were submitted to anti-HIV
Int Conf AIDS 1996 Jul 7-12; 11:119 (abstract no. We.B.3355)
Petit N, Heuberger L, Gastaut JA; Institut Paoli, Calmettes, Marseille, France. Fax: 91 22 32 34.
Objective: To determine the usefulness of gastric aspirates (GA) for diagnosis of mycobacterial infections among HIV + patients (pts). Methods: A retrospective study of 6 month period from 8/1994 to 12/1994 was done in our HIV inpatients unit. GA were made on 3 following days, at 5 a.m. if the patients had fever, weigh
Int Conf AIDS 1996 Jul 7-12; 11:119 (abstract no. We.B.3356)
Paoletti F, Valenti C, Romani R, Ponzo R, Santopadre P, Folgori F, Mascellino MT; Dept. Infectious and Tropical Diseases, La Sapienza University, Policlinico Umberto I, Viale del Policlinico Rome, Italy. Fax: 39-6-4453760.
Objective: To evaluate the specificity and sensitivity of mycobacterial DNA amplification in the diagnosis of HIV-associated pulmonary tuberculosis . Methods: 90 specimens of induced sputum were obtained from 69 HIV+ patients with suspected pulmonary tuberculosis. All samples were treated with the standard protocol of
Int Conf AIDS 1996 Jul 7-12; 11:119 (abstract no. We.B.3357)
Franca IE, Borges F, Mansinho K, Campos MJ, Exposto F, Prieto E, Poiares-Baptista A, Chorao M; Egas Moniz Hospital, Inst. of Hygiene and Tropical Medicine, Lisboa, Portugal. Fax: 351 01 3632105.
Objective: To emphasize the fact that cutaneous mycobacteriosis may sometimes be the only mean to the diagnosis of a systemic form of infection. Methods: Four patients were observed: patient 1 - two hyperkeratotic chronic lesions on the leg, one of which with previous suppuration; patient 2 - one discrete nonsuppurativ
Int Conf AIDS 1996 Jul 7-12; 11:119 (abstract no. We.B.3358)
Cuesta F; Internal Medicine Department, Juan Ramon Jimenez Hospital, Huelva, Spain.
Methods: Retrospective study of 101 patients with coinfection VIH-TB diagnosed and followed from January 1st 1993, to December 31 1995. Patient medical records were reviewed. TB was diagnosed by identification of M. tuberculosis in Lowenstein media or the association of response to specific treatment with AARB in any s
Int Conf AIDS 1996 Jul 7-12; 11:119 (abstract no. We.B.3359)
Pedreira JD, Juega J, Pereiro C, Castro MA, Pombo F, Pedreira JD; Dpto. of Medicine, Hospital J. Canalejo, La Coruna, Spain. Fax: (981) 178001.
Objective: To evaluate the clinical, immunological, and epidemiological characteristics in Spain of Pulmonary Tuberculosis (PT), which has been accepted as an AIDS-defining condition event by CDC since 1994. Material and Methods: We study the cases of PT in HIV-infected patients in a Spanish General Hospital, in a high
Int Conf AIDS 1996 Jul 7-12; 11:120 (abstract no. We.B.3360)
Juega J, Gonzalez RC, Fernandez BE, Pombo F, Pedreira JD; Dpto. of Medicine Hospital J. Canalejo, La Coruna, Spain. Fax: 981.17.80.01.
Objective: To evaluate the occurrence of Pulmonary Tuberculosis (PT) in comparison with Disseminated Tuberculosis (DT) in patients infected by Human Immunodeficiency Virus (HIV). Material and Methods: We have carried out a comparative study of clinical, immunological, microbiological and epidemiological characteristics
Int Conf AIDS 1996 Jul 7-12; 11:120 (abstract no. We.B.3361)
von Wichmann MA, Rodriguez AF, Idigoras P, Iribarren JA, Arrizabalaga J, Jimenez E; Infectious Diseases Unit, Hospital N. S. Aranzazu, San Sebastian, Spain. Fax: 34-43460782.
Objective: To describe the course and clinical features of Mycobacterium xenopi (Mx), in HIV-infected patients. Methods: From October 1993 to October 1995 we retrospectively reviewed 10 patients with HIV infection from whom Mx had been recovered from sputum or bronchoscopy specimens. The patients were thought to have s
Int Conf AIDS 1996 Jul 7-12; 11:120 (abstract no. We.B.3362)
Okwera A, Loughlin A, Johnson JL, Whalen C, Mugerwa R, Ellner J; Makerere University, Kampala, Uganda. Fax: 011-256-41-532-282. E-mail: cwru@mukla.gn.apc.org.
Objective: To determine the incidence of Isoniazid (INH) induced peripheral neuropathy (PN) in patients taking INH compared to those not taking anti-TB medication, and identify risk factors for PN in this HIV-1 infected cohort. Methods: HIV-1 infected adults (n=2736) were enrolled into a TB prophylaxis trial, with 788
Objective: To describe a case of Mycobacterium kansasii scalp infection invading the central nervous system. Method: Retrospective chart review by the clinician following the patient prospectively. Results: A 31-year old white, male, homosexual, found to be HIV-positive in 1987, was admitted to the hospital for fever,
Int Conf AIDS 1996 Jul 7-12; 11:120 (abstract no. We.B.3364)
Koudriakova T, Iatsimirskaia E, Gerber N; The Ohio State University, Columbus, OH, USA. Fax: (614) 292-4253. E-mail: tkoudria@magnus.acs.ohio-state.edu.
Objective: To study metabolism of rifabutin (R) in human liver microsomes and interaction with the macrolide antibiotics erythromycin (ER), clarithromycin (CL) and azithromycin (AZ). Methods: 14C-R (2.36 micromolar) was incubated with human liver microsomes alone and in the presence of different concentrations (1, 10,
Int Conf AIDS 1996 Jul 7-12; 11:120 (abstract no. We.B.3365)
Breaux K, Graviss E, Lahart C; Houston Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX. Fax: (713) 794-7538. E-mail: breaux.Katharine_g.houston.va.gov.
Objective: Disseminated Mycobacterium avium (DMAC) is one of the most debilitating infections occurring in patients with HIV infection with CD4 counts of less than 100 cells/mm3. Approved prophylactic regimens are rifabutin (Rif) or clarithromycin (Clari), but other drugs with known antimycobacterial activity have been
Int Conf AIDS 1996 Jul 7-12; 11:121 (abstract no. We.B.3366)
Dorman SE, Sax PE; Infectious Diseases Division, Brigham and Women's Hospital, Harvard Pilgrim Health Plan, Boston, MA. Fax: (617) 732-6829. E-mail: pesax@bics.BWH.harvard.edu.
Despite advances in the treatment of disseminated Mycobacterium avium complex ( MAC ), patients may have progressive symptomatic disease even with continued antimycobacterial therapy. Objective: To review the efficacy of corticosteroids as adjunctive salvage therapy in patients with disseminated MAC and refractory symp
Int Conf AIDS 1996 Jul 7-12; 11:121 (abstract no. We.B.3367)
Szabo S, Bincsik AK, Chanpimol S, Holloway W; Medical Center of Delaware, Wilmington, DE, USA. Fax: (302) 428-6264.
Objective: To identify the incidence of DMAC in RIF+ and RIF- pts, occurrence of drug to drug interactions, and active Mycobacterium tuberculosis infection (MTB). Methods: A retrospective chart review of the 700 adult patients accessing care with the HIV Program at the Medical Center of Delaware during the period of 6/
Int Conf AIDS 1996 Jul 7-12; 11:121 (abstract no. We.B.3368)
Arbulu MM, Weisburd G, Biglione J, Terrazzino JC; Sala 1-Infectious Diseases-Pol. I. Carrasco-Rosario-Argentina, Santa Fe, Argentina.
Introduction: The increase of the tuberculosis in AIDS patient and the outbreak of multidrug resistant strain is a fact described in the world, our objective is to communicate ours experiences about these during the years 1994-1995. Methods: We analyzed the clinical histories of 160 AIDS patients along 1994-95. The dir
Int Conf AIDS 1996 Jul 7-12; 11:121 (abstract no. We.B.3370)
Greco D, Oliveira E, Tupinambas U, Fonseca JJ, Carvalhais LM, Greco M, Toledo Jr; ACC for the Clinical Trial Group of Minas Gerais National AIDS Vaccine Center, Federal University of Minas Gerais, Brazil. Fax: 55 31 224 8801.
Objective: To evaluate the immunogenicity and safety of UBI HIV-1 MN candidate vaccine. Methods: This is the first HIV/AIDS vaccine trial in Brazil and enrollment started in February 1995 at Minas Gerais (MG-NAVC) and Rio de Janeiro National (RJ-NAVC) National AIDS Vaccine Centers. Fifteen volunteers, including three p
Int Conf AIDS 1996 Jul 7-12; 11:121 (abstract no. We.B.3371)
Salassa B, Zucco S, Macor A, Sciullo D, Ruffatto R, Piro F, Soranzo ML; Infectious Diseases Department B, Amedeo di Savoia Hospital, Turin, Italy. Fax: 39114393810.
OBJECTIVE. To compare the influenza vaccine response between HIV + and HIV - subjects and to check in HIV + patients the value of CD4 Lymphocytes below which there is no response to vaccine. METHODS. In autumn 1993 one hundred and sixty five HIV + patients and 11 control subjects were submitted to influenza vaccination
Int Conf AIDS 1996 Jul 7-12; 11:122 (abstract no. We.B.3372)
Honda M, Ami Y, Someya K, Ando S, Okamoto Y, Matsuo K, Yamazaki A, Shinohara T, Luu Y, Yamazaki S; AIDS Research Center, Tokyo, Japan. Fax: 3-5285-1183. E-mail: mhonda@nih.go.jp.
Ojective: To study if this recombinant BCG-based candidated vaccine can induce both humoral and cellular immunities that contribute to protection from SHIV infection or progression to disease states. Materials and Methods: A recombinant Mycobacterium bovis BCG (BCG) that secretes a chimeric protein consisting of V3 pri
Objective: To estimate immunogenicity of HIV vaccine candidates (peptide vaccine and DNA vaccine) by modification delivery system and addition of some adjuvants. Methods: Peptide vaccine was inoculated with alum, Incomplete Freund adjuvants, cationic liposomes and MPL (Ribi immunochem Co.). DNA vaccine (pCMV IIIB/REV)
Int Conf AIDS 1996 Jul 7-12; 11:122 (abstract no. We.B.3374)
Bratt GA, Leandersson L, Eriksson L, Gilljam G, Hinkula J, Sandstrom E, Wahren B; Department of Dermatovenereology, Sodersjuklhuset, Stockholm, Sweden.
Objective:To evaluate the long term safety and efficacy of a GP160 vaccine produced from HIV IIIB GP160 (VaxSyn HIV-1; MicroGenSys). Methods: 40 asymptomatic HIV+ individuals with a CD4-count greater than 400 x 106/L have received regular immunizations with VaxSyn HIV-1 for 4 years. CD4-levels and T-cellproliferation t
Int Conf AIDS 1996 Jul 7-12; 11:122 (abstract no. We.B.3375)
Rubinstein A, Mizrachi Y, Petoello-Mantovani M, Goldstein H, Spirer Z, Cryz S; Albert Einstein College of Medicine, Bronx, NY, USA. Fax: (718) 430-8982.
Objective: To develop a polyvalent peptide-based HIV vaccine capable of inducing broad immune responses in HIV-infected and uninfected individuals. Methods: Guinea pigs and HIV-infected individuals were immunized with PPD-conjugated to a mixture of six 13 a.a. peptides (PND-V3-hexapeptide) with sequences corresponding
The Chiron Biocine HIV gp 120 SF2/MF59 Vaccine has been tested in the US and in Thailand , alone or combined with other HIV vaccines, in 13 phase I and one phase II studies involving approximately 730 HIV-seronegative adult volunteers and 70 newborns born to HIV-infected mothers. One of these trials focused on the comp
Int Conf AIDS 1996 Jul 7-12; 11:122 (abstract no. We.B.3377)
Kenji S, Kazuhiro M, Shuji A, Yasusi A, Katuaki S, Tosihiko K, Hitomi Y, Katuhiko K, Satosi N, Akihiro Y, Hirosi Y, Shudo Y, Mituo H; AIDS Research Center, National Institute of Health, Tokyo, Japan. Fax: 81-3-5285-1183.
Objective: It is one of the most important problem to develop HIV candidate vaccine. We have demonstrated that rBCG-based candidate vaccine rBCG-V3J1, which inserted principal neutralizing epitope of Japanese Consensus Sequence DNA of HIV-1 could induce strong protective immune response against HIV-1 in small animal mo
Int Conf AIDS 1996 Jul 7-12; 11:123 (abstract no. We.B.3378)
Hitomi Y, Matsuo K, Kitamura K, Okamoto Y, Watanabe K, Miyamoto K, Someya K, Ando S, Nakasatomi T, Yamazaki A, Haga S, Moritsugu Y, Yamazaki S, Honda M; AIDS Research Center, NIH, Tokyo, Japan. Fax: (03)5285-1183. E-mail: yossy@nih.go.jp.
Objective: A recombinant Mycobacterium bovis BCG (rBCG) vector-based vaccine that secretes a chimeric protein composed of alpha-antigen protein and V3 principal neutralizing determinant (PND) of human immunodeficiency virus (HIV), designated rBCG-V3J1, was able to induce HIV specific immune responses to the epitope and
Int Conf AIDS 1996 Jul 7-12; 11:123 (abstract no. We.B.3379)
Okamoto Y, Matsuo K, Eda Y, Amagai T, Shibata S, Asano T, Someya k, Yoshizaki Y, Nakasatomi T, Ando S, Takamatsu J, Katsura Y, Haga S, Tokiyoshi S, Yamazaki A, Honda M; AIDS Research Center, NIH, Tokyo, Japan. Fax: 81-3-5285-1183. E-mail: okapie@nih.go.jp.
Objective: The neutralization of HIV clinical isolates has been one of the most urgently required subject in developing anti-HIV candidate agents. In this study we examined the neutralizing profile of recombinant BCG-based vaccine, rBCG-V3J1 and reshaping antibody Rmicron5.5 on HIV primary clinical isolates of clade B.
Int Conf AIDS 1996 Jul 7-12; 11:123 (abstract no. We.B.3380)
Read S, Major C, Li X, Strunc G, Galli R, Fearon M, Fisher M, Palmer R, Strathdee S, Calzavara L, Peter A, Rachlis A; Division of Infectious Diseases, Hospital for Sick Children, Toronto, Ontario, Canada. Fax: (416) 813-5032.
Objective: To investigate the usefulness of viral load testing in the prognosis of HIV infection. Methods: Sequential serum specimens collected between 1983 and 1992, from 28 HIV-positive individuals recruited to the Toronto Sexual Cohort Study were selected for testing. Clinical follow-up was available to 1995 includi
Int Conf AIDS 1996 Jul 7-12; 11:123 (abstract no. We.B.3381)
Gras M, Spijkerman IJ, Prins M, Goudsmit J, Weerd H, Veugelers PJ, Keet IP, Coutinho RA, de Wolf F; Municipal Health Service, Dep. of Public Health, Amsterdam, Netherlands. Fax: 31-20-5555533.
Objective: To study viral load among homosexual men who stayed free of AIDS for 8 years. Methods: HIV-1 RNA serum levels were assayed, using the nucleic acid sequence-based amplification (NASBA) technique, at year 1 and 8 following the first HIV-positive visit in 62 AIDS-free homosexual men. CD4 and CD8 cell count, T-c
Int Conf AIDS 1996 Jul 7-12; 11:123 (abstract no. We.B.3382)
Gallyot R, McMorrow M, Wilkins EG; Department of Infectious Diseases, North Manchester General Hospital, Manchester, UK. Fax: (+) 44 161 720 2732.
Background: Viral load has been correlated with stage of HIV disease (asymptomatic, ARC, AIDS), predicted progression of disease (for early and late stages), and clinical response to antiretrovirals. It has been suggested that levels of viraemia stabilise soon after infection and are potentially useful markers of predi
Int Conf AIDS 1996 Jul 7-12; 11:124 (abstract no. We.B.3383)
Coombs RW, Speck C, Lee W, Peterson G, Ross S, Dragavon J, Krieger J; University of Washington, Seattle, WA, USA. Fax: (206) 621-4178. E-mail: bcoombs@u.washington.edu.
Objective: To determine the relationship between recovery of infectious virus from the semen and HIV-1 RNA level in seminal plasma. Methods: A cohort of 149 men were enrolled and asked to provide semen specimens three times over a two month interval. HIV-1 was detected using a qualitative infectivity assay and by the R
Int Conf AIDS 1996 Jul 7-12; 11:124 (abstract no. We.B.3384)
Billyard E, Haubrich R, Nunomura K, Garduno F, Ueding K, Mimms L, Debra D, McCutchan A; Gen-Probe Incorporated, San Diego, CA. Fax: (619) 452-5848.
Objective: Develop a single tube quantitative, HIV RNA assay and to evaluate its utility in discriminating HIV disease stage. Methods: The Gen-Probe single tube assay, a novel, quantitative detection methodology, was used to measure HIV-1 RNA in plasma at a single time point from 84 HIV-infected and 5 HIV(-) subjects.
Objective: To describe HIV plasma viral load response to enhancement of natural DHEA as measured by PCR and PMBC culture. Method: 18 males and 2 females comprised the sample. CD4 cell counts ranged from 28 to 242. A 30 day washout for antivirals was required for study initiation. Subjects were randomly assigned to 1 of
Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. We.B.410)
Mellors JW, Kingsley L, Gupta P, Rinaldo C, Phair J, Saah A, Detels R, Schrager L, Margolick J, Giorgi J, Munoz A, White R, Todd J; University of Pittsburgh Medical Center, Pittsburgh, PA. Fax: 412/692-2539. E-mail: jwml+@pitt.edu.
Objective: To determine the relationships between plasma HIV-1 RNA levels, CD4 cell counts and clinical outcome (AIDS and death) in a cohort of men enrolled in the MACS between April 1984 and March 1985. Methods: The version 2.0 bDNA assay (sensitivity = 500 copies/ml) was used to quantify HIV-1 RNA in two sets of plas
Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. We.B.411)
Graham NM, Astemborski J, Saah AJ, Vlahov D, Margolick JB, Farzadegan H; Johns Hopkins University, School of Hygiene and Public Health (SHPH), Baltimore, MD, USA. Fax: 410-955-1836.
Objective: To determine whether infectious HIV viral load predicts clinical disease progression to an AIDS defining condition and survival among cohorts of injecting drug users and gay men. Methods: Quantitative microcultures, using a co-culture technique, were done on aliquots of 106 PBMCs to determine infectious HIV
Int Conf AIDS 1996 Jul 7-12; 11:27 (abstract no. We.B.412)
Weverling GJ, de Jong MD, Lange JM, de Weerdt H, Goudsmit J, de Wolf F; Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Fax: 31-20-6918821. E-mail: g.j.weverling@amc.uva.nl.
Objective: To compare HIV-1 RNA load as measured by two commercially available quantitative assays in ZDV-treated individuals. Methods: HIV-1 RNA load was measured in stored serum samples from Dutch ZDV-treated participants of a ZDV-efficacy study (EACG 017) at weeks -3, 0, 4, and 8, using two commercially available as
Objective: To assess if HIV viremia influences survival and clinical progression. Methods: 398 patients who had frozen plasma collected between 1991-93 were selected after stratification by baseline CD4 cell counts (0-49, 50-199, 200-499, and greater than or equal to 500 /mm3). Outcome variables were death and onset of
Int Conf AIDS 1996 Jul 7-12; 11:27 (abstract no. We.B.414)
Michael NL, Whalen C, Johnson J, Nsubuga P, Hom D, Mugerwa R, Birx D, Ellner J; Division of Retrovirology, WRAIR, Rockville, MD. Fax: (301)762-4177. E-mail: nmichael@hiv.hjf.org.
Objective: To analyze the impact of active pulmonary tuberculosis on HIV-1 RNA load in subjects prior to and following tuberculosis therapy. Methods: Twenty HIV-1 seropositive cases of culture confirmed active pulmonary TB were pair-matched (age, gender, CD4 count, and DTH response) to twenty HIV-1 seropositive control
Objective: To describe trends in incidence and characteristics of MAC in children (less than 13 years) with AIDS. Methods: Initial AIDS-defining conditions (ADC) are reported to CDC for all children with AIDS; subsequent opportunistic illnesses may be updated. We analyzed MAC cases in children with AIDS reported to CDC
Int Conf AIDS 1996 Jul 7-12; 11:27 (abstract no. We.B.421)
Cohn DL, Benson CA, Williams P, Nevin T, Korvick J, Hafner R, Bourland D, Kopek E, Becker S, Hojczyk P, Timmons P, Child C; Denver Disease Control Service, Denver, CO, USA. Fax: 303-436-7211. E-mail: cohnd@essex.uchsc.edu.
Objective: To compare the safety and efficacy and of CLA alone vs RBT alone vs CLA and RBT in combination for the prevention of MAC bacteremia or DMAC. Methods: From 4/93 through 1/94, 1216 HIV-infected pts with CD4 counts is less than or equal to 100/mm3 were randomized to receive treatment (Rx) with CLA (500 mg bid),
Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. We.B.422)
May T, Vincent V, Brel F, Beuscart C, Perronne C, Doco-Lecompte T, Dautzenberg B, Grosset J; Service de Maladies Infectieuses et Tropicales, Tour Drouet Hopital de Brabois, Vandoeuvre.
Objective: A prospective randomized open-label multicenter trial begun in Feb. 1994 compared, in AIDS patients with MAC bacteremia, efficacy and safety of two treatments: group A = Clarithromycin (CLA: 2000mg 2 months then 1000mg) + clofazimin (CLO: 200mg then 100mg), versus group B = CLA (same dosage) + Rifabutin (RBT
Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. We.B.423)
Shafran SD, Singer J, Zarowny DP, Phillips P, Salit I, Walmsley S, Fong I, Gill J; University of Alberta, Edmonton, AB, Canada. Fax: 403-492-7137.
Objective: To compare the efficacy of two oral multidrug regimens for the treatment of Mycobacterium avium complex ( MAC ) bacteremia in adults with AIDS. Methods: 229 patients were randomized to either rifampin 600 mg once daily, ethambutol 15 mg/kg daily, clofazimine 100 mg once daily and ciprofloxacin 750 mg twice d
Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. We.B.424)
Bogner JR, Rusch-Gerdes S, Mertenskotter T, Loch O, Emminger C, Baumgarten R, Stoehr A, Albrecht H, Jablonowski H; University of Munich, Munich, Germany. Fax: ##49-89-51603593.
Background: Little is known about the progression from localized to systemic mycobacterium avium complex ( MAC ) infection and about treatment indications in patients with colonisation or regional signs of infection. Objective: To determine I) the frequency and sites of MAC detection in patients with signs and symptoms
Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. We.B.431)
Ekpini ER; Projet RETRO-CI, Abidjan, Cote d'Ivoire. Fax: 225-24-29-69.
Worldwide, there are currently an estimated 1.5 million children who are living with HIV infection, most of them in sub-Saharan Africa. The impact of the HIV/AIDS epidemic on childhood morbidity and mortality in Africa is dramatic, as the majority of HIV-infected children develop AIDS and die in the first five years of
Int Conf AIDS 1996 Jul 7-12; 11:37 (abstract no. We.B.433)
Bologna R; Hospital de Pediatria, Buenos Aires, Argentina. Fax: 54-1-826-1643.
The increase on both HIV infection among intravenous drug users and heterosexual transmission correlates, in South America, with an increase in the number of HIV-infected women and, consequently, their children. Almost 90% of HIV infection in children is vertically transmitted; thus, the epidemiological pattern of pedi
Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. We.B.530)
Herman SA, Sakahara N, Garrett P, Schumacher RT, Stramer S, Busch M; Roche Molecular Systems, Somerville, NJ, USA. Fax: 908-253-7665. E-mail: steven.herman@roche.com.
Objective: Recent studies determined minimum estimates of the HIV growth rate in HIV-infected patients by examining the decay of viral burden after treatment with drugs that block new rounds of infection. The purpose of the present study was to determine how the viral growth rate during primary infection (prior to sero
Int Conf AIDS 1996 Jul 7-12; 11:29 (abstract no. We.B.531)
Azar R, Conway B, Rouleau D, Patenaude P, Craib K, Fransen S, Shillington A, Manning J, Schechter MT, O'Shaughnessy MV, Montaner JS; B.C. Centre for Excellence in HIV/AIDS, Vancouver, B.C., Canada. Fax: (604) 631-5527. E-mail: razar@unixg.ubc.ca.
Objective: In a pilot study to evaluate the safety and efficacy of combination antiretroviral therapy with nucleoside analogues for the treatment of acute HIV infection. Methods: Patients were referred to our tertiary care clinic with symptomatic primary HIV infection. All were initially evaluated between March and Dec
Int Conf AIDS 1996 Jul 7-12; 11:29 (abstract no. We.B.532)
Perrin L, Yerly S, Lazzarin A, Tambussi G, Hermans P, Clumeck N, Hirschel B; Laboratory of Virology, Geneva University Hospital, Geneva, Switzerland. Fax: 4122-372-2990. E-mail: perrin@cmu.unige.ch.
Objective: To assess the impact of AZT- ddI treatment in patients with primary HIV infection (PHI). Methods: Longitudinal follow-up of viremia and CD4/CD8 ratio in 15 untreated PHI patients and 16 AZT treated patients (historical controls) and 18 PHI patients with a 12 month treatment associating AZT (250 mg bid) and d
Int Conf AIDS 1996 Jul 7-12; 11:29 (abstract no. We.B.533)
Saget BM, Elbeik T, Guthries J, Drews B, Scheibel S; San Francisco, CA, USA. Fax: 415-864-5117. E-mail: bssstt@aol.com.
Objective: To determine the efficacy of aggressive combination antiretroviral therapy (CAT) in subjects with recent HIV-1 infection. Methods: Six recently HIV-1 infected subjects (less than 6 months) were treated using a 4 or 5 drug combination of zidovudine ( AZT ),
Int Conf AIDS 1996 Jul 7-12; 11:29 (abstract no. We.B.540)
Palefsky JM, Holly EA, Hogeboom C, Berry M, Jay N, Darragh T; UCSF, San Francisco, CA, USA. Fax: 415-476-4204. E-mail: joelp@labmed.ucsf.edu.
Objectives: The incidence of invasive anal cancer is elevated among men with a history of receptive anal intercourse. Anal cancer may be preventable through identification and treatment of its putative precursor, high grade squamous intraepithelial lesion (HSIL). The goal of this study was to characterize risk factors
Int Conf AIDS 1996 Jul 7-12; 11:301 (abstract no. We.B.541)
Hillemanns P, Ellerbrock TV, Dole P, Sun XW, Chiasson MA, Wright TC; Dept of Pathology, New York, NY, USA. Fax: (212) 305-5562.
Objective: To determine the prevalence of anal human papillomavirus ( HPV ) infections and anal cytologic abnormalities among HIV-seropositive and HIV-seronegative women. Methods One hundred two HIV-seropositive and 96 HIV-seronegative women were selected from a cohort of women with known HIV serostatus from the greate
Int Conf AIDS 1996 Jul 7-12; 11:30 (abstract no. We.B.542)
Larsen C; European Centre for the Epidemiological Monitoring of AIDS, St-Maurice, France. Fax: 33 1 43 96 50 81. E-mail: idvceses@b3e.jussieu.fr.
Objective: To identify risk factors for cervical Squamous Intra-epithelial Lesions (SIL) in HIV(+) women. Methods: The analysis is based on data collected at inclusion in a multicentre European cohort of HIV(+) women with a known date of infection. Pap smear tests were performed on all women at inclusion and cervical l
Int Conf AIDS 1996 Jul 7-12; 11:30 (abstract no. We.B.543)
Six C; European Centre for the Epidemiological Monitoring of AIDS, Saint-Maurice, France. Fax: 33 1 43 96 50 81. E-mail: idvceses@b3e.jussieu.fr.
Objectives: To identify risk factors for cervical SIL among women presenting risks for HIV infection, whether infected or not. To estimate and to compare the prevalence, incidence and evolution of cervical SIL in HIV(+) and HIV(-) women. Methods: HIV(+) and HIV(-) women were interviewed, had a gynaecological examinatio
Int Conf AIDS 1996 Jul 7-12; 11:30 (abstract no. We.B.544)
La Ruche G, Welffens-Ekra C, Ramon R, Mensah-Ado I, Toure-Coulibaly K, Anoh S, Coulibaly IM; PNLS/MST/TUB, Abidjan, Cote d'Ivoire. Fax: (225) 24.31.19.
Objective: To determine the effect of HIV infection and immunosuppression on the occurrence of cervical intraepithelial neoplasia (CIN) and invasive cervical cancer (ICC). Methods: Non-pregnant women, aged 20 to 50 years, attending 3 gynecologic clinics in Abidjan were included in a cross-sectional study between 06/95
Int Conf AIDS 1996 Jul 7-12; 11:30 (abstract no. We.B.545)
Sun XW, Kuhn L, Ellerbrock TV, Dole P, Chiasson MA, Wright TC; Columbia University, New York, NY. Fax: (212) 305-2426.
Objective: To describe the natural history of cervical human papillomavirus ( HPV ) infections in HIV-seropositive (HIV+) and seronegative (HIV-) women with and without squamous intraepithelial lesions (SIL). Method: Beginning in 1991, 424 HIV+ and 381 HIV- women were followed prospectively with semiannual gynecologic
Int Conf AIDS 1996 Jul 7-12; 11:31 (abstract no. We.B.550)
Frenkel LM, Dankner W, Capparelli E, Wei LJ, Xu J, Spector S, Connor J, Ballow A, Mohan K, Robinson C, Shaver A, Rich K, Thompson M, Read J, Wirkus C, Balsley J, Culnane M, McIntosh K; Dept. Pediatrics, Div. Infect. Dis., Univ. of Washington, Seattle, WA. Fax: (206) 527-3890. E-mail: lfrenkel@u.washingtion.edu.
Objective: To determine the PK properties, maxium tolerated dose and long term safety and tolerance of oral GCV in children. Methods: HIV- and CMV- infected children, 2 weeks to 20 years old, with less than 15% or 150 CD4 cells were given 5 mg/kg of GCV intraveneously (IV), followed two days later by 10, 20, 30 or 40 m
Int Conf AIDS 1996 Jul 7-12; 11:31 (abstract no. We.B.551)
Mueller BU, Zuckerman J, Nelson RP Jr, Sleasman J, Vora S, Saulis R, Higham C, Brouwers P, Jarosinski P, Lewis LL, Sei S, Wood LV, Zeichner S, Heath-Chiozzi M, Berg J, Pizzuti D, Pizzo PA; Pediatric Branch, National Cancer Institute, Bethesda, MD, USA.
Objectives: To assess the pharmacokinetic profile and to determine the safety and tolerance of the protease inhibitor Ritonavir in HIV-infected children, and to study the preliminary antiviral and clinical effects by monitoring clinical status, viral burden in plasma, and markers of immunologic status.
Int Conf AIDS 1996 Jul 7-12; 11:31 (abstract no. We.B.552)
Maldonado YA, Hersh A, Araneta M, Caldwell B; Dept. of Pediatrics, Stanford University School of Medicine, Stanford, CA. Fax: 415-725-8040.
Objective. To determine the combined effects of zidovudine and TMP/SMZ administered before the development of AIDS on the outcome of early perinatal HIV progression. Methods. HIV progression to AIDS in the first 3 years of life was determined in a population-based cohort of 153 children with perinatal HIV infection fol
Int Conf AIDS 1996 Jul 7-12; 11:31 (abstract no. We.B.553)
Sekaly RP, Soudeyns H, Holloway C, Ringuette N, Paquet C, Samson J, Lapointe N, Silvestri GU; Dept of Microbiology and Immunology, McGill University, Montreal, Canada.
Objectives: Although differences in clinical manifestations, kinetics, and outcomes are observed, it is clear that HIV-infected children and infants experience a form of acute HIV infection that is highly analogous to that seen in HIV-infected adults. Transient, high-level TCR VBeta-specific T cell expansions are often
Int Conf AIDS 1996 Jul 7-12; 11:37 (abstract no. We.B.554)
Mueller BU, Smith S, Sleasman J, Nelson RP Jr, Meyer C, Deutsch P, Zwerski S, Mistry G, Sei S, Wood L, Zeichner S, Brouwers P, Jarosinski P, Lewis L, Pizzo PA; Division of Clinical Sciences, National Cancer Institute, NIH, Bethesda, MD.
Objectives: To assess the pharmacokinetic profile and to determine the safety and tolerance of the protease inhibitor indinavir in HIV-infected children and to study the preliminary antiviral and clinical effects by monitoring clinical status, viral burden in plasma, and markers of immunologic status.
Int Conf AIDS 1996 Jul 7-12; 11:124 (abstract no. We.C.3390)
Ouiroga A, Savinon C; Colectivo Nancy Cardenas, Monterrey, N.L. Mexico.
When the community of men who have sex with men is disjointed, the government and authorities,along with the conservative and homophobic groups, make grow their vulnerability before AIDS. With the organization of some groups that involve citizens, we can build an atmosphere of tolerance and solidarity, making ea
Int Conf AIDS 1996 Jul 7-12; 11:124 (abstract no. We.C.3391)
Bindels PJ, Krol A, van Ameijden EJ, Veenstra J, Coutinho RA; Municipal Health Service, Dept. of Public Health and Environment, Amsterdam, Netherlands. Fax: +31-20-5555 533.
Objective: To investigate the frequency of major post AIDS morbidity and the occurrence of a second major post AIDS event among homosexual men diagnosed with AIDS between 1985-1992 and participating in a cohort study in Amsterdam. Methods: In 145 homosexual men who survived the initial AIDS diagnosis (1987 CDC case def
Int Conf AIDS 1996 Jul 7-12; 11:125 (abstract no. We.C.3392)
Sobesky M, Dabis F, Letenneur L, Pradinaud R, Le Beux P; CISIH, Hospital of Cayenne, Cayenne, French Guyana. Fax: (594)395177.
Objective: To analyse the influence of gender on the progression to AIDS and survival with AIDS in patients who acquired HIV infection through heterosexual contacts. Methods: A prospective cohort study of 270 HIV-infected patients contaminated by heterosexual contacts has been followed since January 1992 in French
Int Conf AIDS 1996 Jul 7-12; 11:125 (abstract no. We.C.3393)
Galai N, Burstein R, Kalinkovich A, Sudakov M, Weisman Z, Bentwich Z; Department Of Medical Ecology, The Hebrew University Hadassah School Of Public Health, Jerusalem, Israel.
Background: Since 1991 a whole community of Ethiopians immigrated to Israel . They showed high levels of immune activation and about 2% were HIV-1 (type C) positive. With the change in environment it was of major interest to compare disease progression in the Ethiopian immigrants (ET) with a group of HIV type B infecte
Int Conf AIDS 1996 Jul 7-12; 11:125 (abstract no. We.C.3394)
Tovanabutra S, Rungruengthanakit K, Mundee Y, Suriyanon V, Nantachit N, de Boer M, Nagachinta T, Nelson KE; Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand. Fax: 6653 221849.
Objective: To describe the association of beta2-Microglobulin (B2-M), neopterin (NPT) and CD4 lymphocyte levels in a cohort of HIV-positive male blood donors in Northern Thailand who had been infected from a sex worker with the prevalence of HIV infection in their regular female partner. Methods: HIV-infected male bloo
Int Conf AIDS 1996 Jul 7-12; 11:125 (abstract no. We.C.3395)
Deschamps MM, Pape JW, Jhohnson WD Jr; Division International Medicine, Cornell University Medical College, New York, NY, USA.
Objectives: To determine the Natural History of HIV infection in heterosexual seroconverters with known date of seroconversion in Haiti . Methods: From 1987-1995, 34 individuals heterosexually active, with documented date of seroconversion were prospectively followed for the following endpoints: 1. Development of sympt
Int Conf AIDS 1996 Jul 7-12; 11:125 (abstract no. We.C.3396)
Lopes GS, Hofer CB, Pinho AM, Schechter M; Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Fax: 55(21) 590-1615. E-mail: Maurosch@omega.lncc.br.brazil.
Objective: To investigate the epidemiology and natural history of HIV infection in women in Rio de Janeiro. Methods: We prospectively collected data on all female participants of a cohort study that began in August 1991. Results: Two hundred and six women were studied. Median age at study entry was 33.3 y (range 15- 69
Int Conf AIDS 1996 Jul 7-12; 11:126 (abstract no. We.C.3397)
Mandigo K, Hogg RS, Craib K, Strathdee SA, Gataric N, Yip B, Schechter MT, O'Shaughnessy MV, Montaner JS; Centre for Excellence in HIV/AIDS and University of British Columbia, Vancouver, BC, Canada. Fax: 604-631-5464.
Objective: To compare the baseline characteristics of HIV-infected women and men who have ever been prescribed antiretroviral therapy in the province of British Columbia (BC). Methods: The distribution of antiretroviral drugs in BC is free of charge through the province-wide HIV/AIDS Treatment Program. To prescribe ant
Int Conf AIDS 1996 Jul 7-12; 11:126 (abstract no. We.C.3399)
Quinson AM, Mars ME, Ermeneux D, Loi S, Suzan V, Gallais H; Infectious Diseases Unit, La Conception Hospital, Marseille, France. Fax: (33)91-94-22-03.
Objective: To determine the influence of pregnancy and AZT prophylaxis in a cohort of HIV-infected women. Patients and Methods: Between July 1st 1992, and December 31st 1995, more than 800 women were followed; 85 were pregnant. We studied the clinical and biological evolutions during and after pregnancy.
Int Conf AIDS 1996 Jul 7-12; 11:126 (abstract no. We.C.3400)
Perucci CA, Rapiti E, Brancato G, Abeni D, Pezzotti P; Osservatorio Epidemiologico Regione Lazio, Roma, Italy. Fax: 39-6-8603752. E-mail: OER.C.GREGO@AGORA.STM.IT.
Objectives: To describe the incubation time in a seroprevalent cohort in which a seroconversion date has been estimated through the multiple imputation method. Methods: A cohort of adult subjects (greater than or equal 13) with a first diagnosis of HIV positivity in 1984-1992 in Lazio, Italy , was enrolled. The sero
Int Conf AIDS 1996 Jul 7-12; 11:126 (abstract no. We.C.3401)
Stephenson JM; UCLMS, Lonoon.
Objectives: To compare the rate of reproductive events before and after HIV diagnosis within a cohort of 503 women with HIV infection, and to consider the impact of HIV diagnosis on reproductive decision-making. Methods: Using date of birth, date of HIV diagnosis, the outcome of all lifetime pregnancies and the date of
Int Conf AIDS 1996 Jul 7-12; 11:126 (abstract no. We.C.3402)
Greenblatt RM, Barkan S, Delapenha R, Silver S, Garcia P, Riester K, Burns D, Mathur U, Augenbraum M, Palefsky J; UCSF ID Division, San Francisco, CA, USA. Fax: 415-476-8528. E-mail: ruthg@itsa.ucsf.edu.
Objective: To determine the prevalence of lower genital tract infections, associated symptoms and findings among HIV seropositive (HIV+) and seronegative (HIV-) women. Methods: Between October, 1994 and November 1995, 2080 HIV+ women and 575 HIV- women received baseline evaluations in a multisite natural history study
Int Conf AIDS 1996 Jul 7-12; 11:127 (abstract no. We.C.3403)
Kloser PC, Correll P, Eyassu R, Bean-Mayberry B; University of Medicine & Dentistry of New Jersey, Newark, NJ, USA. Fax: (201) 982-2252.
1) What opportunistic infections (OI) and disease conditions affect women during the course of their HIV infection; 2) what are the findings of Papanicolaou (PAP) smears and pelvic examinations after the institution of specific diagnostic and treatment protocols at the Newark Women s AIDS Clinic (NWAC). Project:
Int Conf AIDS 1996 Jul 7-12; 11:127 (abstract no. We.C.3404)
McLaughlin TJ, Soumerai SB, Weinrib D, Aupont O, Cotton D; DACP/HMS, Boston, MA, USA. Fax: 617-859-8112. E-mail: THMCLAU@warren.med.harvard.edu.
Objectives: To examine the association between primary source of ambulatory care (PSAC) among adult heterosexuals with AIDS (PWAs) and access to zidovudine (ZDV) treatment and PCP prophylaxis; and whether any observed variation in access to treatment was related to differences in death rates. Methods: Of 1,860 PWAs ide
Int Conf AIDS 1996 Jul 7-12; 11:127 (abstract no. We.C.3405)
Lai KK; Univ. of Massachusetts Medical Center, Infectious Disease, Worcester, MA, USA. Fax: 508-856-2211.
Objective: To study the incidence of cervical dysplasia (CD) and its association with the Human Papilloma virus ( HPV ) infection among HIV-infected women (HIVW). Methods: Pelvic examinations and Papanicolaou (pap) smears were performed on HIVW every 6 months to a year. Patients whose pap smears showed CD were referred
Int Conf AIDS 1996 Jul 7-12; 11:127 (abstract no. We.C.3406)
Palacio H, Anastos K, Kalish L, Benson C, Delapenha B, Chirgwin K, Stonis L, Telzak E; San Francisco General Hospital, San Francisco, CA, USA. Fax: 415-476-6953.
Objective: 1) To determine the prevalence of and risk factors for cutaneous anergy in HIV-positive (HIV+) and HIV-negative (HIV-) women. 2) To compare the utility of 3 antigens in assessing delayed type hypersensitivity. Methods: The WIHS, a multi-site prospective cohort study of HIV-infected and at-risk women, enrolle
Int Conf AIDS 1996 Jul 7-12; 11:127 (abstract no. We.C.3407)
Barkan SE, Preston-Martin S, Kalish L, Melnick S, Weber K, Sacks H, Marx E, Padian N, Feldman J; New England Research Institutes, Watertown, MA, USA. Fax: (617)926-8246. E-mail: susanba%neri@mcimail.com.
Objective: To compare characteristics of WIHS HIV(+) women (WM) to national statistics on AIDS in U.S. WM (1994), and to describe and compare baseline characteristics of the WIHS seropositive and seronegative cohorts. Methods: Data from the entire cohort of 2655 women enrolled in the WIHS b/w 10/94 and 11/95 will be pr
Int Conf AIDS 1996 Jul 7-12; 11:128 (abstract no. We.C.3408)
Sobel JD, Schuman P, Mayer K, Klein RS, Rompalo A, Smith D, Warren D, Duerr A; Wayne State University, Detroit, MI, USA. Fax: 313-993-0302.
Objectives: To determine, in women with or at risk for HIV infection, the prevalence and factors associated with mucosal Candida colonization and the distribution of Candida species among isolates. To determine the prevalence and factors associated with oral (pseudomembranous, erythematous or angular cheilitis lesions)
Int Conf AIDS 1996 Jul 7-12; 11:128 (abstract no. We.C.3409)
Rompalo A, Vlahov D, Astemborski J, Schoenbaum E, Schuman P, Carpenter C, Holmberg S, Smith D, Warren D; Johns Hopkins School of Medicine, Baltimore, MD.
Objectives: To compare the prevalence of HIV-related clinical symptoms, physical examination findings, and hematologic variables among women whose risk for HIV is intravenous drug use (IDUs) versus sexual contact (SC). Methods: Participants of the HER Study, a multi-centered study of HIV infection in women, were admini
Int Conf AIDS 1996 Jul 7-12; 11:128 (abstract no. We.C.3410)
Laine C, Markson LE, McKee LJ, Hauck W, Turner BJ; Jefferson Medical College, c/o Merck & Co., Inc., West Point, PA. Fax: (215) 652-0860.
Purpose: Provider experience has been reported to be an important factor in improving outcomes for HIV-infected persons, but this work has focused largely on inpatient settings. Since most care now occurs in outpatient settings, we studied the relationship between clinic HIV experience and survival for women with AIDS.
Int Conf AIDS 1996 Jul 7-12; 11:128 (abstract no. We.C.3411)
Liomba G, Taha TE, Chiphangwi JD, Dallabetta G, Miotti PG; School of Public Health, Johns Hopkins University, Baltimore, MD, USA. Fax: 410-955-1836.
Objective: To examine trends of HIV-1 and STDs prevalence among women of childbearing age in Malawi , Africa. Methods: After counselling and obtaining consent, consecutive, first visit antenatal women at a tertiary care hospital (Queen Elizabeth Central Hospital) in Blantyre, were screened for HIV-1 and STDs. Three sur
Int Conf AIDS 1996 Jul 7-12; 11:128 (abstract no. We.C.3412)
Chiasson MA, Kelley KF, Williams R, Vazquez F, Mikl J, Forlenza S, Smith PF; New York City Dept. of Health, New York, NY, USA. Fax: (212) 788-9810.
Objective: To determine the incidence of ICC in HIV+ women and to describe the demographic and clinical features of these women. Methods: Analysis of NYC AIDS case surveillance data and hospital chart review for confirmation of ICC and HIV. Results: Seventy-one (71) ICC cases were confirmed by chart review and 27 addit
Int Conf AIDS 1996 Jul 7-12; 11:129 (abstract no. We.C.3413)
Murphy R, Palella F, Bonnet J, Bennett C, Phair J; Northwestern University Medical School, Chicago, IL, USA.
Objective: To determine if there is appreciable temporal difference in the rate of disease progression and survival between men and women diagnosed with AIDS and cytomegalovirus retinitis ( CMV ). Methods: Records from 94 patients with cytomegalovirus (CMV) retinitis diagnosed between 4/88 and 7/95 at the Northwestern
Int Conf AIDS 1996 Jul 7-12; 11:129 (abstract no. We.C.3415)
Davoli M, Perucci CA, Rapiti E, Bargagli AM, D'Ippoliti D, Forastiere F, Abeni D; Osservatorio Epidemiologico, Regione Lazio, Roma, Italy. Fax: 39-6-8603752. E-mail: OER.C.GREGO@AGORA.STM.IT.
Objective: To analyze overall and cause-specific mortality in a cohort of injecting drug users (IDUs) enrolled and followed-up before and after the spread of the AIDS epidemic. Methods: A cohort of 4200 IDUs enrolled in the three largest drug treatment centres in Rome, 1980-88, were followed-up as of 12/1992. Age-stand
Int Conf AIDS 1996 Jul 7-12; 11:129 (abstract no. We.C.3416)
Webber MP, Schoenbaum EE, Klein RS; Montefiore Medical Center/Albert Einstein College of Medicine, AIDS Research, Bronx, NY, USA. Fax: 718 652-1343. E-mail:webber@aecom.yu.edu.
Objective: To examine changes in the distribution and time to development of initial AIDS-defining illnesses in a cohort of seropositive IDUs. Methods: 277 IDUs enrolled in a prospective study of the natural history of HIV infection with a CD4+ count measurement prior to AIDS (1987 definition) and at least 3 years of f
Int Conf AIDS 1996 Jul 7-12; 11:129 (abstract no. We.C.3417)
Lifson AR, Thompson S, Lorvick J, Grant S, Hilk R, Kawamura LM; Division of Epidemiology, University of Minnesota, Minneapolis, MN, USA. Fax: 612-625-8950. E-mail: lifson@epivax.epi.umn.edu.
Objectives: To evaluate the prevalence of skin test anergy among HIV-negative and positive injection drug users (IDUs) Methods: 481 IDUs recruited from street-based settings in three Bay Area neighborhoods (two in Oakland [N=344] and one in San Francisco [N=137]) received HIV antibody tests and three skin tests: (1) pu
Int Conf AIDS 1996 Jul 7-12; 11:129 (abstract no. We.C.3418)
Jones JL, Hanson DL, Ward JW, Kaplan JE; Centers for Disease Control and Prevention, Atlanta, GA, USA. Fax: (404) 639-2029. E-mail: JLJ1@CIDHIV1.em.cdc.gov.
Objective: AIDS-defining opportunistic illnesses (AOIs) are the major cause of HIV-related illness and death. We compared trends in the 12 leading AOIs from 1990 through 1993 among injecting drug users (IDUs) and men who have sex with men (MSM). Methods: We analyzed record reviews of HIV-infected persons done every 6 m
Int Conf AIDS 1996 Jul 7-12; 11:130 (abstract no. We.C.3419)
Shor-Posner G, Zhang G, Quesada J, Lai H, Fletcher MA, Page B, Baum MK; Department of Epidemiology, University of Miami School of Medicine, Miami, FL, USA. Fax: 305-243-4687. E-mail: gshor@mednet.med.miami.edu.
Objective:To determine the impact of HTLV infection on immune parameters and nutritional status in HIV-1 infected intravenous drug users (IDUs). Methods: Standard methodology was used to determine plasma nutrient levels of zinc, copper, and vitamins A, E, B6 and B12 and immune status (CD4, CD8 cell count, beta2 microgl
Int Conf AIDS 1996 Jul 7-12; 11:130 (abstract no. We.C.3420)
Baum MK, Zhang G, Page B, Fletcher MA, Quesada J, Lai H, Shor-Posner G; Department of Epidemiology, University of Miami School of Medicine, Miami, FL, USA. Fax: 305-243-4687. E-mail: mbaum@mednet.med.miami.edu.
Objective: To evaluate the relationship between nutritional parameters and immune status in HIV-1 seropositive male and female intravenous drug users (IDUs). Methods: Standard methodology was used to determine plasma levels of prealbumin, zinc, and vitamins A, E, B6 and B12 in 63 HIV seropositive men and 31 HIV seropos
Int Conf AIDS 1996 Jul 7-12; 11:130 (abstract no. We.C.3421)
Pajeau TS, Bennett CL, Horner R, Curtis JR, Weinstein RA, DeHovitz JA; Lakeside Veterans Administration Medical Center, Chicago, IL, USA. Fax: (312) 640-2120. E-mail: tsp-hsr@nwu.edu.
Objective: To determine if intravenous drug users (IDUs) receive a lower intensity of care and have poorer outcomes when hospitalized for AIDS-related PCP . Methods: Medical records for patients with PCP (n=1563) at 14 VA and 82 non-VA hospitals in Chicago, New York, Miami, Los Angeles, and Durham NC during 1987 to 199
Int Conf AIDS 1996 Jul 7-12; 11:130 (abstract no. We.C.3422)
Farzadegan H, Levy D, Astemborski J, Saah AJ, Vlahov D, Graham NM; Dept. of Epi, Johns Hopkins University, School of Hygiene and Public Health, Baltimore, MD, USA. Fax: (410) 955-1383. E-mail: HFARZADE@PHNET.SPH.JHU.EDU.
Objective: To determine the relationship between infectious HIV viral load and type/frequency of injection drug use, race, gender and disease stage among IDUs and gay men with HIV. Method: Quantitative microculture using a co-culture technique was used to determine infectious viral load on 547 participants in two cohor
Int Conf AIDS 1996 Jul 7-12; 11:130 (abstract no. We.C.3423)
Orr SM, Fisher DG, Brooks KJ, Paschane DM; University of Alaska-Anchorage, Anchorage, AK, USA. Fax: (907) 786-4866.
Objective: Streptococcus pneumoniae is a recognized pathogen. This study examines the prevalence and risk factors for carriage of Streptococcus pneumoniae in Alaskan drug users and compares the sensitivity of nasopharynx (nose) vs. oropharyngeal (throat) specimens. Methods: Data were collected with the Risk Behavior As
Int Conf AIDS 1996 Jul 7-12; 11:130 (abstract no. We.C.3424)
Davenny K, Smeriglio V, Coulis P, Khalsa J, Genser S; National Institute on Drug Abuse (NIDA), NIH, Rockville, MD, USA. Fax: (301) 443-2317.
Understanding the biological and behavioral factors associated with drug use which may affect the HIV disease process is critical to prevention and treatment of disease. Drug-using populations are characterized by high background rates of infectious disease morbidity, mortality, and abnormal laboratory parameter
Introduction and Objectives: Before the AIDS pandemic, the leading cause of death in hemophiliac patients was bleeding due to lack of coagulation factors. Our aim is to evaluate the causes of deaths in hemophiliacs with blood tests positive and negative for HIV-1. Material and Methods: Medical records from 470 male hem
Objective: To determine persistence of anti-HIV-1 reactivity in sera of blood donors with indeterminate Western blot for anti-HIV-1 antibodies and detect HIV-1 sequences in peripheral blood mononuclear cells (PBMC). Methods: The significance of indeterminate test for HIV-1 is still difficult to evaluate, especially in
Int Conf AIDS 1996 Jul 7-12; 11:131 (abstract no. We.C.3427)
Christiansen CB, Scheibel E, Ryder LP, Gottschau A, Dickmeiss E; Dept. of Virology, Statens Serum Institut, Copenhagen, Denmark. Fax: +45 3268 3141.
Objective: To evaluate different prognostic markers in a cohort of haemophiliacs infected with HIV-1 from 1979 to 1986. All fifty patients were co-infected with HCV. Methods: This cohort has been followed since 1986. In the period from 1986 to 1991, different parameters were measured at 3-6 months interval (PWM, PHA, H
Int Conf AIDS 1996 Jul 7-12; 11:131 (abstract no. We.C.3428)
Ghirardini A, Puopolo M, Rossetti G, Perugini L, Farchi F, Alba B, Scaraggi FA, Tagliaferri AR, Chiarotti F, Mannucci PM; Istituto Superiore di Sanita, AIDS Unit, Roma, Italy. Fax: 39-6-4460120.
Objective: To understand the natural history of HIV infection, 722 HIV-positive hemophiliacs were enrolled in a retrospective and prospective cohort study. Methods: The National Hemophilia Registry has information on 95% of the HIV-infected hemophiliacs in Italy , who are reported, maintaining anonymity, by the Italian
Int Conf AIDS 1996 Jul 7-12; 11:131 (abstract no. We.C.3429)
Cooper D, El-Bassel N, Schilling RF; Columbia University School of Social Work, New York, NY. Fax: 212-854-8549. E-mail: dc49@columbia.edu.
Objective: To examine the relationship between personal social network characteristics and HIV status among female methadone patients. Methods: One hundred and fifty-one female methadone patients in New York City were interviewed regarding their sexual and drug risk behavior and personal social networks. Logistic regre
Int Conf AIDS 1996 Jul 7-12; 11:131 (abstract no. We.C.3430)
Rabkin CS, Goedert JJ; NCI Multicenter Hemophilia Cohort Study Collaborators, National Cancer Institute, Bethesda, MD, USA. Fax: (301) 402-0817. E-mail: rnn@cu.nih.gov.
Objectives: To determine the types and rates of cancers occurring in excess in HIV-1 infection and identify risk factors for their occurrence. Methods: Prospective cohort study of 1241 HIV-1 seropositive (HIV+) and 800 HIV-1 seronegative (HIV-) hemophilia patients followed at 18 centers in the U.S. and Europe. Observed
HIV-Center for Clinical and Behavioral Studies, New York, N.Y., and Columbia University, New York, N.Y. Objective: Hemophiliacs are an ideal cohort to search for evidence for non-progressors (asymptomatic over greater than 25 years) and male-to-female transmission, because they (1) became infected within a short period
Int Conf AIDS 1996 Jul 7-12; 11:132 (abstract no. We.C.3432)
Proietti F, Passos V, Calazans F, Martins MV; Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil. Fax: 55-31-222-0300. E-mail: proietti@oraculo.lcc.ufmg.br.
Introduction: HTLV-I/II it is highly prevalent among Brazilian eligible blood donors. We have demonstrated a seroprevalence of 42/10.000 donors in Belo Horizonte, MG, Brazil. We report here preliminary results of a case-control study conducted in this population, in order to elucidate possible determinants of seropreva
Int Conf AIDS 1996 Jul 7-12; 11:132 (abstract no. We.C.3433)
Cervi MC, Isaac ML, Mussi-Pinhata MM, Lima M, Negrini BV, Mucillo P; University of Sao Paulo, Ribeirao Preto, SP, Brazil. Fax: 55-16-6330136.
Objective: To describe the clinical signs and symptoms related to HIV infection/AIDS and to evaluate nutritional support, prophylactic and therapeutic measures. Methods: Prospective clinical and laboratory follow-up of children born to HIV-positive mothers. Group I (1978-89): 25 children receiving no support measures.
Int Conf AIDS 1996 Jul 7-12; 11:132 (abstract no. We.C.3434)
Matida LH, Caminada S, Tayra A, Santos NJ, Domingues CS, Ruiz EA; Sao Paulo State Health Department AIDS/STD Program, Sao Paulo, SP, Brazil. Fax: 55 11 833 9439.
Objective: Analyse the occurrence of AIDS in cases under 13 years of age according to modes of transmission of HIV, in Sao Paulo(SP), from 1984 to 1994. Methods: Analysis of AIDS cases reported to the disease surveillance system of SP from 1984 to 1994. Variables analysed were age, sex, modes of transmission of HIV, da
Int Conf AIDS 1996 Jul 7-12; 11:132 (abstract no. We.C.3435)
Giaquinto C, De Rossi A, Laverda A, Mazza A, Rampon O, Giacomet V, D'Elia R, Zacchello F; Dipartimento di Pediatria, University of Padova, Padova, Italy. Fax: +39.49.8753865. E-mail: carlog@child.pedi.unipd.it.
Objectives: To study the natural history of pediatric HIV infection. Methods: All children born to seropositive mothers were identified and followed from birth clinically, immunologically and virologically (PCR and virus culture) every 4-6 weeks in the first 6 months, and 6 monthly there after. Children were defined as
Int Conf AIDS 1996 Jul 7-12; 11:133 (abstract no. We.C.3436)
Rosado L, Neves C, Bessa A, Cavaco SP, Santos AC, Lourenio MH, Santos Ferreira MO; Hospital D. Estefania, Lisboa, Portugal. Fax: 35113151787.
Objectives: To determine the morbidity and mortality of HIV-2 vertical transmission in a paediatric population. Methods: This retrospective study was conducted at the Lisbon Paediatric Hospital and envolved all children born to HIV-2 seropositive mothers attending the hospital since January 1989. Other routes of transm
Int Conf AIDS 1996 Jul 7-12; 11:133 (abstract no. We.C.3437)
Ortiz IR, Perez CM, Lugo RG, Albizu C, Caldwell B; Puerto Rico Pediatric Spectrum of Disease Project, UPR School of Medicine, Puerto Rico. Fax: (809) 763-0399. E-mail: ORTI102W@WONDER.EM.CDC.GOV.
Objective: To determine whether factors associated with transmission are also associated with AIDS progression and to investigate clinical characteristics associated with AIDS diagnosis among perinatally HIV-infected children in Puerto Rico . Methods: Active surveillance of HIV-infected children has been ongoing in Pue
Objective: To better define the relationship among the HIV biological phenotype, replicative capacity of viral isolates, HIV RNA copy number in plasma, CD4 T cell counts, and evolution of HIV infection in HIV-infected infants. Patients and Methods: We performed a prospective follow up lasting from 1 to 30 months of evo
Objective: To apply the CDC 1994 clinical classification to a prospective cohort of children with vertical HIV infection, describe its temporal dynamics, and determine its prognostic value. Methods: 63 children with confirmed vertical HIV infection were followed up prospectively from birth for a median of 35months (m),
